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Joint Committee on Science and Technology 
December 2, 1988 
9:00 a.m. 
P R 0 C E E D I N G S 
DR. BOYER: I'm Paul Boyer, head of the University 
of California Systemwide Program of Research and Education 
in Biotechnology, one of the cosponsors of this meeting. 
And I come with a perspective which in one way 
is better than anyone else in the audience, and that is of 
55 years since I received my Ph.D. in biochemistry. And 
at that time, the possibility that some half a century later 
there would be a conference on looking at the possibilities 
and problems of sequencing the human genome was just utterly 
beyond my imagination. 
What has been accomplished in our science has been 
really a revelation. The wisest decision I ever m0de was 
to become a biochemist at the time that I did. 
But you don't want to hear about my background 
and perspective. We're here today to look at one of the 
most interesting challenges in biology, to examine the pros 
and cons. 
1. 
We're fortunate to have as a chairman of an excellent 
morning panel, Dr. Julius Krevans, Chancellor at the University 




of California, San Diego --
DR. KREVANS: San Francisco. 
DR. BOYER: -- a fine clinician University 
4 of California, San Francisco -- Professor of Medicine for 
5 a long time there, Dean of the college before he became 
2. 
6 Chancellor, and who has had a keen interest in the development 
7 of the biotechnology and related facets that come out of 
8 our studies. And it's a pleasure to introduce Dr. Krevens 
9 who will moderate the morning session. And I apologize 
10 
11 
for moving you south. 
DR. KREVANS: 
12 want your science, Paul. 
I'd take your land, but I don't 
13 I would welcome all of you to this session on 
14 the Human Genome Projects. And the title right off the bat 
15 is a little disarming. Is it going to be a project? Is 
16 it going to be projects? 
17 And what we're really here this morning and this 
18 afternoon to share is a discussion of how and where we should 
19 go in this exciting prospect of sequencing the human genome. 
20 Now, I'm going to make the assumption that no 
21 one in this audience thinks it would be a terrible thing 
22 if we knew the sequence of the human genome. I don't think 
23 that we should make the assumption, however, that there 
24 aren't people in the United States or in the world who think 
25 it would be a terrible thing. 
Pike Court Reporting 
3. 
1 There remains a potent, and perhaps even growing, 
2 group of intellectual Luddites who find the prospect of 
3 new knowledge terrifying. And the idea that a group of 
4 people are interested in finding out what the sequence of 
5 the human genome to this logic is terrifying and awful and 
6 something to be resisted. 
7 I grew up in New York City -- one of our next 
8 speakers, we were talking about it -- and I recall reading 
9 about what New York City was like in the 19th century. 
10 We used to study history in those days in the public schools. 
11 They've now given that up as you know. 
12 And when I hear people railing against the internal 
13 combustion engine as having destroyed the world, I would 
14 say to myself that the little knowledge I have of the history 
15 of New York that without the internal combustion engine, 
16 given the means of transportation which preceded it, New 
17 York would be at least shoulder high in the same substance 
18 of which the logic of the nay-sayers is made. 
19 At any rate, the interest of the University as 
20 a partner in this symposium is a genuine and important one. 
21 Biomedical science, biomedical research in the United States 
22 is a result of a social contract between the people of the 
23 United States as expressed by the legislature and the government 
24 and a variety of institutions, independent research entities, 
25 the National Institute of Health itself and the universities 
Pike Court Reporting 
4. 
1 of the United States to produce new knowledge. 
2 So we have a stake, and an important one, in the 
3 answers to the question as to how and when we might embark 
4 on a project as exciting as knowing the sequence of the 
5 human genome. 
6 We're fortunate to have on the program today some 
7 very interesting and, I think, informative perspectives. 
8 And the first of those will be given by James Watson who 
9 is formerly of a lot of places. 
10 His office sent me an extraordinarily brief CV. 
11 This is the James Watson CV. 
12 Currently, Jim Watson is looking at the human 
13 genome initiative for the NIH. He has, of course, been 
14 Professor of Biology at Harvard. He's been the Director of 
15 the Cold Spring Laboratories. He did some interesting research 
16 work at Cambridge and is one of the people who changed the 
17 wa.y we even think in biology. 
18 
19 remarks. 
So, Jim, we're looking forward to hearing your 
20 DR. WATSON: It's a pleasure to see such a small 
21 group of people. I got used to the fact that if I go to 
22 a university that everyone in the audience is not there 
23 to listen to me but to get my autograph. And it's very 
24 inhibiting and makes me feel rather creepy. So I realize 
25 now that I'm talking to people who actually want to listen 
Pike Court Reporting 
5. 
1 to what I have to say. 
2 Now I have the position of Associate Director 
3 of the NIH for genome research. 
4 And can you hear me all right? I speak softly 
5 and if someone could --
6 [At which time the microphone was adjusted.] 
7 Is that better now. Okay. And if you can't hear 
8 me in the back, please yell because I get lower and lower, 
9 probably because I don't believe in what I'm saying so if 
10 it doesn't go very far I won't get into trouble. 
11 Anyway, I have now a position now at NIH. I'm 
12 also at Cold Spring Harbor. And I have committed myself 
13 to spending two days a week on the Genome Project which 
14 probably won't be enough, but if I spent more, I'd have 
15 to resign from Cold Spring Harbor and that would put me 
16 in a bad position because it's very useful to have two jobs 
17 because if you don't like what you're doing, you can say 
18 that you'll resign and you'll have another one, which I 
19 found useful when I was both at Harvard and Cold Spring 
20 Harbor. 
21 Those I have a little say because I found -- at 
22 least at Harvard, not very often, and even at Cold Spring 
23 Harbor -- that occasionally you had to threaten to resign, 
24 not very often, but sometimes issues really count. 
25 Now, I felt-- I mean there's the two talks, one 
Pike Court Reporting 
by Charlie Cantor and one by myself -- and I feel slightly 
2 weak because Charlie actually knows what he's talking about 
3 and he's a pro in it. And I've been brought in, I think, 
4 really to make decisions as to which pro's to listen to. 
5 So I don't know anything, and I'm going to try 
6 and learn something. Eventually, we can get the project 
7 done fast. 
8 
9 
Now, I felt -- to me it has always been pretty 
obvious we should do the project. But a lot of people, 
10 at least to start with, felt it was a scandal, and really 
11 intelligent people. 
12 So a lot of things have been written which I think 
13 we won't drag out to embarrass them later in the future. 
14 I thought maybe I would give a history of sort 
15 of where I see the genome project and why it's so necessary 
16 and what are the phases of genetics, which I've been in 
17 some form or another, I guess, now for 45 years, since when 
18 I went to the University and decided I wanted to find out 
19 what the gene was. 
20 Now, if one looks at genetics, I think the first 
6. 
21 phase was the classical Mendelian one, which was gene mapping. 
22 At the turn of the century it became clear that hereditary 
23 was controlled by discreet units, which got the names genes, 
24 ~nd that these were located on chromosomes. 
25 And really first through the work of the fly group 
Pike Court Reporting 
7. 
1 at Columbia, it is clear that the genes were arranged in 
2 linear order, which sort of made sense because the chromosomes 
3 were linear. And this phase of people mapping genes goes 
4 on today. And what we're talking about is the ultimate 
5 in gene mapping, sort of the map of the nucleotide level. 
6 But sort of showing the traits were controlled 
7 by genes is the sort of dominant theme of genetics for about 
8 40 years. And one could say that that sort of phase in 
9 which genes were discreet objects, where you didn't think 
10 in terms of chemistry, we saw the banding of the Drosophila 
11 chromosomes in the early '30s. And Calvin Bridges made 
12 a complete map of the Drosophila chromosomes in the late 
13 1930's at Cold Spring Harbor. So that was the first ultimate 
14 genetic map. 
15 And it wouldn't have been except that the director 
16 had money from the Carnegie Institution of Washington. Bridges 
17 came to Cold Spring Harbor and laboriously did the banding 
18 pattern. 
19 Now, the second phase of genetics was really: 
20 What is the genetic material? What was it chemically? And 
21 that was interconnected with not only what the gene was, 
22 but what did it do? And that was going full blast when 
23 I became a student and I learned the slogan "One gene, one 
24 enzyme." And it was really at Cal Tech where I guess it 
25 was promoted the best, but the idea really goes back to 
Pike Court Reporting 
1 the metabolic defects in man going back to around 1910, 




And when I was a student, it was -- I heard about 
And then when I went to Indiana and took Luria's course 
8. 
6 on viruses, I certainly learned the details of transformation, 
7 and that focused me on DNA. 












I guess for a variety of reasons. One was that even at 
that time one didn't know the chemical structure of DNA. 
And suddenly about 1951, '52, there was unambiguously established 
to be a 3-5 linkage. So one couldn't have made the model 
of DNA before '51 because the chemical structure wasn't 
there. 
I think the number of people who were interested 
in DNA at the time we found the double helix was at most 
a couple hundred. And they were interested for a variety 
of different reasons. And most people had a sort of: What 
is the gene DNA? I think the geneticists would have said, 
20 "Yes," and the biochemists would have said, "No." 





they wen' il 11 protc,in chemists, and they wanb'd proh•ins 
to be important. So they preferred to think of DNA as a 
sort of unspecific scaffold into which the interesting things, 
the genes, were sort of attached. I think that was the 
Pike Court Reporting 
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1 conventional viewpoint. 
2 Paul, I guess, says that the luckiest thing for 
3 him was that he became a biochemist. I guess you could 
4 say that the luckiest thing for me is that I didn't because 
5 I probably would have become a protein chemist, very interested 
6 in proteins whereas, in fact, geneticists knew that the 
7 chromosomes were filled with DNA, and so they were more 
8 likely -- I mean you could see Hermann Muller, he would 
9 have taken the discovery quite seriously. 
10 Anyway, that phase -- What is the Gene? -- ended 
11 in '53 when we saw the gene had the complimentary double 
12 helix, because if the DNA had the structure it should have, 
13 it was going to replicate itself. And that was the question 
14 which the geneticists had raised: How did it replicate 
15 itself perfectly? 
16 So there was Cold Spring Harbor symposium in 1953, 
17 and everyone agreed -- there was only person, and it was 
18 really odd, he didn't like it, and that was Barry Commoner. 
19 He just was sort of mad. I think in more than one way. 
20 So that phase of genetics ended as to what the gene was 
21 chemically. 
22 And then the next phase was how the gene acted 
23 and, essentially how you translated the four-letter alphabet, 
24 four-letter messages of DNA into the 20-letter messages 
25 of proteins. And that went incredibly fast, from 1953 to 
Pike Court Reporting 
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1 1966 when the code was established and you could say we 
2 had our Rosetta stone. You could translate it from one 
3 language to another. 
4 There are still details being worked out, but 
5 it was sufficiently a big event that people reacted to it 
6 in several ways. Some people thought the field was over 
7 and so moved on to the brain or embryology. 
8 And in retrospect, now you can say that they were 
9 pretty silly. But, in fact, if we come that DNA hadn't 
10 come along, the DNA sequencing, you might as well be working 
11 on the brain because we weren't going to get very far. 
12 But the next phase of genetics, which really now 
13 you see, was made possible only b¥ the discovery of recombinant 
14 DNA and by working out the Sanger and Gilbert sequencing 
15 methods was: What controls gene functioning? And I guess 
16 that's the dominant theme of genetics now. How do genes 
17 function? What are their control? And there are all sorts 
18 of protein factors. And it's moving very fast and unbelievably 
19 competitive because now, in a sense, it's almost easy to 
20 do because you can work out the sequence of DNA and do lots 
21 of things. 
22 When we know these rules for gene functioning, 
23 then we will now permit, you can say, the ultimate aspect 
24 of genetics, that's really genetic manipulation and genetic 
25 engineering. And that's what many people in this room are 
Pike Court Reporting 
1 interested in, and you could say it's the end of genetics. 
2 I mean, if we know what the rules are. And then you can 
3 go out and make new sorts of organisms. 
4 You could then, I think, go to the next stage, 
5 whether you call it genetics or not, it is arbitrary. I 
6 guess I wouldn't. 
7 Now one can actually approach the question of: 
8 Really what is a cell? I mean really if all the information 
9 for a cell comes from the DNA, if you can go to the DNA 
10 level, you will see the instructions for how a cell can 
11 divide, and you can go beyond that in embryology. Within 
12 the DNA are all the instructions for embryologic development. 
13 So if you can look at the DNA level, you actually ought 
14 to be able to work out the way development occurs. And 
15 that will be very complicated. 
16 And you have to -- if you say that a fly develops, 








at all its proteins and say that a fly is a sum of 20,000 
proteins or something like that. But now that you can go 
to the DNA level, if you wanted to find what a fly is, the 
simplest thing is just to get the DNA sequence of Drosophila. 
This will tell you how many genes there are. You can begin 
to say that some are DNA binding proteins and others will 
be any number of anyway, you can begin to get an idea 
25 of what a fly is. 











And if you have all the genes plotted out, you 
can find which time they function during development, and 
we can completely describe a fly. And so there's really 
nothing more than the instructions in its DNA. And I like 
that idea, maybe it's because I have no affection for flies 
and the fact that there's nothing but DNA seeing that the 
right proteins appear at the right time, and we'll understand 
the fly. It's complete reductionism. 






there's more to the fly than its genetic instructions manifested 
itself through development. But it will be extraordinarily 
exiciting, but to really do it, you need the DNA sequence. 
And if you go to humans and say, "We really want 
14 to understand ourself. We understand all sorts of different 
15 aspects of ourself," but you want the total picture, you 
16 might as well go the DNA and say: What is man or woman? 
17 And it's really the instructions from the DNA. 
18 Some people say that it's more than that. I don't 
19 want to get into any arguments, but I'll be satisfied to 
20 know what's in the DNA. 
21 So as a biologist, the prospect of now seeing 




instructions of the DNA, is to me very exciting. And nothing 
could be more exciting than to you know -- if you were 
trying to say, "Well, how does the Drosophila brain function?" 
Pike Court Reporting 
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Well, you want to know all the proteins in it. 
2 And you can lead to some people saying that they 
3 are dull projects. But I don't see any other way to go 
4 about it. So I think we have to go to the gene. 
5 If we want to go to these big problems: What 
6 is a cell? How does it divide? You've got to know what 
7 a cell is. In the same sense, we had to know what DNA was 
8 before we could say what a gene is. 
9 So if you want to ask what human being is, well, 
10 it's all these genes correctly functioning. So you better 
11 find out the genes. Cancer would be just still as bad as 
12 ever to work on if we hadn't been able to go to the DNA 
13 level. When you can go to the DNA level, you can define 
14 your problem. 
15 So if you want to define embryology, you just 
16 better go the DNA level. 
17 And so I think working -- and, of course, we've 
18 done it in the case of viruses where we got the complete 
19 sequence alligned. And it's only in the you could say 
20 unsatisfactory because lambda replicates in the coli cell, 
21 and we don't have the sequence for coli. And until you 
22 have the coli sequence, you won't really be able to understand 
23 it completely. 
24 So I guess that's my general reason for saying 
25 we have to know the sequences if we want to, say, go on 
Pike Court Reporting 
14. 






So if you want to say, "Well, who's going to control 
the yeast world? Who's going to be on top of the Drosophila 
world?" I would think that I wouldn't want someone else 
to own th(~ sequence in the sense that I think you rc~ally 
have to get at it because I think we're going to get lots 
7 and lots of surprises. And we ought to go forward. 
8 Now, if you say, "Well, why until recently was 
9 all this controversy as to whether we should do it?" Well, 
10 I think common sense was that we should. I think the reason 
11 was that we talked about sequencing the human genome. And 
12 no one can really sequence it today, so it's not really 
13 a question of it's too expensive or we don't have the right 
14 techniques. And so as long as you see the sequencing, you 
15 see people wasting money, and knowing that the only people 
16 who are going to do massive sequencing are sort of idiots. 
17 And no one wants to see a group of idiots consuming a large 
18 fraction of the national budget. 
19 So it was probably very bad public relations, 
20 or at least confused the issue by saying that one is going 
21 to sequence it; whereas, in fact, one should say, "Who's 
22 going to map it?" and really a good high-resolution genetic 
23 map. And when you say that to people, I can't see anyone 
24 who doesn't want the genetic map. 
25 And that has to be done first, and it needs an 
Pike Court Reporting 
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1 organized program. So you're going to have to set up a 
2 program to do the map; whereas you got into all this controversy: 
3 Why spending all this money sequencing junk? which Joe Gall, 
4 a very intelligent person, managed to waste his time by 
5 writing that letter to Science saying that it was silly 
6 to sequence junk. 
7 The only problem is that you don't know where 
8 the junk is. So whereas it sounds sensible, now that you 
9 have introns and ectrons, and you don't know the borders 
10 between genes, it would cost more money to find out where 
11 the junk is than to sequence the genome. So that would 
12 be an even more ridiculous sort of effort, I think. You 
13 have to do the map. 
14 And not all -- you could say -- why do we -- what 
15 are the problems in getting the map? And I guess there 
16 are several and Charlie will really talk about it --
17 one is that we don't really know how to do it yet. But 
18 there are a lot of ways that might work. And I think the 
19 sort of perspective that we should have is that we really 
20 want the human map in roughly five years. 
21 If you said 10 years, really you will waste five 
22 not making real decisions. But if you say five years, then 
23 we will then have to even organize it and you will be sensible. 
24 And that says that if we get the map in five years, then, 
25 hopefully, someone will have clever ideas on DNA sequencing 
Pike Court Reporting 
16. 





That doesn't mean that we shouldn't try and sequence 
a couple megabase fragments because that probably won't 
inspire people to do it, and you'll actually find out the 
true cost. Everyone says a dollar a base pair, but I think 
6 it's really two if you look at it closely. And if you do 
7 it twice, it comes out to --you know-- you're up around 
8 $10 billion. And no one wants to spend that. At least 
9 I can't see the reasoning. 
10 The map -- if you can't do it for $200 million, 
11 we're really in pretty bad shape, which means three to five 
12 years effort. And we have to do three maps. And Charlie 
13 will say-- and I'll just emphasize too-- we really need 
14 the high-resolution genetic map. 
15 And there we have to, I think most of us, rely 
16 on Maynard Olson's experience from yeast; and he says you 
17 have better have a mark for every million base pairs. And 
18 so to do that, there are various estimates that will cost, 
19 say, $50 million based on how much it costs now, but maybe 
20 we could do it for less. 
21 What has happened so far has been fairly interesting. 
22 It really got off the ground only because of the Howard 
23 Hughes supporter, Ray White, in Utah. And, secondly, Collaborative 
24 Genetics spent some of their own money to do it in Boston. 
25 And they spent their own money only because some stupid 
Pike Court Reporting 
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study section at NIH turned down the application to pay 
2 for it out of NIH money under the theory that I guess it 
3 was dull repetitive work and didn't show intellectual sparkle. 
4 And so one has to have great respect and see the 
5 need for peer review committees but also to be aware that 
6 sometimes they make terrible decisions and generally don't 
7 think heroically, and sometimes rather pedantically, I think. 
8 So we're lucky that the Howard Hughes money was 
9 there to support Ray White and lucky probably also that 
10 Collaborative made the business decision and spent $10 million 
11 getting it going. 
12 The only problem is that we've got two competitive 
13 groups. And as everyone knows, we've got to get one map. 
14 And we're going to support both of these groups to go on, 
15 and we hope that they will integrate their data. 
16 If they don't, then we have to in some way, I 
17 guess, either decide to support one at the expense of the 
18 other or withhold the money until they get together. But 
19 I think that we should just assume that they'll get together, 
20 and we'll get the map. And in five years, we'll have it. 
21 Then we have to have the overlapping fragments 
22 and those nodels. And later whether that can be done by 
23 clever tricks involving cosmids, or whether YAC's would be the 
24 procedure is what we have to find out. And grants have 
25 been given out, and I would think there's a time frame of 
Pike Court Reporting 
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1 about Wlthin one to two years, we're going to have to decide 
2 what to push. And right now all you can do is push everything. 
3 But at some point, I think it would be irresponsible if 
4 you really think one method is much better than the other, 
5 just to support the other because it happens to be in some 
6 state. You want to spread the money around. It's nice 
7 to spread the money around, but on the other hand, we want 
8 to get the job done, and there's got to be some balance 
9 between actually seeing that someone can do it and then 
10 putting your faith in them and getting it done. 
11 Now, as to the organization of NIH, we have money 
12 first in fiscal '88, and now we have money in fiscal '89 
13 to the tune of roughly $30 million. And the projection 
14 and hope is that it will be above $50 million in fiscal 
15 '90, which should allow us to do quite a bit. 
16 Up to now NIH has just sent out -- sort of notified 
17 people that will support genome studies, and a lot of grant 
18 applications have come in and special study sections have 
19 existed, and the money has been passed out in the absence 
20 of any real plan for how to do it most efficiently. 
21 Now there has been created an office of genome 
22 research at NIH, and there's an advisory committee that 
23 has been appointed, and we're to have our first meeting 
24 on the 3 rd and 4th of January. And I would tell you th(? 
25 mc~mbPrs, but T can't because until they've all accepted, 
Pike Court Reporting 
1 there's some government rules that we can't announce them, 
2 and some of them are obvious, and I think it's a very strong 
3 and good committee. 
4 And the function of this committee, I think, is 





for how to proceed and get the job done, so a real plan. 
And at the NIH-sponsored meeting, and less than a year ago 
there was talk that we should have a rolling five-year plan 
and that we should update it every year. And I think that's 
a good idea. 
Now, it would be very simple if it was only NIH, 
but it's also parallel effort in DOE. And there's been 
a memorandum of understanding between the two agencies for 
a joint committee. And I would hope we will meet fairly 
soon. And since there is really one genome, I think 











having two plans. So this joint committee may be more important 
than the individual committees. I hope it is because that 
19 would indicate that we're working together. 
20 The money of NIH is -- we have an advisory committee, 
21 but there's no authority to give out the money, which now 
22 has to go through General Medical Sciences. If the money 
23 increases, we would hope that the authority will be given 
24 so that the genome office can make grants and contracts 
25 itself. 
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1 That's a big step because you really have to create 
2 a new bureaucracy. And you don't really want to get into 
3 it until there is sufficient money to justify it. But if 
4 the money goes up, then I think such an office will be created, 
5 and then this office will begin to really look at the study 
6 sections and probably give them more direction. 
7 And to use a term which frightens a lot of people, 














we're not giving a grant for $1 million to do what you please. 
We are saying that we're giving $1 million to get the coli 
sequence or someth~ng like that. I know that there are 
a lot of people for whom the word contract sounds -- smells 
of mediocrity. 
But a lot of this work is going to be, hopefully, 
routine. And it should be managed, and probably a contract 
is the best way. So I'm sure that there will be a lot of 
controversy to start with as to whether we should go to 
contracts or keep it all on grant money. It all depends 
on your contract offices. So it depends on whether your 
bureaucracy is good or bad. 
Besides the mapping, and something which really 




least to start with of the data bases which have been 
supported in a variety of ways by General Medical Sciences, 
by Howard Hughes. They were started when the problems were 
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1 relatively simple. And everyone has agreed that they're 
2 going to have to be totally reorganized. And who is going 
3 to handle them isn't clear. A bill was passed giving the 
4 National Library of Medicine considerable sums of money, 
5 and in a sense they're a natural body to have something 
6 to do with the -- at least the dissemination of the data 
7 once it is collected, and I think that may be the area where 
8 we're going to have to make firm decisions the soonest. 
9 On mapping, we don't really know how to proceed, 
10 but in something like a GenBank and so on, I think a major 
11 problem, which is how to give what is inherently very dull 
12 work -- interest very intelligent people in very dull work, 
13 which is sort of what data bases are. If you say, "Well, 
14 it's too dull for me to be worried about," then it's almost 
15 like nuclear power plants, they're in charge of people who 
16 know what intelligent would be in the control room waiting 
17 for a crisis which develops every 20 years. 
18 And we have a separate data base system for the 
19 protein sequences and for the nucleic acid and so on. And 
20 they have got to be put there, which means we somehow have 
21 to get people that everyone generally respect to make the 
22 decisions so that they will stick. 
23 If the decisions are made by ad hoc committees 
24 of people who really aren't that interested, but just show 
25 up, and then you decide whether GenBank has another year, 
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1 and on and on, and I think a lot of -- we could waste a 
2 lot of money. 
3 And I think that we have two things that we want 
4 to ask for and need a lot of money, but we really have to 
5 realize that it would certainly be irresponsible to other 
6 people if it could be pointed out that our research -- we 
7 give money to grants to people who wouldn't get it through 
8 an R-01 system. 
9 That's why I'm actually pleased that we have such 
10 a good advisory committee for NIH because I think that we 
11 can't stand as the conscience to see that this dull work 
12 is not done wastefully. 
13 Now, maybe the last thing I should say is that 
14 all our discussions of the relative roles of NIH and DOE 
15 all sounds like we're the only who are doing it; 
16 but, in fact, the project has excited enormous interest 







And other nations are go to be involved, and we're going 
to have to collaborate with a lot people. 
And toward that end, we've set up a human genome 
organization. Johns s is the head of it. And it's 
aim, I think, will be certainly to keep everyone informed 
of what everyone else is doing through holding meetings 
24 and, hopefully, actually to have an even more greater world 
25 for how to do t so that we don't get totally in a 
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1 competitive situation. 
2 I see no reason why within the United States there 
3 really has to be competition, I mean in a sort of nasty 
4 sense. Naturally, some groups will work better than others, 
5 and they will be rewarded by having bigger roles. But in 
6 the world we really have to somehow get together. And the 
7 first place that we're going to have to do something is 
8 on the data bases and seeing that they're set up. 
9 So I expect that I and I'm sure Charlie will spend 
10 more time than we want to going to meetings about seeing 
11 that the data bases are done correctly. 
12 Ideally, the cost of the project could be shared, 
13 one-third by Japan, one-third by Europe and one-third by 
14 the United States, or roughly some sort of thing. Whether 
15 this will happen, I don't know. 
16 We both, I guess, have a sort of fear, unless 
17 we act intelligently at least, that the whole sequencing 
18 end of the project will be done by the Japanese. On the 
19 other hand, when you get near them they say, "We don't have 
20 any money to do anything, much less help pay for anything." 
21 So I don't know what the final answer should be, 
22 but I think that if we're going to provide data to the other 
23 parts of the world that it should be reciprocal at least 
24 in terms of cost. We just shouldn't send all our genetic 
25 maps across the Pacific at the expectation that it's a free 








I'm sure that there will many tortured negotiations, 
which always have some reason for not succeeding. But I 
can just that we an work ther. And at the level 
of individual scientists, the Japanese that we know, we 
like and they're a sure to be with. 
7 It s just that everyone sort of expects that the 
8 United Sta tcs has paid for science, and NIH has paid for 
9 science, and they he the rest of the world. But the 





I think we've 
support. 
to work to try and actually get some real 
Europe, I think, will come together. There's 
an initiative in the EEC and ly, I would guess, would 
15 be the body that would final some money. 





of ethical issues, which I think are t because the 
l 
11 
i -- we 
thi 
f them wil rema 
And 
work to educa them as 
ion is go to tell us. Many 
matter how we try -- essentially 
go to have to constantly fight of 
a battle of who don't understand what we are doing 
23 or really don't want us to do what we are doing. 
24 And I think that we should, at the level of the 
25 nome program, pass out money, and I think it should be 
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1 one of the functions of our advisory committee as to how 
2 much, under the circumstances, to discuss the ethical issues 
3 through the holding of courses, through the writing of books, 
4 through mass meetings in one which talks genetic screening 
5 and what it means and doesn't mean. And who does your DNA 
6 belong to, the police or to yourself? These are important 
7 issues. 
8 Actually, at Cold Spring Harbor this week, we 
9 are having a meeting that I had to miss on DNA fingerprints 
10 with joint funding partly from legal bodies, or the police, 
11 and partly from the companies who are selling the fingerprint 
12 methods. And we have a federal appeals judge and we had 
13 some legal types to really come in to the question. And 
14 I think we're going to have to fairly soon have laws that 
15 at least define that if some of your blood is taken what 
16 rights someone else has to look at your DNA, not only to 
17 see whether you are actually the son of your parents, which 
18 could be great mischief if in the wrong hands. 
19 It would be silly to go under the assumption that 
20 since we now can screen for things, we won't be able to. 
21 And I feel very strongly that no screening should be done 
22 without someone's consent. And that's not as easy as it 
23 seems because many people give consent knowing not what 
24 they are doing. And, in fact, should you be asked to give 
25 consent? 
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1 If we found that schizophrenia was due to some 
2 transposable ailment or something which gets such high frequency, 
3 and we could really detect it, then you don't want someone-- you 
4 don't want the right before you hire someone to look at 
5 the person's DNA to spot the things that your group health 
6 
7 
insurance doesn't cover. 
We raised the ethics it was fairly interesting -- the 
8 ethics question in front of HUGO, and I was really amazed 
9 at some of the clinical geneticists, ethics was terrible. 
10 I mean really it was sort of a pain because you had to deal 
11 with ethicists, and they're a phony lot. 
12 But maybe we don't have to deal with ethicists. 
13 We have to become one ourselves. I think maybe rather than 
14 passing it off to other people, we need to become part of 
15 the discussions instead of thinking that we can hire ethicists 
16 who are going to solve the problems. 
17 The people in the room, I don't think that you're 
18 going to have to spend much of your time talking about ethics 
19 or thinking about it. But I think that at my level I'd 
20 better think about it a lot because we certainly don't want 
21 to mislead Congress. We'd better be very frank with where 
22 we're going. And I think that what we're doing is completely 
23 correct. 
24 But just the thought of all the complications 
25 of a national register of DNA, it sounds very good. Upon 
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1 apparently the time on that is running down, Charles, so 
2 you better make up your mind quickly. 
3 Dr. Cantor had the good sense to be born also 
4 in New York City, and then had his education at Columbia, 
5 undergraduate, and then took his Ph.D. at the University 
6 of California in Berkeley. He has had a distinguished career 
7 as a geneticist, and brings to the problem -- and the exciting 
8 initiative of the human genome project/projects, et cetera -- an 
9 extraordinary record of accomplishment and a promise of 
10 an exciting colleague for those of us at the University 
11 of California. 
12 Charles. 
13 DR. CANTOR: In trying to figure out what to say 
14 to you this morning, I called Jim last week in New York 
15 and asked him what he was going to say, and he said that 
16 he didn't know. So that made it a bit of challenge. And 
17 I think, as you'll see, I've guessed at least partly right 
18 in figuring out how to follow him. 
19 Jim has really painted a beautiful overview of 
20 the history of this project and stressed sort of really 
21 way into the future some of the ethical implications. 
22 What I'm going to try to do is to fill in the 
23 middle ground and try to give you a feeling, in a little 
24 bit more detail, for the scope of the project. What exactly 
25 is the Humane Genome Project? What does it entail? 
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1 If we actually look at such a chromosome by electron 
2 microscopy, rather than by a light microscopy, what you 
3 see is shown here. This is the protein scaffold that makes 
4 up the sort of core of the metaphase chromosome, covering 
5 almost the entire rest of the slide, probably not visible 
6 to anyone over the age of 40, but younger people can see 
7 little hints of single DNA fiber on the left. 
8 I estimate that on this slide, you're looking 
9 at somewhere between 50 and 100 million base pairs of DNA. 
10 So these are really incredibly large molecules by anybody's 
11 standards. Our goal is to learn the structure of a molecule 
12 like this. 
13 We can't work with these molecules today. The 
14 kinds of molecules that we'~e much more comfortable with 
15 are shown here. Jim actually mentioned bacteriophage lambda. 
16 This is a single molecule of lambda DNA. It's 50,000 base 
17 pairs long, give or take a factor of 2 or 3. This is the 
18 kind of material that we really can manipulate biologically 
19 today. This is the kind of stuff that we can clone, have 
20 as much of as we want to, understand the genetics of and 
21 so on. 
22 Now the problem in trying to describe the Human 
23 Genome Project is that we're crossing many, many orders 
24 of magnitude and size and dealing with a number of different 
25 descriptions on the human genome. And I'll try to define 
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order. And this is, I think, the area where the technology 
2 is in the greatest state of flux at the moment. And I'll 
3 return to that theme a few times. 
4 But this is still a physical map because you're 
5 dealing directly with DNA molecules. 
6 Now, the other type of map, which is really totally 
7 different, is a genetic map which for a human is a linkage 
8 map. You measure biotic recombination, that is you measure 
9 where the two inheritable markers -- Huntington's disease, 
10 blue eyes, or what have you -- where they are coinherited 
11 and passed from a parent to a child where they can separate. 
12 And we know, as Jim already mentioned, that the order of 
13 the markers on such a map is linear and must correspond 
14 to the same order as their gene on the physical map. 
15 Unfortunately, the relative distances along these 
16 two maps in the human, and in other mammals, is variable. 
17 It is the meaning of this that prior to gening things in 
18 base pairs can vary by a factor of 100 on different regions 
19 of the human genetic map. And this is a very serious complication 
20 which will have to be dealt with. 
21 A second problem is that recombination does not 
22 occur uniformally throughout the human genome. And so, 
23 in fact, the genetic map in many respects is a discontinuous 
24 map. It will have clusters of genes that are rather difficult 
25 to discriminate between genetically, followed by other clusters. 
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1 That's a major problem, and we need new technology to try 
2 to deal with that, and people like Dave Cox in the room 
3 are really in the process of developing that technology 
4 which could produce maps that are sort of almost hybrids 
5 between genetic maps and physical maps. 
6 Now, one of the other problems in thinking about 
1 these different types of descriptions of the genome is that 
8 they occur on very different size scales, and that's summarized 
9 for you here. The Human Genome Project overall, the goal, 
10 is to get a fine genetic map, complete your physical map, 
11 acquire the genome as a set of samples in freezer, clone 
12 DNA, or amplify DNA and determine the complete sequence. 
13 Find all the genes. 











in the human genome. Each one codes for a protein. Roughly 
half of these, as far as we know, are brain specific. 
we probably have no other way to get those genes except 
this type of global approach. It's rather difficult 
to do biochemical ,p_xperirnents on the human brain. 
And 
The goal is to find all the genes, and really 
the most important goal, and I think the goal that many 
of us have stressed since the onset of this project is in 
addition to getting all this information to develop the 
tools to use it for interesting biology in medicine. 
And that really means two things. That means 


























to have improvements in technology that allow us to do rapid 
comparative studies and to have parallel records on a series 
of different organs because a human is not an experimental 
animal. If we have a human gene, it's very difficult to 
35. 
do direct experiments to test what it does. So we need 
parallel studies o~ the mouse, Drosophila, even though Congress 
is probably less interested in those organisms, or less 
excited anyway, than they are in the human. And that's 
the goal of the project. And this project covers almost 
10 orders of magnitude in scale. 
And I want to quickly give you a feel for that 
because I'd like to convince you that the types of thinking, 
the types of information we're likely to get, and the types 
of technology that we need to work across these different 
areas vary tremendously because we're covering such a wide 
size range. 
So you'll find a model of the human genome as 
the earth as seen from outer space. That corresponds to 
the whole genome. On this scale, this is the genetic map. 
It's an aerial view of the city of Chicago, which I don't 
know if you can see these. So this is the genetic map. 
It's very interesting, but it's still fairly coarse. 
The physical map is about a factor of 20 in higher 
resolution. And you're now looking at Soldier Field in 
part of Lake Michigan. This is the physical map, but you 
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1 can't sequence directly from such a scale. This could only 
2 correspond to a typical clone, at least that's ready for 
3 sequencing. We're now down to the scale of about 5,000 
4 base pairs, and the actual sequence itself is represented 
5 by this, which is a lOx magnification of man's hand. So 
6 the problem with this project is that it covers a very large 







Now, there are several things about this project 
that I think are unique. And this slide is really made 
to -- more or less for a different audience, but I think 
it's -vmrth going through. 
Unlike most other large -- first of all, I should 
say this is biology's one large science project. Unlike 
36. 
14 most large science projects, this one is basically closed-ended. 






Unlike many large physics projects, I think that we can 
guarantee that the results will be interesting, no question 
about it. And that, unfortunately, has not been true for 
all large accelerators, right? 
I think we could also guarantee that an important 
21 new technology will emerge as the project proceeds. And 
22 the reason for this is that I think all of us have accepted, 
23 and Jim has really underscored already, that we're going 
24 to do this project as an evolving technology model. That 
25 is that rather than try to slam into the project with today's 
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1 technology, even though it is feasible, we're going to basically 
2 develop new technology over half a decade, and maybe the 
3 one percent of the overall project with at least sequencing 
4 with today's technology. And then, hopefully, with technolgoy 
5 in order of magnitude better do about 10 percent of the 
6 sequencing project. And then finally, maybe in 10 years 
1 from now, start the completion of the project with technology 
8 that we can't even anticipate today. 
9 The other thing that is unique about this compared 
10 to most other large science projects -- and this is really 
11 a challenge -- is that coordination of work at this first 
12 location is necessary. There is no particular reason to 
13 do all of this project in one place. And I think it would 
14 make it politically unsalable. 
15 So we have to coordinate it. And I think scientists 
16 are, by and large, individuals and not terribly used to 
17 being coordinated. And we need to develop some effective 
18 mechanisms of doing this. And I think that's probably the 
19 biggest challenge for the project. 
20 Let me give you a scorecard of where we are and 
21 where we are going. I think this is helpful in thinking 
22 about how far we have to go. This slide was made about 
23 six months ago. It's out of date. 
24 
25 
The largest continuous DNA sequence now known 
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1 it's 250 kilobase. It's about the same size as the smallest 
2 chromosome that has more or less all the goodies we think 
3 of when we think of what a chromosome is biologically, which 
4 is roughly a quarter of a million base pairs. 
5 The largest genome where we have a complete contiguous 
6 library and a fine restriction map, where we really have 
7 a good description, and probably the first genome that will 
8 be sequenced is the E. coli, which is .46 megabases. The 
9 largest autonomous piece of DNA, where we have any kind 
10 of complete map at all is just a little bit bigger than 
11 that. It's the largest S. pombe chromosomes, just under 
12 6 million base pairs and, in fact, we have a complete map 
13 of the S. pombe genome. And I think Maynard also virtually 
14 also has a complete map. So mapping is feasible on this 
15 size scale. 
16 But the human genome is 3 billion base pairs, 
17 and it's not so easily subdividable. The smallest human 
18 chromosome is 50 megabases. The largest human chromosome 
19 is a quarter of a billion base pairs and, unfortunately, 
20 these don't grow individually. 
21 A number of groups in the national labs have developed 
22 methods of sorting individual human chromosomes to hand 
23 you this. And if you could get enough of such material, 
24 it wouldn't be that much more romplicated than the yeast, 
25 but you can't get very much of it, unfortunately. 
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1 And people -- many people have developed methods 
2 basically of cloning human chromosomes in hybrid cell lines 
3 so that you have a single human chromosome living in a rat 
4 cell, or a hamster cell, but the problem is that you still 
5 have the rat or hamster's background so that these numbers 
6 don't look very much bigger than those numbers. It looks 
7 like almost a factor of 3, a stretch from yeast to human. 
8 But that's very misleading because this purified and this 
9 is contaminated with all of that. And working on human 
10 maps is much more difficult than working on yeast maps. 
11 And I'll come back and show you that. 
12 Now, the human genome is three gigabases, in the 













If you want a really large number, our goal in the long 
run is not to understand simply a single-reference human 
being, because that's basically almost useless, but we want 
to be able to compare human beings because that's how we're 
going to learn about interesting human diseases. 
And if you realize that there are 4 billion humans 
on the earth, and we differ each of us from another, at 
the average of 3 million base locations, if you multiply 
15 3 million by 4 billion, you get 12 x 10 , 12 picabases. 
That's the size of the data base we really need to describe 
human diversity. That's ultimately the information we want 
to get. And that is really tough. That is a long, long 
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2 
way off. That's a large data base from anybody's point 
of view at the moment. And to even dream about such data 
3 acquisition, we need to have vastly superior technology. 
4 Now, let me spend a few minutes just showing you 





and why a human is much harder than bacteria. 
There are basically two approaches. 'l'hey are 
called in slang top down and bottom up. This is the divide 
and conquer. This is the constructionist approach. 
10 In the top down approach you take a chromosome, 
11 you cut it into pieces, you figure out the order of the 
12 
13 
pieces. If you want more information, you take each piece, 
you subdivide it again, reorder it and so on. This is 











The bottom up approach, you take a principal randomly 
selected piece of DNA, you try to fingerprint them in one 
way or another, you find identifying marks on them, you 
look for correspondence between identifying marks, and you 
link up by finding such correspondences, adjacent clones. 
Such maps can be extremely detailed; at least in the beginning, 
they are very, very efficient to construct, but they are 
almost impossible to complete, probably impossible to complete 
for any higher organ. And, in fact, most of qs, I think, 
24 now feel that a combination of these two approaches is going 
25 to be what is effective for human mapping. 
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1 Let me show you just what this looks like at two 
2 extreme levels to try to convince you that humans are not 
3 bacteria. 
4 If you take the E. coli genome and you cut it 
5 into pieces, the genome is small enough and the pieces are 
6 big enough so, in fact, we actually can fractionate -- what 
7 you're looking at is separated DNA pieces ranging in size 
8 from 50,000 base pairs up to about l million base pairs -- we 
9 can separate every one of those pieces -- in this case the 
10 genome has been cut into just 22 fragments -- and making 
11 
12 
a map is simply determining the order of those pieces. 
critical thing is that you can see all the pieces. You 
The 
13 know how many there are. Putting them in order turns out 
14 to be relatively simple. 
41. 
15 If you do the same experiment with the human genome, 
16 the human genome is cut in the same way into 3 to 5,000 









that would allow us to subdivide the genome into a smaller 
number of discreet fragments. People like Dave Sigman are 
working on such techniques, but they're not functional today. 
And this is an area where great technology development is 
needed. 
Unless we have it, we're faced with the fact that 
we have to do a jigsaw puzzle with 3 to 6,000 pieces, and 
we can't see the pieces. So that makes it into a great 
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challenge. 
2 How do we do it? Well, we do it slowly and painfully 
3 at the moment. We start with the genetic map because that 












points for us that is based on the average about 10 million 
base pairs apart. The pieces that we can cut from the human 
genome are average about 1 million base pairs in size. 
We can take each gene whose location we know on 
the genetic map and use it as a physical DNA probe to identify 
the corresponding large DNA piece on which that gene resolves. 
And the trouble when we do such an experiment in coli, 
what happens is we link up the physical map, and it's complete 
because the genes are close together. 
In the human genome, the genes we know of today 
are far apart, and so these fragments are very distant 
16 from one another, and we have to somehow bridge the gap 
17 between them. 
18 And this slide is meant for a fairly technical 
19 audience, and I'm not going to go through it in detail. 






are difficult, but they all work. But I'll show you just 
a simple one because I think it really does represent where 
the future is going. 
These are large pieces of DNA that have been generated 
by cutting the genome with a particular enzyme. It turns 











out that it's possible to get now quite efficiently small 
small pieces of DNA that overlap to large pieces of DNA, 
that is they contain on them the same cutting site that 
generated two adjacent large fragments. Such linking probes 
can be used as analytical tools to identify the two large 
DNA fragments and prove they're adjacent. This turns out 
to be a rigorous and relatively effective method of making 
maps. 
I'll show you one example here for the human which 
I like particularly because it deals with molecules that 
43. 
11 are very, very large. 
12 This is data from chromosome 21. These are two 













by the same DNA probe. One of these fragments is 2.5 million 
base pairs, the other one of them is about 2.7 millibn base 
pairs. These are a different set of cell lines, and the 
fragments are the same in most cell lines, but not all. 
And this single probe then actually makes a map of two fragments 
that cover 5 million base pairs over more than 10 percent 
of the whole chromosome. So this is a very easy way of 
making a very low resolution map. 
Now, they probably need to think about over the 
next couple of years is how not just how to make a restriction 
map but how to actually make it in the order of a library, 
how to actually possess pieces of DNA in order in a form 
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1 where they amplify, where we have as much of them as we 
2 want. And a number of people have been thinking about effective 
3 strategies to do this. 
4 And many of those strategies boil down to this 
5 type of an approach in which you try to make a yeast artificial 
6 chromosome library of DNA fragments and make n complimentary 
7 small library of ordinary size clones, but these are linking 
8 clones, and so they overlap two adjacent yeast clones, and 
9 then in principle such linking clones could be used efficiently 
10 to tell you that two larger clones are adjacent. 
11 And if anybody could get this strategy to work 
12 in practice-- there's not at the moment-- then it would 
13 probably be a very efficient way to put a genome together. 











do this. Tony Carrano in the room has been developing effective 
fingerprinting methods for DNA fragments. Cassandra Smith 
and Sydney Brenner are both worried about efficient ways 
to actually do this step, which turns out to be very time 
consuming at the moment, and Bob Mortimer and Mike Esposito 
at Berkeley are looking at alternative ways to do some of 
this. So I think that this is an area where I agree with 
Jim that in the next year or two we're going to see explosive 
developments, and then we'll be able to make an evaluation. 
But there's a problem, and it's this: In any 
25 mapping project, and it's also true for sequencing, it's 






very easy to start but very hard to finish. And so I pose 
this question for you: How do you navigate if you have 
a map that somebody has erased 20 percent of the lines? 
It's very difficult, right? 
What do we do about that? Well, we don't have 
6 any answers at the moment, but I'll show you what the problem 
7 is. 
8 One of the major justifications for doing the 
9 Human Genome Project, for doing whole chromosome maps, whole 
10 genome maps, is an economy of scale. You have a chromosome, 
11 and you want to make a complete map, any piece you get from 
12 it, any clone you get from it to start with is as interesting 
13 as any other one. So you have a tremendous economy of scale. 
14 You don't have to do sorting. 
15 The moment that you are forced-- let's say we 
16 have a map that's complete except we have a hole in this 
17 region -- the moment you are forced to focus on one region, 
18 unless you have an efficient way to go into this region and 
19 cut it out, you're back to facing the fact that you have 
20 to sift through large numbers of fragments, most of them 
21 are uninteresting, but you've done the Hork anyway, and 
22 so the economy of scale is lost. And you're back to problems 
23 which even for mapping are too expensive to be realistic. 
24 So what we desperately need is some new technology 
25 that will allow us to focus, let's say, on a region of DNA 
Pike Court Reporting (805)658-7770 
45. 
46. 
1 that's of particular interest. 
2 
3 
Now, this is a realistic problem. This is a serious 
problem today, and it's because of the following: It turns 
4 out that a certain fraction of the human genome -- we don't 
5 actually know what that fraction is, but we know it's 
6 significant -- is not clonable. You cannot immortalize 
7 it in any vectors that we have today. It's not clear why. 
8 And so in any attempt to make a map, there are going to 
9 be segments that are simply not represented. Nobody has 
10 probes, nobody has clones. 
11 So how do you get into such regions and work 
12 with them? Well, I think the seeds of the technology arc 
13 there, but they need to be developed. 
14 One of the things that I'm interested in trying 
15 to stimulate at Berkeley is the development of methods for 
16 working with single DNA molecules because, in principle, 
17 if you had this molecule, and that was the region you wanted, 
18 and you had the appropriate micromanipulation methods, you 
19 
20 
would just go in and cut out that piece. And then you could 
use the PCR technique and several of the developers of 
21 that technique are in the room -- to actually amplify this 
22 material even if you couldn't clone it, you could at least 
23 have some of it to work with. So that's one possible wa;r 
24 that we're going to solve the problem of completing maps, 
25 but thZI t is just a speculation at the moment, zmd it remil in[; 
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1 to be seen. 
2 Well, let me turn now from the science to the 
3 organization. And these are the major players and how I 
4 see them in the U.S; NIH and DOE. The role of private industry 
5 is unclear to me at the moment. I'd love to hear more about 
6 it. I'm sure that the instrument makers are heavily involved 
7 in the Human Genome Project, or will be. But it's not clear 
8 to me that a lot of the large pharmaceutical companies are 
9 interested in this. There is tremendous foreign interest. 
10 It is my impression that thus far that interest 
11 is mostly intellectual. There has not been a large financial 
12 commitment on the part of most European countries today. 
13 Italy has probably been in the most advanced position in 
14 investing money except for the U.S.S.R., which apparently 











the Human Genome Project. I don't know exactly what that 
corresponds to in dollars, but it's a lot. It's a significant 
fraction of the U.S. genome project. I don't think that 
the U.S.S.R. has a significant fraction of the U.S. talent 
to go along with that funding right now, but we shall see, 
and HUGO is going to attempt to coordinate all of this. 
Let me spend just a couple of minutes giving you 
a sort of view of what DOE is doing. DOE loves organizational 
charts. And I just really want to point out to you two 
major things. DOE is supporting research today at both 






universities and industry and at the national laboratories. 
Roughly, at least in the future, the support ratio between 
these two types of projects is estimated at about somewhere 
between 1-2 and 40-60. So the majority of the funding will 
48. 
go to the national laboratories, but not by much. A significant 
6 fraction will be in extra [inaudible.] 
7 The work at both the national labs and universities 







All this is coordinated by the Office of Health and Energy 
Reseach which has an advisory committee somewhat affluent 
as far as I can tell to an NIH council. vvhat is new and 
slightly different about the DOE organization today is something 
that needs, and I hope will be coordinated with NIH, is 
something called the Human Genome Steering Committee. That 
15 is actually a committee made up of some of the major contractors, 
16 and it is designed to actually try and coordinate the science 
17 at a very intense level. How it will function remains to 
18 be seen, but it is just beginning to function, and in a 







And it's going to mostly function by setting up 
specific task forces to try to deal with problems like data 
bases. And I suspect that most of these will wind up being 
coordinated intimately with NIH activities, Hughes activities, 
and foreign activities. 
I want to stress what Jim has already said. There 
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1 really is only one genome project. There are many players. 
2 And the major challenge is how to coordinate all of these 
3 efforts. 
4 Now, I thought I'd just show you what DOE is actually 
5 supporting today. The large support at the national labs 
6 is mostly at three, Los Alamos, Livermore and Berkeley. 
7 There are smaller levels of support at Oak Ridge and Brookhaven. 














grant in Yugoslavia, and all the rest in the U.S., and then 
a number of companies, a number of small businesses have 
some smaller levels of support. That is the current program. 
DOE's budget for the Genome Project in FY '89. 
It was $18 million. It will probably be something around 
$28 million in fiscal 1990, we hope. 
This is the Human Genome Steering Committee, which 
I chair for the first two years. It consists of representatives 
from George Bell of Los Alamos, Tony Carrano who is here 
from Livermore, myself. It has ex officio representatives 
from OHER, that's EOE, Elke Jordan who is Jim's assistant 
at NIH, and Diane Hinton from Hughes. 
And its charge ... ~ and it remains to be seen whether 
22 it can live up to this charge is to coordinate at least 
23 the DOE funded effort striving for the same degree of cooperation 
24 and efficiency that would occur if everything was in a single 
25 location; obviously, it isn't. 




This committee actually exists. And to prove 
that, it has met once. This slide was kindly sent to me 
just last week by Tony Carrano, who I'm sure never thought 
I'd shmv it. This shows one of the great strengths of the 
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5 national labs. I think it's important to keep in mind that 
6 they have always had great photography. That is the committee. 













things look quite frightful. 
Now, let me spend a couple of minutes first seriously 
and jocularly talking about the differences between NIH 
and DOE. I think that both agencies are bringing to this 
project different points of view, and that there really 
is in the true Hegelian sense, that the opposites will actually 
complement and make a stronger project overall. 
I think one of the thihgs to stress Jim 
didn't say it, so I will is NIH really represents the 
people who by and large are waiting with bated breath for 
some of this data are mostly supported by NIH. And I should 
say theirs is a retrospective view. And Jim's comments really 
20 suggest that NIH will change and move a lot closer to the 
21 DOE view. 




most of its resources in relatively small aliquots, individual 
research grants. There is no question that NIH is very 
strongly committed to study a number of different organisms, 
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1 and not just human. And there's no question that NIH is 
2 supporting extensive high resolution human mapping. 
3 DOE is very comfortable with long-term large projects. 
4 It has mechanisms to coordinate efforts tightly, particularly 
5 those in the national labs. It's very strongly computing 
6 in engineering, which I think turn out to be major parts 
7 of the Genome Project in terms of technology that needs 
8 to be developed. And its emphasis at the moment is almost 
9 totally limited to human physical mapping and sequencing, 
10 not genetic mapping, not parallel studies in other animals. 
11 Both agencies, I think, are strongly committed 
12 to supporting technology development, which is the future. 
13 This is one way, I think to try to summarize what 
14 I've just said. DOE is strong in engineering and NIH is 
15 strong in biology. I think that no one would disagree with 
16 that. 
17 This is another way, I think, to try to illustrate 
18 both the organizational problems and the differences. DOE 
19 is putting a large amount of its funds into interdisciplinary 
20 efforts at the national labs, or relatively large programs 
21 in other places. NIH is supporting a lot of terrific biology 
22 and smaller programs which may combine instrumentation and 
23 materials. But it was unlikely, at least in the past, to 
24 combine all of these at a single location. 
25 And there are advantages to this. It allows for 
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1 a much higher probability of innovation. And there again when 
2 you're trying to get a boring job done, it helps to have 
3 a structure like this to do it. 
4 Let me turn back to science for a second. I'm 
5 trying to decide one piece of science to highlight, and 
6 naturally I will choose something that's related to something 
7 that we're working on. 
8 But this starts from, I think, one of the most 
9 interesting things which has emerged in the Human Genome 
10 Project in the past year is a discovery by Bob Moyzis 
11 Los Alamos of a DNA probe that detects the end of the chromosome 
12 of all higher organisms, that's both its strength and . .._ l t.-S 
13 weakness. It detects the ends of the chromosomes in a human 
14 cell, in a mouse cell, a hamster cell or what have you. 
15 Unfortunately, in the hamster it also detects centromeres, 
16 which makes it not so useful in the hamster. 
17 Now, this is a great probe, but the trouble was 
18 that it looked at every organism. It was not human specific. 
19 And to actually take advantage of this for human studies, 
20 it was necessary to try to find a probe like this that would 
21 be human specific. And we were able to find such a probe 
22 in the last few months by using Bob Moyzis' approach. 
23 And the scheme which we used is a very simple 
24 one. We gambled that if we took half a yeast artificial 
25 chromosome and demanded that it lie in a free-living form 
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1 that we could compl~ment its missing head with the end of 
2 a human chromosome. If we had a bottle containing the ends 
3 of the human chromosomes then we could select these out 
4 of the bottle and clone them in yeast. Because we gambled 
5 correctly as it turns out, the human genome telomeres would 
6 be functional in yeast. 
7 And so we've actually fished out clones, and 
8 this is one of them which have on their end Bob Moysiz's 
9 repeating sequence still in yeast, so we know where it came 
10 from. 
11 Fortunately for us, the first clone had a human 
12 ALU repeat, the kind of thing that Carl Schmid studies here, 







not exist in yeast, and we were very lucky because this 
region turned out to be a human specific -- at least in 
most, if not all, human chromosomes the human specific 
DNA sequence, which we're beginning to characterize in some 
detail. 
Why is this so important? Well, if you're going 





is not knowing left from right. Since we can't see the 
molecules, as you start to map you don't know \vhat direction 
you're going in. The only way that you would know what 
direction you were going is by starting at one end. If 
53. 
25 you start at one end, the maps are unequivocal, and in roughly 
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1 10 percent of the effort you can at least creep about 20 
2 percent of the way down a chromosome. And so by having 
3 such clones we now have the ability to start from chromosome 
4 ends. And I think it's going to make things much simpler. 
5 And, of course, the ends are biologically interesting. 
6 Now, in the last few minutes let me start with 
7 why we do this, what's coming out of it and where we are 
8 going in the future with this project. 
9 The most interesting reason to have high resolution 
10 physical maps is to find genes. We have a physical map 
11 if we actually possess the DNA in this region. What the 
12 genetic map tells us is that Gene B is between Gene A and 
13 Gene C; if we're lucky, we can combine some information 
14 about where in between. 
15 But, frankly, in those cases as you really bump 
16 
17 
the resolution up, it doesn't tell you where. 
you that it's in between. 
It just tells 
18 But with the physical map, which after all is 
19 10 or 100 times more detailed, you begin to know where to 
54. 
20 look for Gene B. The problem is that there's a lot of uncertainty 
21 in where this is. And as I mentioned earlier, techniques 
22 like those that Dave Cox is developing may start to cut 
23 down on that uncertainty considerably, but right now it's 
24 a real mess. 
25 How do you know when you've found the gene you're 
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1 
2 
looking for? Well, that depends on what disease alleles 
you have that correspond to that gene. If you're lucky, 
3 there will be disease alleles that represent cataclysmic 
4 rearrangements of the DNA of the genome, translocations, 
5 deletions, insertions, something major. 
55. 
6 This shows, for example, the case of Duchenne muscular 
7 dystrophy where roughly half of the known disease allele 
8 are large deletions; and, furthermore, the gene is gigantic. 
9 
10 
It's 2 million base pairs. So the gene is of the same order 
as the resolution of the qenetic map. So in the case of 
11 Duchenne dystrophy once you're in the neighborhood of the 
12 gene, you're in the gene. And you know it because the disease 




and you know that you are there. That's the great fortunate 
case, and I fear it's not going to be all that common. 
remains to be seen. 
It 
17 The more usual case, the case we're almost truly 
18 up against is Huntington's disease, cystic fibrosis, with 
19 many of the others that we're interested in is that the 
20 disease represents a single base change. 
21 This presents the following problem: Genetics 
22 will locate if we are today to within 10 million base pairs. 
23 If we're lucky, eventually to within 1 million base pairs. 
24 Maybe if we're extremely lucky, and there's not too much 
25 linkage to [inaudib~]within the region, to 10 percent of 
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that we know of today in genetics. 
Jn this reqion, there will be 100 to 1,000 DNA 
polymorphism. Actually, I shoulcl mention bcfon~ l <JO on 
that there is a sort of super genetics, which is potentially 
available from the recent work that Norman Arnheim has done. 
And if that proves to be generally applicable, it may allow 
8 us to go from 1 million base pairs to a tenth million base 
9 pair resolution providing that linkage to [inaudible] 
10 does not get in the way in that region. But there are real 
11 possibilities of technical advances here. 
12 But even so, even if you shrink it to a tenth 
13 of a megabase, there will be 100 to 1,000 DNA polymorphisms 
14 1n that region of the genome because we vary, 1 in every 
15 1,000 bases. And of these 100 to 1,000 DNA polymorphisms, 
16 only one of them is responsible for the disease. The others 
17 are just noise. 
18 To actually prove that we found the disease allele, 
19 the only sure way to do it is to sequence the region and 
20 look for the single base variation that correlates with 
21 the disease. And what you have to do is sequence lots of 
22 individuals. There will be many, many differences. One 
23 particular difference will show a 1-1 correspondence with 
24 
25 
a disease. You have the 'c' every time you have the 
you don't every time you don't. 
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mean this means that you're doing millions or tens of millions 
of base pairs of sequencing every time you're trying to 
find a disease gene. And that either requires much faster, 
much cheaper sequencing technology. It's one of the major 
forces, I think, which is really driving this project. We 
can't do this kind of thing -- I mean with cystic fibrosis 
8 we're actually in this position. We have the gene -- not 
9 me personally -- people have the gene localized to about 
10 800,000 base pairs, but nobody can conceive of doing 8 million 
11 base pairs of sequencing right now to try to prove that 
12 we've got the gene. 
13 There is another approach -- and Rick Meyers in 
14 the room has been one of the innovators of it -- and that 
15 is that you may not have to sequence all of this region 
16 if you have specific ways of trying to look just at the 
17 bases which vary, you might be able to focus in on those 
18 one at a time, or in groups, and not have to actually repeat 
19 this kind of massive test. That remains to be seen. 
20 Now, what's going to happen from the Human Genome 
21 Project? At the end of it we're going to have 3 billion 
22 base pairs of sequence. And I want to dwell on that a bit 
23 because it's a very large amount of information. 
24 To put it into the scale for you, perhaps tangible, 
25 if you wrote it out in the same size type as the Manhattan phone 
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book, it turns out that it would fill 200 volumes of 1,000 
pages each. That is what it actually takes to write out 











today, the whole world supply of DNA sequence is one telephone 
book, or roughly equal to the yeast genome. 
10 
So we have to expand our data base by a factor 
of 200. And, clearly, in doing that, we have more than 
just a managerial task, we have an analytical task. 
And I think that one of the areas where enormous 
advances need to be made -- and there are a number of people 
11 in the room who worry about such problens already -- is 
12 ~n fast multiple text matching. 
13 What's going to happen progressively through the 
14 Human Genome Project is someone will sequence a region and 
15 want to know whet. her it's interesting, vmn·t to know whc· t \tl' r· 
16 somebody r;hould immediately follow it up biologically or 
17 just store it into an archive and forget about it for the 
18 moment. 
19 And the way we do that is we compare it with all 




that we understand and ask: Does it match? But the way 
we do that is tremendously crude. We tend to match text 
tv10 at time without any regard for their meaning. And we 
24 need methods which will do that faster, will make multiple 
25 comparisons, and will consider the meaning of the text and 
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1 not just the raw text itself. And I think that as we develop 
2 methods to do this, which are not so simple, these methods 
3 will have a major impact on other problems where a large 
4 amount of text has to be analyzed rapidly, problems having 
5 nothing whatsoever to do with biology. 
6 Now, let me talk for a moment about the meaning 
7 of the text. What do I mean by that? Well, raw sequences, 
8 just alphabets -- a, t, g, g, c, c -- but we know several 
9 things about it. We know that sequence is expressed in 
DNA structure. DNA is not a constant bordering helix. It 10 
11 bends, it rides, it does all kinds of things. People like 
12 Dick Dickerson in the room have been making their living 
13 on this for the last few years. And we now know that certain 
14 types of bending or arriving may be important in control 
15 of gene expression. 
16 But nobody has really developed a methodology 
17 yet for combining our understanding of DNA structure and 
18 this text matching. 
19 At the much more sophisticated level, we know 
59. 
20 that genes come from proteins that follow up in three dimensions. 
21 And three-dimensional structures are much more conserved 
22 than the text itself. And if we had better ways to guesstimate 
23 what those three-dimensional structures would look like -- that's 
24 a very, very difficult problem -- we'd be able to analyze 
25 this text much better. 
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1 Let me show you an example now -- a practical 






It was made for a different audience. 
message literally. 
So don't take the 
These are three texts. Text 1 and Text 2 differ 
or have 23 out of 35 units the same. Similarly, Text 2 
and Text 3 have 25 out of 35 units the same. So in this 
8 way that we score text comparisons today, we would say these 
9 two are as similar as those two. And if you read the text 
10 
11 
it says, 11 I know NIH shouldn't be a lead genome agency. 11 
"I feel DOE should be the lead genome agency. 11 11 I feel 
12 DOE should study lead genome toxicity." Clearly, these 
13 two are related in a way that those two are not. 
14 I really want to stress though that we can't do 
15 this today with DNA sequence information. We don't know 
16 hovl to do this kind of comparison. So we have a long way 
17 to go. 
18 In the last two minutes, or three minutes, let 





believe that in the next five years these kinds of advances 
will be made in terms of technology; essentially, automated 
genetic mapping rather than the type of manual techniques 
that are being done today. Automative high-speed DNA sequencing 
24 is rapidly upon us. Automative physical mapping, computerized 
25 image scanning and analysis, protein structure prediction, 
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1 at least better than we do today, improvements in manipulating 
2 and cloning large DNA and multiplexy tricks that will enable 
3 us to analyze many samples in the same tube rather than 
4 one sample at a time by George Church's sequencing technology. 
5 What's this going to do for us when we have this? 
6 Well, DOE I should say is supporting work in all these areas; 
7 and to be perfectly honest, NIH is also supporting work 
8 in all of these areas. 
9 Data bases and clone maps. We're going to get 
10 two types of things from the Genome Project, and it's important 
11 to realize that we get them both. We're going to get technology, 
12 vast improvements in technology. Once we have it, it's 
13 applicable to all living species, not just to humans. So 
14 I think one of the major fallouts will be in agriculture, 
15 and that will also lead, I think, to substantial improvements 
16 in handling data and samples which probably will have a 
17 major impact in places like supermarkets, as well as the 
18 Genome Project itself. 
19 The samples and the data are key because once 
20 we know the sequence of a single human genome, it allows 
21 us to have access instantly to any region of the human genome 
22 we want using the ability to amplify with PCR, any piece 
23 of sequence gives us the gene, gives us the material to 
24 do experiments with in humans. It gives us the equivalent 
25 genes in other animals if they're there. 
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So this is really an enormous resource, and it 
2 will form a basis of probably the next 100 years, or part 
3 of the next 100 years, of research and development. 
4 To say it in a slightly different way, the instruments 
5 that are qoing to be developed as part of the Human c;,~nomo 
6 Project will be instantly usable in diagnostic testing. 
7 The methods development will be applicable to a host of 
8 plant and animal species of commercial importance. The 
9 data base design the major problem that we have to start 
10 with and coordinate -- I agree with Jim completely on this, 
11 it's where we have to begin. 
12 Designing a data base and implementing it with 
13 the peculiar needs of the Genome Project requires solving 
14 a number of problems in computer science and informatics 
15 which are going to be broadly applicable to other fields. 
16 And, finally, to clone DNA samples will eventually le~d 
17 to, I believe, improved pharmaceuticals because if we were 
18 to understand the gene involved in many serious diseases, 







Let me close with one specific example which gets 
very much to the heart of the first problem that faces us 
because today we pretty much have a Tower of Babel. There 
are a whole bunch of different data bases. They don't talk 
to each other. They run on different hardware. They run 
on d i ffen•nt soft_ware. Some of thc•m --God hc~lp us ---- <1n' 
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2 
not documented. It's a mess. 
We need to have what I think probably Tom Marr 
3 in the room first called a human genome work station. We 
4 need to have a package of software and hardware that sits 
5 on everybody's desk who is interested in this project, can 
6 address any data base regardless of what it looks like, 
7 contains all the tools you need to integrate and manipulate 
8 a variety of genome data. And since none of us are going 
9 to be monopolistic, this data base has to run on a wide 
10 variety of different hardware. 
11 We would like it to allow the user to see the 
12 same screen wherever in the world he or she is. And also, 
13 because we're all individuals, we would like it to allow 
14 the user to be able to customize it. 
15 And the typical problem that we get into -- it's 
16 a marvelous problem in the Huntington Disease Collaborative 
63. 
17 Research Project, which a couple of us in the room are involved 
18 in -- every lab uses different nomenclature. You use your 
19 own names for your own DNA samples. When you try to get 
20 together in a room and discuss the work that you're cooperating 
21 on, you're talking a different language. 
22 And it's extremely difficult when you-- it's 
23 very easy if you have two DNA probes. You agree on a name. 
24 When you have 40 DNA probes, or 400 DNA probes, and you've 
25 been working with them for three or four years, it's very 
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difficult to get people to learn a new language. 
2 So we need the types of data bases that will automatically 
3 translate from our local language, that we're not going 
4 to give up I fear, to a global language that can communicate 
5 between laboratories. We almost need computer translators 
6 in order to be able to work with them. 
7 And there are two aspects to this. The first 
8 is that someone needs to take this very coarse description 
9 and firm it up. In terms of writing the specifications, 
10 \lhat do we all want? And it looks like there is about to 
11 be created a joint DOE, NIH, Howard Hughes committee to 
12 try to do that, which would be a very great start, at least 
13 for the U.S. And I hope that group will have foreign representation 
14 so it will sort of encompass the world at the same time. 
15 That's the easy part. It's just politics. People 
16 have to decide what they want. 
17 Once we get past that part, then there's a much 
18 more difficult challenge -- and you may hear about that 
19 later from other people this afternoon but how do you 
20 actually implement it? Because to say "I want this" is 
21 easy. To say "Can we do this with current computer technology?" 
22 I think the answer is, "Yes," but it's not a trivial problem. 
23 Finally, I want to close with almost the same 
24 way that Jim closed -- not quite -- the Human Genome Project, 
25 what do you do about the 90 percent which is garbage, the 
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1 90 percent of the text that we can't interpret today? Well, 
2 I love this quote from Sydney Brenner-- I think that's 
3 correct to attribute it to him -- and that is that this 
4 extra stuff in the human genome is not g~rb~ge, it's junk 
5 because garbage you throw out and junk you keep. So the 
6 human genome has kept all this stuff, so it must be there 
7 for a purpose. 
8 First of all, there are some people interested 
9 in this garbage. The human genome has 500,000 copies of 
10 a short-repeated sequence. Carl Schmid in the room has 
11 been studying that for many, many years. And it contains 
12 interesting clues about human evolution. So it's not just 
13 junk. 
14 I agree with Jim, today we don't knou enough to 
15 be sure what's junk and what's not junk. It would be reckless 
16 to simply throw all this 90 percent aside. 
17 Furthermore, even if we knew for sure, we don't 
18 really have easy methods right now to sort the junk from 
19 the good stuff. And so at today's cost, in terms of sequencing, 
20 I think nobody is going to sequence 500,000 repeated sequences 
21 that are all the same except for a few bases. There's simply 
22 no one that is going to take on that project voluntarily. 
23 But as sequencing becomes much more automated, 
24 I think people will become more enthusiastic about prowling 
25 through the junk. And I think that when they do so, there 
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1 will be some interesting surprises. 
2 I think with that I'm going to stop. I hope I 




DR. KREVANS: To show you the effect of the adv,1nccd 
6 technology that is a part of anything we do about the Human 
1 Genome Project, unbelievably, we're right on time. We'll 
8 have a 15-minute break. We'll reconvene at 11:00 o'clock. 
9 










DR. KREVANS: The final paper this morning lS 
on the status of federal legislation and appropriations. 
7\nd we arc n~ally very lucky that. we rwve sorn(•onc: who <tetually 
knows something about it as opposed to someone who will 
criticize it. There are plenty of people available for 
criticisms of federal policies and appropriations available, 
but relatively few who know something about it. 
Robert Cook-Deegan is currently a Senior Associate 
20 with the Office of Technology Assessment. As I remember, 





DR. COOK-DEEGAN: I'll get into it. 
DR. KREVANS: Yes, he's got two jobs. Everyone 
has two jobs. He was educated at Harvard College in his 
undergraduate school, and took his medical school degree 
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1 at the University of Colorado, was trained in the clinical 
2 specialty of pathology and then was a post-doctoral student 
3 with Erikson on the molecular biology of retroviruses, and 
4 did some interesting work in the early understanding of 
5 the biochemistry and the enzymes in the energy systems of 
6 the oncogenes. 
7 Following that, his career has taken him more 
8 in the direction of an analyst and someone who understands 
9 and studies public policies, ethics, the interaction of 
10 those, working at the Kennedy Institute, as well as in the 
11 Office of Technology Assessment. 
12 So it's a great privilege to introduce Dr. Robert 
13 Cook-Deegan. 
14 DR. COOK-DEEGAN: Thank you. 
15 Again, my name is Bob Cook-Deegan. And for the 
16 rest of this week I work at the Office of Technology Assessment, 
17 OTA. 
18 The reason that I'm here really is principally 
19 because OTA did a study of federal policy relating to human 
20 genome initiatives that began about two years ago and culminated 
21 in the release of a report in April of this year. 
22 We get into the act, typically at OTA, when there 
23 is a policy question relating to either science or technology 
24 that is clearly going to be a congressional concern. That 
25 usually means that it's going to last for a couple of years 
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1 and that it's likely to be fraught with some controversy 
2 with lots of different opinions about how some things should 
3 be done or how much of some things should be done, or questions 
4 of that nature. 
5 It became clear in the middle of 1986 that the 
6 Human Genome Project meant many different things to many 
7 different people, and it was causing a lot of controversy 
8 since there were two federal agencies involved already at 
9 that point. 
10 In what was by then already beginning to become 
11 a major topic of discussion in biology, it was immediately 
12 apparent that Congress was going to have to get involved 
13 because Congress is where budget decisions are made. And 
14 when there are two agencies in separate departments of the 
15 federal government, there are only two places where those 
16 can meet, one is in the Executive Department, which is essentially 
17 the President, and the other is in the Congress. 
18 And in recent years, in fact, most science policy 
19 decisions have been made by a combination of the Office of 
20 Management and Budget, which is under the President, and 
21 the Appropriations Committees of the U.S. Congress. 
22 The history of biomedical research, in fact, is 
23 very largely the history of Congress kind of forcing money 
24 
25 
down the throats of the executive agencies. That's my perspective 
as a congressional employee. That's one reason I'm here. 














There's a second reason that I'm here that grew 
out of the OTA project, and that's that I'm currently doing 
a kind of-- it's not an informal-- but it's almost a 
verbal history that will soon be written down into a book. 
The Sloan Foundation has given me a grant to record the 
politics and the science of the early genesis of Human Genome 
Projects. 
half time. 
So I've been doing that since June of this year 
And relating some of the questions that both 
Dr. Watson and Dr. Cantor have raised earlier this morning, 
sometime next week, I'll be starting a new job. It's for 
the Biomedical Ethics Advisory Committee and the Biomedical 
Ethics Board. This is a new congressional entity whose 
69. 
14 mandate is to look at ethical questions in biomedical research 
15 and in health care. 
16 One of the topics that that committee has to deal 
17 with initially is the topic called "human genetic engineering," 
18 which is being interpreted by the committee to include gene 
19 therapy, use of genetic diagnostic tests -- both medically 
20 and nonmedically --and also following what's happening 
21 in the Human Genome Project because a lot of people in Congress 
22 are interested in it but are concerned about the ethical 
23 implications of mapping the human genome. 
24 What I would like to do I was going to show 
25 some slides, and I'm not going to do that now since I think 
Pike Court Reporting (805)658-7770 
70. 
1 most of what I was going to say on the slides has already 
2 been said more eloquently by somebody else. 
3 What I think is probably the most useful for me 
4 to do now is to talk about kind of the national context 
5 for human genome projects. And I won't take the scientific 
6 point of view or the technological point of view because 
7 I think those have already been articulated to some degree. 
8 What I would like you to do is transport yourselves 
9 into being a member of the U.S. Congress or into being a 
10 high-level administrator in NIH or DOE or some other executive 
11 department that has something to say about genome projects, 
12 and think about: Why would you be interested in this project 
13 or set of projects? 
14 It seems to me that there are principally five 
15 things that you'd be worried about on the one hand, or very 
16 supportive of on the other hand. 
17 The first thing -- I think the first reflex of 
18 most people in Congress is to support the science. They 
19 don't fully understand the scientific implications, but 
20 they hear from the experts, the best experts, that having 
21 a map of the human genome is very important to understand 
22 the human genetic disease and, in fact, just to understand 
23 other diseases that are not necessarily genetic. 
24 
25 
That has obvious implications. That's the main 
basis for the rather generous support of biomedical research 
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in the United States compared to any other country in the 
2 world. So there's a reflex to say "Yes, this is a very important 
3 thing to do." And I think the fact that both the DOE and 
4 NIH budgets have been relatively unscathed in the last couple 
5 of years in times of great fiscal austerity is testimony 
6 to the fact that people in Congress and in the executive 
7 agencies think this is very important. 
8 There's a second line of support for anything relating 
9 to biotechnology. And that is the economic implications 
10 of human genome projects. The thinking there seems to be 
11 that work on human genetics is related to biotechnology. 
12 And biotechnology at least eventually is going to be related 
13 to jobs and wealth. And if you're a member of Congress you 
14 care about your district, you care about what you're paid 
15 to do is to represent the people in your district. And what 
16 they care about most is how they're doing. And jobs and 
17 wealth are the things that are on the top of that list. 
18 The linkage is not very direct, but that is something that 
19 is in the front of most people's minds as they're making 
20 decisions about human genome projects at the federal level. 
21 There's a third issue, and that's national pride. 
22 And this is, in fact, driven some of the decisionmaking in 
23 Washington; that is, there are lots of arguments about if 
24 we don't do it then the Japanese are going to beat us or 
25 the Europeans are going to beat us. And those arguments 
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1 actually play relatively well for short periods of time. 
2 Generally, you eventually get down to making judgments about 




of something you're ing money on. But you don't have 
to necessari do that initially. 
The fourth concc~rn relates to i:hE~ other three. 




in Washington for the next year is going to be the deficit. 
And now that the election is over I shouldn't say election, 
the multiple elections -- members of Congress also worry 
11 about things on a two-year cycle. The President worries 
12 about things on a four-year cycle. And all the cycles have 
13 stopped simultaneously now. So what you're going to see 
14 in the next year is that people will worry less about ng 
15 elected and more about managing the government. And that 
16 is going to thrust the deficit problem right to the top of 
17 the list. 








in it's coming out of its embryogenesis and real into its 
fetal s right now, I think. And it's coming to that 
s at a time when there are tremendous pressures to restrain 
federal spending. And I, frankly, don't know what's going 
to happen. But that is a major concern for anybody in Congress. 
The fifth area is the social and ethical implications 
of human genetics research. Dr. Watson has already mentioned 










a lot of the things that people in Congress are worried about. 
They're worried about people being able to get insurance, 
the use of genetic information for insurance purposes for 
hiring and firing decisions for eligibility for federal programs 
or non-federal programs, the criminal investigation uses -- that 
is forensic applications. They also worry about the costs 
of the medical uses of a new technology. And perhaps more 
important than all of those is the spotty history of the 
9 use of genetics in politics. And here I'm referring to 
10 eugenics. 
11 Most people in the audience think that the issue 
12 of eugenics was something that happened early in the 20th 
13 century and went away. That is, in fact, not the case. There 
14 are people in prison in Malaysia right now that because of 
15 their beliefs relating eugenics. In fact, the Prime Minister 
16 of Malaysia right now is a -- what would at the turn of the 
17 century have been classified as a classical eugenecist; that 
18 is, he bases theories of race and justifies those in kind 
19 of a pseudo-scientific jargon. 
20 But that history does overlay human genetics, and 
21 it's something that people in Congress worry about. And 
22 I think that what you're going to see in the next few years 
23 is that all these five major interests are going to be thrown 
24 into the same pot. And in the usual chaotic American mode 
25 something will come out at the other end. And I'm, frankly, 
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My guess is that the projects -- well, let me finish 





go on because I don't want to leave it on a negative note. 
Frankly, most of those social and ethical implications 
have nothing to do with the Human Genome Project. The Genome 
Project is the creation of information. And almost all of 
those issue relate to the use of that information and are, 
in fact, things that are part of the normal social fabric, 
and they are things that legislatures are well prepared to 
deal with. Who has access to this or that thing? Who owns 
this or that thing? Those are legislative questions. Those 
are legal questions. The system of government is actually 
14 pretty well prepared to deal with questions of that sort 





The creation of the information is really on separate 
And the only question that has been raised to date 
is: If this information is going to be abused, why would 
19 we create it in the first place? But, generally, that sort 
20 of argument doesn't go very far because most people in policy-making 
21 positions understand the distinction between generation of 
22 information and its use. That is, again, a distinction between 
23 discovery and application. 
24 The final thing I wanted to talk about -- although 
25 it has nothing to do with the legislative status these days -- is 










the management prospects for genome projects. You've heard 
about the DOE and NIH efforts to organize the projects. I 
think, actually, if you compare development of the genome 
projects in the United States to development of any other 
biomedical research program. 
frankly. 
It's been remarkably efficient, 
Two years after the beginning of discussions about 
how much controversy there was about genome projects, NIH 
and DOE seemed to be living somewhat compatibly on the same 
10 planet with the same budget mechanism and, in fact, have 
11 a piece of paper that you can point to and it say, "This 
12 is how we're going to cooperate." And that has resulted 
13 in things happening in the real world. 
14 If you follow the history of a project within NIH, 
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15 that's not always the case. And that's within a single executive 
16 agency. 
17 There are, nonetheless, going to be lots of complicating 
18 factors. And Dr. Watson and Dr. Cantor referred to this. 
19 So far France, Italy and the U.S.S.R. have got pieces of 
20 their federal budget, their national budget, devoted to genome 
21 work. The Japanese government is now kind of in the stage 
22 of trying to formulate its policy. 
23 There's a lot of talk from people in the four major 
24 research agencies in Japan about who's going to take the 
25 lead. It's kind of the debate that was going on here two 
















years ago. It's going on right now in Japan except that 
in the United States it's done on the pages of Science and 
Nature magazine. In Japan we'll probably only know about 
it when the results are pretty well established. 
One overarching comment about the level of effort, 
however, is in order. The U.S. effort right now is at $50 
million this year, and it sounds like it will be somewhere 
around $80 million next year, and maybe even higher than 
that. That totally dwarfs all the other efforts put together 
from all the other nations. It's probably more than double 
that all other nations are going to put together in the next 
years. Perhaps it will change over time. 
But one thing about the international efforts is 
they are much more difficult to coordinate because there 
is no point where all decisions converge as there is in one 
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16 government. And HUGO is, I think, the only hope for fulfilling 
17 that role. But I'm not sure that unless it's fiscally healthy 
18 and has some sort of agreement from the various governments 
19 to cooperate with its planning efforts, I'm not sure how 
20 that's going to work out. This is totally unprecedented 
21 in biology that there would be a concerted well-planned effort 
22 involving more than one nation. There are examples in other 
23 sciences, but the history of their success is somewhat spotty. 
24 A final comment on the international aspects of 
25 the genome project. I think the key issue there will data 
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1 sharing. And I think there is widespread agreement among 
2 the scientists of all nations that data should be shared. 






scientific value. And there is a tendency to blur distinctions. 
It's very clear that scientists left to their own devices 
would share journal articles and the sort of normal pieces 
of scientific communication. It's less clear that they would 
share data base structures, but that has been done with some 
9 success in the cases of GenBank and, in fact, in the RFLP 
10 mapping efforts, the efforts of CEPH have been really pivotal 
11 in keeping the groups doing RFLP mapping unified at least 
12 to some extent. 
13 So there is some hope for cooperation at the data 
14 level. It's equally clear, however, that governments to 
15 the degree that they see investment in genome projects as 
16 an economic investment see this as a way of creating new 
17 instruments, new technologies, new ways of making products. 
18 And that's going to be an area where economic nationalism, 
19 I think, will be the norm. 
20 And the game will be to try to separate the data 
21 gathering and data sharing from the commercial aspects of 
22 the human genome projects because it's clear that on one 
23 hand there's going to be competition; on the other hand, 
24 there's an agreement that there should be cooperation. 
25 But the decision-making apparatus in the United 




States are very different from what it is in most other 
nations. 
around 
The people in this room today are -- as I look 
principally scientists. And, in fact, scientists 
4 have a great deal of power over the decisions over spending 
5 money for science in the United States. They have a much 
6 greater degree of control over spending in the United States 
7 than in most other nations. And particularly in Japan, most 
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8 of the role of the government is in influencing private corporations 
9 spend their money. It's an indirect role rather than a direct 








Japan much more difficult to explain some of the difficulty 
of the Japanese government being able to say, "Yes, we'll 
pay for this or that thing." They don't do that in any area. 
And, in fact, the research budget in the United 
States is about 50/50 private/public. In Japan it's much 
more highly private research money in the biomedical area. 
So it's going to be a difficult impedance match among the 
18 various nations, particularly between the U.S. and Japan, 
19 because there's so much room for trade fiction. 
20 I'll end there and just open it up for discussion. 
21 Thank you. 
22 DR. KREVANS: Thank you very much. 
23 I'd like to ask Dr. Cook-Deegan and Dr. Cantor and Dr. Watson 
24 to please come to the table. We have now a free time for 
25 comments, discussion, questions for our panelists. And they 
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can question one another or you all can comment and question 
2 them. And I'd like to just start out by calling on people 
3 for questions and comments. 
4 Could you please identify yourself so that you 
5 can be recorded, and 10 years from now you can point out 
6 what a mistake you've made. 
7 DR. SHANKAR: Robert Shankar, University of Southern 
8 California. 
9 I haven't heard any participation from the United 




DR. WATSON: I would hope that we would have none 
13 in the sense that they're large bureaucracies, and I don't 
14 think they'd bring any expertise. And we would spend even 
15 more time in meetings if we had to bring them in. And I 
16 think that the reason for forming HUGO is to keep an organization 
17 run by the scientists instead of, essentially, civil servants. 
18 DR. KREVANS: Do other analysts want to comment 
19 on that? 
20 DR. CANTOR: UNESCO has been sending observers 
21 to some Human Genome meetings recently, but they've been 
22 keeping a low profile. 
23 DR. COOK-DEEGAN: They're very interested in following 
24 the projects. They're particularly interested in if there 
25 are data generated in the Human Genome Project promoting 


























Third World applications of that information; for example, 
sickle cell disease, or something like that, the diseases 
that are highly prevalent in Third World countries. They 
want to make sure that their data are rapidly made applicable 
for the needs of Third World countries. 
And they have been quite interested in fact, 
at the Valencia meeting about a month and a half ago, there 
were three representatives there. And they were extremely 
enthusiastic; more so, I think, than the scientists were 
about having them involved. 
DR. KREVANS: Next. 
DR, NEUFELD: Elizabeth Neufeld, UCLA. 
Dr. Watson, what proportion of resources does the 
NIH plan to put into genomes of other organisms versus the 
human genome? 
DR. WATSON: I don't think we've made any decision. 
I think 
DR. NEUFELD: Would it be minor? 
DR. WATSON: No, I think it would be major. I 
80. 
mean in any sense of the word, we want to get the coli sequence 
out as fast as possible, and then you want yeast, and then 
you want to really see that we get the Drosophila sequence, 
I mean certainly a map of it. 
And I think one thing is that we hope that bodies 
will appear which say, "We want to do something." That would 
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1 go a long ways away from the human. We won't end up being 
2 sequenced in Europe because they actually put their act together. 
3 Or will some group from the United States say, "We really 
4 want to find out what a plant is"? 
5 So I would hope that there would be bodies in the 
6 United States, or groups, which will have rather heroic objectives. 
7 DR. CANTOR: Let me add to that because I sit on 
8 the GenomeCouncil, and so I have seen what has thus far come 
9 through and been funded with genome, I mean even before Jim 
10 was on board. And I think, roughly half of NIH's genome 
11 budget thus far has been spent on organisms other than human. 
12 Some direct attempts to explore those organisms, some using 
them for model systems to develop technology. I don't know 13 
14 how that pertains to the future. But that's what has happened 
15 thus far, which is very reasonable. 
16 DR. WATSON: Maybe, I think, we sort of want to 
17 put a lot of money in the mouse. But you're going to have 
18 to find people who really can do it well. I think there's more 
19 a problem of finding people who can do it than the desire 
20 to do it. And I think there are going to be a lot of people 
21 saying, "We want to do it," and then we're saying, "Well, 
22 we're not interested." 
23 DR. KREVANS: Is the extensive, fairly extensive, 
24 data base on mouse genetics a reason you say we should use 
25 the mouse in terms of one of the manmals? 
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1 DR. WATSON: Well, you want to compare the mouse 
2 sequence just really to identify genes in nonsense regions. 
3 DR. CANTOR: The mouse is really, I think, especially 
4 useful for comparison because as expensive as transgenic 
5 experiments are on mice, they are more expensive than probably 
6 almost any other animal, and they will be more expensive 
7 in any other animal you can think of. 
8 And the problem that you're going to be faced with 
9 in so many cases is: You have a gene, whether you've originally 
10 gotten it from human or a mouse almost doesn't matter, you 
11 want to know what it does. The first experiment you want 














out. You can do that in the mouse today inefficiently; three 
years from now probably efficiently. You can't do it in 
a human ever probably, and you can't do it in larger organisms 
because no one will pay the bill. 
DR. WATSON: The mouse world now -- and maybe I 
shouldn't say this -- is rather mouselike. And we really 
don't expect to get much. So we have to develop leaders 
of the mouse >mrld who really think big and have the same 
ambition as the human people. And it's unfortunate that 
the center of the mouse world has to be in Bar Harbor which 
is so far removed from everyone. They have great difficulty 
in recruiting such molecular types. But that would have 
been the natural center for it. But it doesn't look like, 
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1 in fact, it would be the place where --
2 DR. KREVANS: Those of us who summer in Maine think 
3 that Bar Harbor is much more attractive than Cold Spring 
4 Harbor. 
5 DR. WATSON: I think it is in the summer. But 
6 I think that we're going to find a way to encourage major 
7 groups working on it. 
8 Yes. 
9 DR. LAKE: Jim Lake, UCLA. 
10 I wanted to ask -- a lot of people seem to think 
11 that one of the most informative organisms for comparison 
12 to put us in the proper background would be the chimpanzee. 
13 Is this the sort of thing that you would perceive as following? 
DR. WATSON: No. 14 
15 DR. LAKE: You wouldn't. You think it might have 
16 some political ramifications? I think scientifically it 
17 must be central --
18 DR. WATSON: We really can't do the experiments 




DR. LAKE: But in terms of comparative questions? 
DR. WATSON: When someone gets all the costs down, 
23 then we can look at the chimp. But I think right now -- I 
24 personally think I wouldn't think vle' d develop a big group 
25 working on chimp DNA. 
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1 DR. CANTOR: rtve heard that the chimp is also 
2 a little too close evolutionary to the human. And that if 
3 you could ever afford to do :the experiment, some more distant 
4 related monkey might be a better choice. I mean that's probably 
5 debatable. 
6 DR. WATSON: The way things are going it would 
7 be harder to do experiments on the chimps than on humans. 
8 
9 
DR. KREVANS: Certainly more expensive. 
DR. WATSON: So I really shudder at the thoughts 
10 of the problems. 
,, MR. HURST: Steve Hurst, UCSF. 
12 I'm a patent counsel with UCSF, and one of the 
13 areas that I have noticed a deafening silence on is the issue 
14 of patent rights related from proprietary technologies developed 
15 by the participants in the Human Genome Project. 
16 I see it as being anything from a minor nuisance 
17 to a major problem within the project in terms of how those 
18 rights are going to be coordinated. And I think it's a question 
19 that industry will at least have some interest ln. 
20 I wondered if the three of you could comment the 
21 coordination efforts in that area, any thinking other than 
22 the proposed solution of putting all patent attorneys on 
23 a boat and sending them off to China? What are the solutions 
24 to the potential problems associated with having to fuse 
25 proprietary rights? 





DR. KREVANS: I don't want to discard that solution. 
Do you want to take that on, gentlemen? 
DR. COOK-DEEGAN: We thought long and hard in connection 
4 with OTA project about what we were going to say about patent 
5 rights. And, frankly, the federal policies on it are fairly 
6 straight forward. 
7 The Institution of Human Research get the rights, 
8 whatever the rights are. The problem as I see it is that 
9 we don't know what those rights are because there's no case 
10 law in the area. 















frankly. It's very clear who gets a patent. There are serious 
problems in harmonization of patent criteria among nations, 
and procedures and things like that. 
But in terms of a federal effort involving DOE 
and NIH or NSF, it's very clear of how they're supposed to 
distribute the patents. And I don't see that as being a 
very --- from the federal perspective -- as being all that 
important. It's going to matter a lot to the people who 
are doing the research, but then it's going to be up to them 
to negotiate who owns the patent. The Institution and the 
people doing the research would make those decisions now. 
That's federal policy. 
DR. KREVANS: Charles, do you want to comment on 
this? 
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1 DR. CANTOR: I just want to second what Bob said 
2 about harmonization because already a significant fraction 
3 of the effort in the Human Genome Project are international. 
4 And the differences in the patent laws and constraints about 
5 disclosure in different nations is really cumbersome. I 
6 mean that's a problem that transcends this enormously, but 
7 it's a mess. And I would hope that patent attorneys can 
8 one day straighten this out. 
9 DR. KREVANS: All the way in the back, please. 
10 UNIDENTIFIED SPEAKER: There was no mention of 
11 the Department of Defense in the funding role of this. Are 
12 there implications to DOD? And if so -- [Rest of the question 
13 was inaudible.] 
14 DR. WATSON: I don't really think that their help 
15 is needed. You know, at a different level, I think they're 
16 very interested in the DNA fingerprint for body identification, 
17 and you can get that sort of a question. Do they want to 
18 DNA fingerprint everyone who enters the armed services. And 
19 I don't really feel qualified to make any comment on that. 
20 DR. KREVANS: Charles. 
21 DR. CANTOR: Well, they're also interested in autorr.atic 
22 pattern analysis. And that technology is relevant to the 
23 Genome Project. There's no question about it. Patterns anywhere 
24 from DNA sequences to automatic analysis of photographic 
25 images. But, again, I agree with Jim; I don't think that 
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they're needed in this project. 
2 DR. KREVANS: I just want to pursue that. Hasn't 
3 a lot of the advance in pattern analysis come out of DOD 
4 research on how to analyze patterns from satellites; the 
5 other direction, if you will? 
6 
7 
DR. CANTOR: As far as I know, yes. 
DR. KREVANS: Do you want to comment on this, Bob? 
8 DR. COOK-DEEGAN: No, that's absolutely right. 
9 The DOD has got some interest in this. They've got a few 
87. 
10 little bits and pieces here and there. They've got the world's 
11 best treasure house of odd pieces of the human body at the 
12 Armed Forces Institute of Pathology. It's a wonderful resource 
13 that probably will eventually be quite useful to their genetics 
14 and things like that. 
15 And I think that at the hardware end, their artificial 
16 intelligence is in large part supported b7 DOE. It's highly 
17 relevant to these projects. But I think at that level, I 
18 think it will probably trickle down from DOD. Frankly, they 
19 would probably be a little worried about being perceived 
20 as getting into this because everybody would immediately 
21 think that this was pretty nefarious purposes. 
22 
23 
DR. KREVANS: Yes, right here. 
DR. LONGERBEAM: Gordon Longerbeam, Lawrence Livermore 
24 National Lab. 
25 I have a question about technical data rights excluding 
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1 patents, perhaps from Dr. Cook-Deegan, but the others may 
2 respond. 
3 Do you see any progress at the federal level on 
4 differentiating between technical data which has economic 
5 value and technical data which is principally scientific 
6 value which should be open to share? Or is that still a 
7 very sticky question? 
8 DR. COOK-DEEGAN: That's a mess. And it's all 
9 tied up also with the question: Who owns the data and all 
10 that? And that's a total mess right now, and I'd just as 
11 soon not talk about it too much. We don't know very much 
12 about it, and it's undoubtedly going to change in the next 
13 two or three years. 
14 Access to technical data and who owns it and all 
15 that is very unclear. 
16 DR. KREVANS: But this, I think, is the question 
17 that Mr. Hurst was trying to get at. As these things evolve 
18 in cooperative studies where we talk about ways in which 
19 to make data accessible, then when something comes from it, 
20 who owns it? 
21 DR. COOK-DEEGAN: If that was the point of your 
22 earlier question, I missed the point, and I apologize. 
23 MR. HURST: If I could maybe elaborate just a little 
24 bit on the issue. 
25 DR. COOK-DEEGAN: Sure. 
Pike Court Reporting (805)658-7770 
1 MR. HURST: I think you'll see within the industry 
2 that there is a lot of -- I think the relevant point of the 
3 whole project is that at some point the Genome Project will 
4 translate itself into a technology transfer effort that will 




Those technologies are expensive to develop and 
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8 require some incentive. And usually the industry will perceive 
9 incentive as being exclusivity, or maybe even free competition 
10 where someone can't come in and close them down, all of which 
11 is relevant. 
12 And I think that if you find that in a project 
13 as profuse as this, those patent rights rest in 40 or 50 
14 or 60 different places, I think you're going to at some point, 
15 maybe not in the basic research, but certainly where the 
16 tech transfer efforts take place, I think you're going to 
17 find a real bottleneck that, hopefully, will straighten itself 
18 out. It will eventually straighten itself out in the sense 
19 that all the patents expire at some point in time. 
20 But I wonder, perhaps, should we wait 30 years 
21 after the technology is developed for all the patents to 
22 be out of the way before the industry can really take off? 
23 And I think if you don't have a coordinated effort within 
24 a project of this scope, can look at exactly what you've 
25 cited, which are the federal laws on ownership and the fact 
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1 that each institution can elect ownership, and in a project 
2 of this scope I'm not sure that sounds reasonable. 
3 And I think that's what I was getting at because 
4 you're going to find an impedance in progress at some point 
5 along the way by virtue of proprietary rights in data, techniques, 
6 products. 
7 And I think the law is clear that gene sequences, 
8 protein probes, et cetera under the U.S. patent law are clearly 
9 patentable right now. This is a real issue. 
10 DR. COOK-DEEGAN: Yes, I think just to make sure 
11 that I understand where you're going with this, I think the 
12 real issue is not: What's patentable and what's not patentable? 
13 Although, that's still in question. 
14 It's also clear that if you've got something that's 
15 patentable, it's clear who owns the patent. What is unclear 
16 is what you do with information that goes into the process 
17 of documenting that you have an invention. 
18 And I think that patent laws as they're currently 
19 construed do have -- it is a serious problem for the project 
20 in the sense that people will be reluctant to disclose sequence 
21 information; for example, that is relevant to a patent they 
22 found until they file it. And that could lead to a delay. 
23 But if you aggregate it over hundreds of labs where 
24 you're trying to pool data, it does matter a lot. It delays 
25 things by years if you add it all up. That is a serious 
Pike Court Reporting (805)658-7770 
91. 
1 problem. 
2 There are things that the federal agencies could 
3 do to encourage data sharing if they just had explicit policies 
4 saying that this sort of information needs to be shared as 
5 a condition of accepting this grant. But there's always 
6 going to have to be a clause in there. And there's going 
7 to be inevitable uncertainty because the agencies can't cross 
8 that line if it gets in people's way when they're filing 
9 patent applications. 
10 It's against the law for them to put any impositions 
11 on recipients of grants if it's going to interfere with their 
12 intellectual property rights. 
13 So there's a gray area there, and it's just going 
14 to have to be thought about a lot by the federal agencies. 
15 And I think it's going to be muddled through, frankly. 
16 DR. SALSER: Winston Salser, UCLA. 
17 Regarding the earlier question about the interaction 
18 of the Department ofDefense, it seems to me there's more 
19 likely to be an interaction and a problem with the intelligence 
20 community because one of the things that they do is analyze 
21 huge amounts of communication to sift through, trying to 
22 sift through it. 
23 And they must have contemplated for at least 10 
24 years the various kinds of data analyses that will also be 
25 needed here. And, presumably, they could tell us a lot about 
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1 how to do it. I don't think they will. 
2 But more problematically, if we look at the basic 
3 researchers on breaking codes, they really interfered a lot 
4 by classifying a lot things on code breaking. And we may 
5 have them really interfering when someone gets a powerful 
6 outgrowth in decifering DNA and picking up things. They 
7 may feel that that's very threatening to them, and that would 
8 be unfortunate. 
9 DR. COOK-DEEGAN: The Cal Tech chip that is being 
10 used with that style finding is based on one of the chips 
11 that was developed -- so there'sa big area of overlap. And 
12 I think the biologists only got access to it after it was 
13 no longer the first generation technology. 
14 UNIDENTIFIED SPEAKER: I understand that the [inaudible] 
15 of automated instrument in DNA sequencing is important for 
16 this program. 
17 In Japan, companies where [inaudible] instruments 
18 are developing the instruments [inaudible] is support from 
19 government. 
20 Is there any federal support for the development 
21 of instrumentation in this sequencing effort? 
22 DR. CANTOR: Really that's one of the things that 
23 has changed as a result of the Human Genome Project is the 
24 fraction of the money at both NIH and DOE is now being spent 
25 on instrumentation development. That's what was difficult 
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1 before the Genome Project. It was relatively hard for those 
2 kinds of projects to get funded in a conventional way. 
3 UNIDENTIFIED SPEAKER: The money is spent in [inaudible] 
4 or with companies? 
5 
6 
DR. CANTOR: Some of the funds are used 
for SBIR or direct grants. We have a lot of the biotech 
7 companies are quite successful in competing for standard 
8 research grants of NIH or DOE. And so a reasonable fraction 
9 of the funds have gone along those directions. I mean I 
10 can't name names, but I know of at least one major company 
11 which has totally new ideas for sequencing and is seeking 
12 federal support for it, and I imagine will get it, based 
13 on quality. 
14 DR. COLE: Belle, Cole, University ·of California, 
15 Pre~ident's Office. 
16 Dr. Watson, you mentioned that -- you discussed 
17 the ethical issues that confront the project, and mentioned 
18 the role of this advisory committee. And also you mentioned 
19 that Congress will be hearing from many different groups 
20 about the project. You also mentioned there may be some 
21 interest groups out there that will develop and that might 
22 be adverse to the project. 
23 What are some of the things that NIH is thinking 
24 about to deal with these issues, ways of educating the public, 
25 ways of just being prepared? I just wondered if --





DR. WATSON: I think we really don't have a program, 
but I would think that within six months we vlill announce 
one. I think we have to --we haven't had a meeting of our 
4 advisory committee. And when that occurs early in the year, 
5 I would hope that we would form some subcommittee to deal 
6 with these matters and to deal with things like with the 
7 Human Genome Office at NIH to issue proposals for grants 
8 in this area, but at what levels I can't say. 
9 But I would think there should be a level of several 












DR. WHITELEY: Norman Whiteley, Applied Biosystems, Inc. 
In response to: Does the federal government support 
instrument development? They financed the purchase of a 
lot of the equipment. Something like 10 or 12 or 14 percent 
of that money goes back into research. 
support a great deal of research. 
So indirectly they 
I'd like someone to explain the role of HUGO. 
DR. KREVANS: Charles, do you want to handle that 
one? 
DR. CANTOR: The role of HUGO will depend very 
much on how successful HUGO is in fund raising. At one extreme, 
22 if it's very unsuccessful at raising funds, it's likely to 
23 be in discussion forum and very little else. 
24 If it's quite successful at raising funds, it sees 
25 itself modelled after an organization called EMBO, which 
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1 1s the European Molecular Biology Organization, which has 
2 a substantial budget which it gets from participating nations. 
3 And in addition to being very active in training various 
4 post-doctorals of workshops and so on runs a gel. And most 
5 important, it runs one large international laboratory called 
6 the European Molecular Biology Laboratory. 
7 At least some of the major participants in HUGO 
8 at the moment are very enthusiastic about trying to have 
9 the latest stages of the project -- a discreet number of 
10 international laboratories -- that \JOuld do the real predominant 
11 efforts in a way that will allow a lot of foreign nations. 
12 Whether that fantasy ever really becomes a reality 
13 will depend on whether the governments are willing to give 
14 substantial amounts of money to a truly international organization. 
15 Other people in the room may know more about EMBL 
16 than I do. It's my impression that EMBL is a very delicate 
17 year-by-year political negotiation of participating nations 
18 
19 
to try to keep a budget going. It's very, very tricky. 
And what I'm worried about with HUGO is that since 
20 it's the whole world, and not just a small European nation, 
21 
22 
it's going to be even more complicated. 
So I've given you two extremes. 
23 is likely to be somewhere in the middle. 
I think the reality 
24 DR. WATSON: Right now HUGO has $75,000. 
25 DR. KREVANS: It's certainly not going to do a 
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1 lot of harm with that, Jim. 
2 DR. WATSON: I would just like to say that I think 
3 it will need roughly $1 million a year to really have a real 
4 secretary and to be able to hire someone who really has this 
5 function of really trying to integrate the activities in 
6 different parts of the world. 
7 I think if Charlie and I try and get bogged down 
8 in bilateral discussions with all the different countries 
9 involved, it would be a mess. And we would like to in the 
10 United States interact with HUGO and not have to, but that 
11 means a secretary. And I think that's about $1 million dollars 
12 a year, which means that the United States itself would have 
13 to make a contribution to it, that is our government. 
14 And I would simply be 1n favor of -- if the means 
15 can be found -- of NIH making a contribution to HUGO when 
16 we really know what HUGO is going to be. 
17 The thought, I think, was that for a year or two 
18 you should get foundations to give money to put together 
19 a secretary so that the governments would know what they're 
20 buying. 
21 DR. KREVAN: One last question, please. 
22 MR. HUNKAPILLAR: Tim Hunkapillar of Cal Tech. 
23 And I was going to real quick follow up on what 
24 Bob said about the TRW. This is an idea. They're actually 
25 so far -- so far there haven't been any real difficulty. 
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In fact, they come looking for people to put the technology 
2 out into the world. And NSF doesn't seem to care one way 
3 or another, not just NSF but those people, don't seem to 
4 care a whole lot. 
5 Where is the NSF in this? NSF obviously is a major 
6 contributor to funding for instrumentation and large data 
7 bases. I know they do a lot of data bases all over the world. 
8 And why do we never hear the NSF in these discussions? 
9 DR. KREVANS: Gentlemen? That's the question that 
10 I asked as you were gathering together. 
11 DR. COOK-DEEGAN: NSF in terms of budget has life 
12 sciences budget that's roughly in the same ballpark as DOE's. 









now but it used to be the largest budget for viewing 
biology instrumentation development. 
So, in fact, they are de facto in the game. And 
they've had a big role as you know. I mean they were the 
only federal agency that ever supported the DNA sequencing. 
So they do have a big role here. 
I think that they've been out of it just because 
DOE and NIH both identified genome projects. And NSF made 
22 a conscious decision not to do that same thing. My guess 
23 is that eventually they're going to have to consolidate their 
24 efforts so that they can have a match to what's going on, 
25 and that's DOE and NIH. 
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1 So I think it's a political answer; that is that 
2 it made a conscious decision not to have that sort of an 
3 approach to genome projects. 
4 DR. KREVANS: I'd like to close this with one question 
5 and an advertisment. 
6 The National Academy Press has just released a 
7 committee report on which both Charles Cantor and James Watson 
8 were members of the committee, and which v7as chaired by a 
9 colleague of mine in San Francisco, Bruce Alberts, and it's 
10 on mapping and sequencing the human genome. And it's available 
11 from the National Academy Press. And the University of California, 
12 San Francisco gets a small royalty on copies sold. 
13 In this book the question is raised: Why sequence 
14 the entire human genome< And then it says that we hope everyone 
15 agrees that it's a wonderful idea. And it says that there 
16 were only three major things that sort of stand in the way. 
17 And the third one is -- and I'll read it: 
18 "Even if the project is worthwhile, the 
19 intensive effort required will divert 
20 funds from other research aimed at 
21 understanding the structure and function 
22 of genes in all organisms and, therefore, 
23 there will be a net loss rather than a 
24 net gain of important biological information." 
25 Now, the narrative goes on and destroys that argument, 
Pike Court Reporting (805)658-7770 
but I would like to hear particularly James Watson and Charles 




DR. WATSON: Well, I think the sum of money, if 
5 you add together the NIH support of biomedical and NSF and 
6 DOE and Agriculture Department, it would only be about two-and-a-
7 half percent of the total biology -- I think in terms which 
8 are buying as [inaudible] it would be a bargain if we can 
9 actually deliver. 
10 The other is, I think, the breadth of the program 















things which a lot of people would have wanted to support 
out of our lungs of program projects even if this program 
didn't exist. 
So I think our -- as I said before -- our aim is 
to see that when we pass out the money, outsiders can't say 
we're passing out money to second-class people who --· that 
are just supported because we have a lump sum of money which 
is of a certain size, and we can't fill it with good people. 
So I think we really have to -- if we believe in 
the project -- really work hard to encourage good people 
to come into. 
And if I could say one thing, I think right now 
the program is structured, for the most part, at NIH in terms 
of almost on a one-type grants. I'm personally a real believer 
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1 in rather large program project. And I would hope that groups 








would come together and put together sort of genome centers 
which we could fund because I think we're going to need a 
variety of diverse talents, and by forming centers, you'll 
be able to, I think, get more done than individually. 
DR. KREVANS: Charles, do you have anything to 
add? 
DR. CANTOR: I think Jim has really said it all. 
10 I would just add as a postscript that that criticism was 
11 leveled at and was valid at the original concept of the project. 
12 That current technology, the moment you broaden the project 
13 to the model which exists today, the criticism is really -- it 
14 just doesn't apply. 
15 DR. KREVANS: What I was hoping our panelist.s would 
16 say is that it's better to spend the money on this than particle 
17 physics, but they're very ecumenical. 
18 I'd like to thank our panelists very much and turn 
19 the program back to Paul Boyer. 
20 DR. BOYER: We appreciate very much the fine panel 
21 we've had this morning. And I would like to continue to 
22 mention what our program will be. Let me just quickly correct 
23 some mistakes. It won't take 10 years. As you know, I've 
24 tried to give Julius two jobs, both at San Diego and here. 
25 That was a mistake on the thing. 








I need to take 10 years off my own time since a 
Ph.D. I want to say that in terms of biochemistry, the area 
of proteins and enz:rme molecules uould have been far ahead 
if Jim Watson would have chosen to be in that area. I think 
it would have been a disaster for genetics if I would have 
chosen to try to do Jim's research. 
I want to also say something about how this meeting 
8 developed. And it developed out of an interest of Senator 
9 Garamendi's office and Senator Garamendi. And what's going 
10 to be the role in the future of the activities related to 
11 the Human Genome Project. 
12 And the people who put it together, I want to just 
13 take brief recognition of and introduce Masako Dolan from 
14 Senator Garamendi's staff. 
15 Are you here Ms. Masako? Would you stand up just 
16 briefly. 
17 And I was going to introduce Dr. Sue Huttner of 
18 my biotechnology staff, but she just disappeared with 
19 Dr. Watson. 
20 But I would like to at least say these and their 
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21 staff have done a fine job of bringing all the money together, 
22 and a round of applause would be in order for them. 
23 I would like to mention just briefly our technical 
24 plans now for lunch. We will have a lunch available on the 
25 terrace in which we can pick up lunch. There will be a few 
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1 tables on the terrace where you can sit. Others can proceed 
2 with this meager lunch that you will have out through the 
3 opening of the building and compete for space in the eating 
4 S8rvice called the bomb shelter, which is just across from 
5 the front of the building. 
6 Are there any other technical plans I need to mention? 
7 [No response.] 
8 And we're also very pleased that we can have Senator 
9 Garamendi here to comment on just a bit about the importance 
10 of collaborative research to the state's economy. 
11 Now, I mentioned that Senator Garamendi here has 
12 a strong interest in the University of California; although, 
13 he took his Bachelor's Degree at Berkeley, he has learned 
14 to appreciate at UCLA, San Diego, San Francisco, Sacramento, 
15 Riverside and so forth. He had an MBA for Harvard University. 
16 He is a very successful cattle rancher, but is also the Chairman 
17 of the Senate Committee on Revenue and Taxation and the Joint 
18 Committee on Science and Technology. And I could say other 
19 on his background, but we're more interested in hearing his 
20 comments. 
21 And Senator Garamendi, if you would tell us a bit 
22 here while we have a few moments before vJe move for lunch, 
23 it would be greatly appreciated. 
24 SENATOR GARAMENDI: It's good to be with you. I'm 
25 delighted to see the size of this audience and the participants 
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that are here. 
2 We, in California, like to pride ourselves as being 
3 on the top of the scientific and technology of the world. 
4 And indeed we have been. And our goal in the state legislature, 
5 certainly the Joint Science and Technology Committee, is 
6 to see to it that we remain at the top. 
7 There are no guarantees that simply because we're 
8 in this golden state and get to enjoy this marvelous weather 
9 when the rest of the country is freezing that we deserve 
10 to be at the top. We have to earn it. We have to earn it 
11 every single day. 
12 You don't get there, and you don't earn this ranking 
13 by letting opportunities pass. We have lost many, many major 
14 research projects in the last six or seven years here in 
15 the State of California. We don't intend to lose future 
16 opportunities. 
17 The project, the Human Genome Project, is a huge 
18 one, and it involves -- it will involve the entire nation. 
19 And as we were hearing a few moments ago, it involves many 
20 other parts of the world in the process of figuring out what 
21 human beings are all about. 
22 California is ahead. We need to do some things 
23 to stay ahead, just in the pure research. My points that 
24 
25 
I want to make to you are not just that area. Obviously, 
you are scientists, most of you. Some of you come from industry 









and you provide certain tools to the scientific community. 
It is that part of the linkage that I want to spend a few 
moments on with you. 
The scientific efforts of the State of California 
104. 
in the past have invariably been translated into an improvement 
the soc in California, in our economic status, in 
the distribution of wealth to the many citizens of this state, 
and to opportunities for every individual in the state to 










We have to see that that continues to occur. I 
think that anyone that looks at the future economies of the 
world have come to the conclusion that those economies are 
going to be based on a large extent on the issues of biotechnology. 
It is a field that is growing and blossoming and holds tremendous 
potential, certainly in the area of human health. I think 
all of you are aware of that, and certainly the Chancellor 
is. 
In the areas of pollution, in the areas of dealing 
19 with -- you name the problems that are out there in front 
20 of us -- feeding people, dealing with the environmental problems 
21 that exist today. All of those things can be reduced or 
22 come back to the issues of biotech and biology. There is 
23 a tremendous potential here. 
24 We have to make sure that the economy of California 
25 has in its foundations for the future a very strong scientific 
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program in biology and biotechnologies of all sort. This 










by the federal government gives us the opportunity in California 







in this area. Out of that, if we're able to position ourselves, 
carry on the kinds of research that are fundamental in this 
area, we see a tremendous potential for all the citizens 
of this state and beyond that, the nation and the world, 
to benefit from our efforts here. 
We see our industries providing the tools necessary 
to sequence the gene and all the other scientific tools that 
are going to be necessary, not only to do the research but 
then to take that research on into products or into medicine 
or whatever it happens to be. 
In order for us to make each of those steps, we 
16 need to have a very, very close collaboration between the 
17 scientific community, the government and the private secto~. 
18 One of the primary goals of this conference is 
19 to pull together all of those elements so that they are all 
20 working together right at the outset. 
21 First, to see to it that we in California have 
22 a reasonable share of the federal research dollars that are 
23 coming out. 
24 Secondly, to encourage our state government and 
25 policy makers in state government to provide the necessary 



























state funding to backfill, to fill in wherever the research 
dollars at the federal level are inadequate or insufficient, 
and also to provide a base of support so that those research 
dollars can be used here to provide the facilities, the research 
grants for the scientists and the others that are going to 
be necessary to conduct that research. 
So we're trying to build that coalition in the 
governmental area, to build the knowledge in the governmental 
area so that the policy makers, those of us that put together 
the budgets for the state and set the priorities are ready 
and willing to provide the money. 
We've also brought together here major players 
in the private sector who have a very, very significant role 
and opportunity to provide, as I said earlier, the tools 
and also later to use the research to develop products, and 
in terms of our whole society develop the economy, to add 
value, to add wealth to this economy so that it can go back 
and do something in the next round of research in moving 
and advancing the citizens of this state and this natiori. 
So our hope out of this conference and I believe 
that there will be subsequent conferences -- is to move this 
process along. We've already made, I think, very substantial 
progress. The fact that so many of you are here today 
I think the first meeting we had we started with three or 
four of us, and now and then it went about to 20 or 30 at 
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1 Berkeley, and now we're well over a 100 here -- that kind 
2 of growth and understanding, collaberation, communication 
3 is going to be essential in building in the State of California, 
4 whether it's at the University of California or Stanford 
5 or Cal Tech or any of the other laboratories or private industries, 
6 the opportunity for this state to carry on this kind of research 
7 and to benefit directly from the research that's going to 
8 be conducted. 
9 We know that we can do it in this state. Challenge 
10 is one of those that comes to us every day. Fortunately, 
11 we have the leaders here among us that will carry it out. 
12 I want you to know that the California State Legislature 
13 is aware of this project. We will be doing what we can to 
14 make it a priority and to fund where appropriate. We need 
15 your input and information to help us in that process of 
16 trying to determine where our resources should be spent. 
17 Now that I have sufficiently wet your appetite, 
18 let's go have lunch. 
19 Thank you very much for being here. 
20 DR. BOYER: Let me just comrnEont, Senator Garamendi, 
21 that had we opened this for full attendance, we would not 




SENATOR GARAMENDI: Good. 
DR. BOYER: What you have are the people that are 
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1 really the most interested. You have the leaders in the 
2 field. These are the important people to carry out these 
3 things. 
4 Thank you very much for your pertinent comments. 
5 We're adjourned for lunch. 
6 
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1 Afternoon Session: California's Participation 
2 December 2, 1988 




7 DR. BOYER: I'd like to welcome you again, but 
8 now to the afternoon session, after what to me was a very 
9 interesting and intriguing morning session posing many promising 
10 prospectives and problems which come ahead. 
11 In the afternoon session, we're going to be looking 
12 with three panels on the impact of the genome initiatives 
13 on basic research, the need in technologies and hardware 
14 and the utilization of the data. 
15 And let me comment that in the organization here, 
16 we've had so much interest in participation by capable people 
17 that we may have put too much into the pie; that is, we may 
18 have more participants that could tell us interesting information 
19 than we have time on the panel. 
20 So I need to comment briefly here of how we would 
21 like the panelists perhaps to proceed would be to take the 
22 information that they have gained in the morning and what 
23 they know themselves about the problems that they want to 
24 address and in a way of self-introduction speak for five 
25 and not longer than 10 minutes each about what their perspectives 
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1 are of the issues that face this on the Human Genome Project. 
2 Then that will allow the audience to know what 
3 the panelists' viewpoints and perhaps areas of interests 
4 are, and then have the balance of the time open for discussion 
5 from the audience among the panelists or with the audience 
6 because otherwise if we were to get all of the information 
7 that would be really useful, our talkers would need to extend 
8 far beyond this afternoon. 
9 Now, Winston Salser, Professor of Molecular Biology 
10 at UCLA who I found had an understanding of the implications 
11 of DNA long before most people in the field, not earlier 
12 than Jim Watson, who also himself has been a student and 
13 contributor to the area is going to chair our afternoon session. 
14 And I will not try to introduce the moderators 
15 of that, but I will turn it over to Winston at this point. 
16 I will mention one other thing. I think this morning 
17 that I mentioned our other sponsors. The Lawrence Berkeley 
18 Laboratory and the California Department of Commerce as well 
19 as the Joint Committee on Science and Technology with Senator 
20 Garamendi and the U.C Biotech Program. If I left anyone 
21 out, I thank you anyway. 
22 DR. SALSER: I remember as a young kid driving 
23 from a farm that we farmed in western Kansas to Wichita 
24 where my dad was also a school principal hearing on the radio 
25 a popular program about -- it must have been right after 




the discovery of how DNA replicated. And I was really intrigued 
by that. I guess I was a teenager. 
3 Let me tell you a little bit about my perspective 
4 on DNA sequencing because I'm going to make a couple of comments 
5 that I hope will stimulate discussion. 
6 During the past year I've been -- among other 
7 things -- setting up a DNA sequencing facility which will 
8 provide automated sequencing for the more than 60 labs here 
9 at UCLA that have need of that. 
10 And we were very pleased that we were quickly able 
11 to get highly accurate sequences out beyond 500 nucleotides 
12 per run. And we think that things are going well and that 
13 in the near future that machines should be able to do all 
14 of UCLA's current DNA sequencing needs with a very cost-effective 
15 manner. So we are very pleased with the technology. 
16 But also I've become aware in doing that about 
17 how much further the technology can be taken with some further 
18 automation. And to facilitate that I've organized an international 
19 sequencing newsletter that now goes out to about more than 
20 700 people that are connected with automated DNA sequencing. 
21 So from these perspectives and from exchange of 
22 information with quite a wide number of people, I think I 
23 have a little bit of insight into how the actual sequencing 
24 part of the genome sequencing initiative might go if it was 
25 based on an extrapolation of the current technology, things 






that are now in at least prototype form without involving 
some new things that no one has discussed yet. A miracle 
happens here, it's another area of magnitude, that really 
would be delightful. 
But I think it's useful to consider: How would 
6 it work if we just extrapolated things that we now have? 
7 In the transparency I've broken things down into 
112. 
8 four areas, and the top is the human genetic map. And actually 
9 my own laboratory in collaboration with Dr. Gatti, was one 
10 of the 20 original labs in the CEPH consortium that's put 
11 together a number of genetic maps of the human genome, and 
12 I think it's very fair to all of us that that works. That 
13 technology is working very well, and undoubtedly it will 
14 be improved and so on. 
15 Incidentally, here at UCLA we've just succeeded 
16 in mapping the gene for Ataxia telengiectasia, which is a 
17 disease probably unknown to you, but it's turning out to 
18 be more important than the disease Ataxia itself since in 
19 the past few years it's become clear that that Ataxia gene 
20 is responsible for an estimated 20 percent of breast cancer 
21 and a large number of other cancers appearing in the heterozygote 
22 carriers of the gene rather than, of course, the patients 
23 with the neurological disease. 
24 But similarly in the second area of physical maps, 
25 Charlie Cantor has pointed out to you the things thore that 
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we don't know how to do and the problems. But from the fact, 
2 the success in the Ceanorhabditis elegans case one can take 
3 encouragement that a great deal can be done, and that ultimately 
4 that will be-- one sort of has a picture of how that's going 
5 to be worked out. 
6 There's also the problem of converting cosmids 
7 or YAC's, whatever the physical maps are made of, to sequencing 
8 clones -- sometimes referred to as the subcloning problem -- and 
9 this is a really important technical problem. And I guess 
10 we'd like to have perhaps automation of the Henikoff deletion 
11 procedure, or something like that, to solve it in a really 
12 powerful method. 
13 But what I want to talk just briefly about is the 
14 four step, the actual sequencing. I think the report, the 
15 NRC report, put it this way: Is the future likely to lie 
16 in scaling up automated techniques that are already at the 
17 prototype stage, or does it lie in revolutionary new methods 
18 which may as yet undiscovered? 
19 Well, as of six months ago when I did a survey 
20 as part of the intersequencer's newsletter, I think I can 
21 say that currently the best machines are actually working 
22 at a rate that would require about 4,000 machine years to 
23 sequence the human genome to a depth of 1. And I think that 
24 that's the kind of thing that Jim Watson was speaking about 
25 when he said that currently sequencing is very expensive; 
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1 although, this may already represent an advance, probably 
2 does, over what he was talking about. 
3 But the encouraging thing is that it's clear that 
4 the machines could go a lot faster. And if we had automation 
5 of template preparation and automation of the sequcncinq 
6 reactions, we could go at half of 10 to th<~ 7th nucleoti dPs 
7 per machine per year. And with minor changes in the existing 
8 sequentures, we could go at about 10 to the 7th nuc1eotides 
9 per machine year. 
10 Now, that means that 300 machine years would suffice 













that's not adequate. Or you could take four years with these 
300 machines to sequence both strands to a depth of 2. 
But on the second one, which repeats a little bit 
of that and goes further to a depth of 2, and the capital 
costs turn out to be not totally unreasonable. It's expensive. 
But 300 machines would cost around $30 million whether you 
bought them from ABI or Dupont, and I don't know if any other 
machines are out, and if you have to build new space to house 
them. So your total capital expenditure might get up to 
$200 million roughly. It's more problematic how much it 
would cost to staff it. This is just for the sequencing 
part, not the other parts. But probably for an equal amount, 
24 equal the capital costs, you could supply about 15 man years 
25 for each of these 300 machines. 
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1 So I think this is perhaps doable, but I think 
2 that Jim Watson really put it very well when he said, "The 
3 question is: How do you interest intelligent people in very 
4 dull work?" 
5 What we're doing now is extremely exciting because 
6 we're pushing it ahead. We're improving the technology. 
7 But now we're talking about -- well, supposing you got the 
8 technology, and you said that we now want to replicate this 
9 and have 300 machines. I don't know at what stage you'd 
10 make that decision. But if you did make that decision, it's 
11 immediately a very different ball game. And I just wanted 
12 people to think about that in more concrete terms than I've 
13 heard of being done before. 
14 And with that, I will turn it over to the first 
15 talk this afternoon which will be by Kenneth Gibson. 
16 He was appointed by Governor Deukmejian in 1987 
17 to head the California Department of Commerce. Ken Gibson 
18 was trained at Princeton University. And he also brings 
19 us the perspective of big business because he served as Senior 
20 Vice-President for Kaiser Steel Corporation before he joined 
21 the state government. 
22 And as Director of the Department of Commerce, 
23 he's the administrative official in the state most directly 
24 concerned with his topic this afternoon which is the California 
25 Competitive Technology Program. 
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1 MR. GIBSON: After hearing Winston's comments, 
2 I hope the group will forgive me if I revert back to English. 
3 It's always helpful. Sey S g€d. invite~(! Inf' down to <1 
4 supPrconductivity symposium a coupln of monthn aqo, c~nd 
5 had exactly the same feeling. Most of the words were~ ···· l 
6 know they were English. They just weren't exactly the same 
7 sequence that I've always heard them. 
8 
9 
Anyway, I appreciate being here, and I'm sorry 
that I missed this morning's session. I understand that 
10 it was very helpful. What I've been asked to do is describe 
11 to you a new program which is just being initiated on the 
12 state level that we think should very definitely be material 
13 and certainly to our state's technology development. 
14 And I'd like to give you, if I may, just a brief 
15 background as to the philosophy of how this program came 
16 about in the first place, and then to bring you up to date 
17 on the status of it. 
18 First and foremost, the Competitive Technology 
19 Program in its initial conception and really the basis for 
20 it throughout is that for us it's an economic development 
21 program. It has always intended to be that. 
22 And I've quoted a couple of phrases out of Simon 
23 Ramo's recent book, The Business of Science, to bring 
24 this across. He says: 
25 "As a nation we can't raise our average 
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personal income by shifting a constant 
total of assets around among our own 
people, nor can we count on discovering 
huge deposits of gold, oil, or diamonds 
on our land. A sure way for the United 
States to raise its living standards is 
to excel in technology. 
"Technology can be applied to increase 
the resources of a nation, to generate 
wealth that would not exist if the 
11 technology were not employed." 
12 Well, I think that obviously what is true in the 
13 United States is even more true in California. And even 
117. 
14 as rich in natural resources as we have been, we've pretty much 
15 run out of those. Coming from the steel industry, I can 
16 attest to that. 
17 But what we have now is the cold hard fact that 
18 there's really only one natural resource remaining in California 
19 vJhich can be converted into finished products to the degree 
20 anyway that it will ultimately increase our standard of living, 
21 and that's to convert our ideas and our brains into finished 
22 products and processes for our state. 
23 So our whole idea, obviously, with this program 
24 is hopefully to bring the resources of our campuses and our 
25 national laboratories into the commercial marketplace in 
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1 the private sector. 
2 Our challenge, as we see it, is to be more efficient 
3 and a lot more prolific in converting these resources into 
4 world-class products and jobs and manufacturing excellence. 
5 And it is this realization really that brought around this 
6 program and its ideas. 
7 All the elements were here when we looked at what 
8 this program should be. We looked at what other states were 
9 doing. And other states have been very successful with programs. 
10 And we determined that we had a unique situation in California 
11 though that allowed us to not have to do some things that 
12 some other states are doing. 
13 We didn't feel that we had to go into the venture 
14 capital business as some other states are. We didn't feel 
15 that we had to get into a position of taking equity positions 
16 in companies, which other states are doing. We felt that 
17 really the components are here. The technological resources 
18 of this state are incredible. We do have the entrepreneurs 
19 in this state that are already here. But what we have not 
20 had is a vehicle to help them bring all these resources together. 
21 We've achieved a great deal in this state, and 
22 our topological excellence doesn't have to apologize to anyone. 
23 But we're at a point in a global economy where we simply 
24 have got to do more and do it better than we ever have in 
25 the past. 
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in of 1987. He issued an executive order, and he introduced 
the program actually with one of his Saturday morning radio 
shows. And in that -- and I'd just like to read you from 
that to give you a bit of the flavor for the idea and philosophy 
behind the program. 
He said that with this new partnership, that is 
the private sector, the academic sector, and the state government, 
we will encourage and support technology breakthroughs that 
10 will have commercial potential through matching funds. We 
11 will stimulate industry to take these discoveries and turn 
12 them into high-quality products that will generate new markets 
13 and jobs for California. 
14 We have neither the need nor the intention to wait 
15 until the federal government or some other entity develops 
16 a selection process to establish these proble~s -- projects, 
17 a process over which California has little or no control. 
18 So the point of this program, hopefully, is to 
19 allow California to take better control of its own destiny. 
20 And that's certainly what part of this program is intended 
21 to do. 
22 The funds that are available from this program, 
23 as far as we're concerned, are for the benefit of California 
24 companies. We don't look upon them so much as an incentive 
25 to California companies as an incentive to -- as a challenge 




















to California companies. The point is that the program will 
provide an opportunity for the private sector which it really 
has not had before. 
We've had some excellent examples on a smaller 
basis, the micro programs with the University, of course, 
we think has been very successful, a couple of other pilot 
programs, RIMTECH as another example. But they are in a 
120. 
very narrow framework, and we simply need a much more broad--based 
program. And I think we're at least on the right track right 
now. 
As I said, the governor introduced this program 
in May. Subsequent to that, Senator Garamendi introduced 
a bill and Assemblyman Chuck Quackenbush introduced a second 
piece of legislature which were passed in August and signed 
into law in September. So those were the two pieces of enabling 
legislation that had now made this new program a reality. 
What it does is that it creates, first of all, 
an Office of Competitive Technology in the Department of 
Commerce. We are funded at a level of $7 million in this 






The governor has stated that he will be asking for $20 million 
a year from then on. 
I have to tell you that with the passing of Proposition 
98, none of us are sure what our budgets are going to look 
like. I won't get into an argument with anyone here over 
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the merits of Prop. 98, but I can only tell you that the 
2 cold hard fact is that it is going to wreck havoc with other 
3 budgets, not the least of which is the University of California. 
4 But in any event, we'll have to just see what that 
5 $20 million next fiscal year looks like. We think it will 




program. It has the very strong support of Senator Garamendi, 
and it has been a very, very successful bipartisan effort. 
So it is not for lack of support that the program 








remains to be seen. In any event there are some reasonably 
significant funds here for us to get started. 
As I said, the legislation was signed in September. 
Since that time, we have been writing the regulations to 
the program. The legislation was passed on an emergency 
basis, which means the regulations are also being written 
on an emergency basis and should be completed in about two 
18 weeks. We have a final draft. And so the regulations are 
19 virtually completed. 
20 The application process for the program is coincidental 
21 to this so that if everything continues to go well the next 
22 two to three weeks, we should have the regulations in place 
23 and the application process ready to distribute by very early 
24 in January. 
25 The program is obviously a technology transfer 














program. It is intended to bring the private sector to the 
labs and to the campuses. Any given project requires, with 
very few exceptions, private sector participation. It is 
for the benefit of California companies. We want this to 
be done in California. And the funding will flow through 
either a public agency, a university, a national laboratory 
or a nonprofit organization of some other type. 
It also comprehends intra-industry collaberation; 
obviously, that would be applicable to the biotechnology 
industry in some areas where discussions with probably three 
or four different discreet industries at this point who are 
interested in putting together intra-industry consortia that 
we think would fit the requirements of this program very, 
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14 very well. 











sector and from California companies. It does not prohibit 
involvement from companies outside of the state as long as 
there is a California company or companies that are involved 
in the project. But the majority -- the great majority of 
the project work, if you will, does have to take place in 
California. 
The purpose of the program again is to address 
the competitive needs of our state. It is to address overriding 
policy issues of our state such as environmental concerns. 
We intend to see this program -- at least hopefully see this 
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1 program addressing environmental concerns, environmental 
2 technologies that hopefully will help companies who are already 
3 here who are suffering from environmental concerns of one 
4 type or another, and find the technological wherewithal 
5 to stay in the state. 
6 So it's going to be heavily emphasizing healthy 
7 companies who are already here, addressing the issues that 
8 companies have existing in California today and, obviously, 
9 serve as an inducement to bring other business and other 
10 companies into California. 
11 That's the rudiments of the program. The program 
12 was written and the statute was written hopefully in a reasonably 
13 general manner so that we haven't locked ourselves in it. 
14 It is intended to be nonintrusive, if you will. We are not 
15 attempting to dictate the policies of any given institution. 
16 We simply are trying to create a catalyst and a program that 
17 will induce collaboration. And the funds are there for those 
18 who see their way to apply for them and to use them. 
19 If there are any questions about this, or if we 
20 have time for a question or two, I'd sure be happy to answer 
21 any if anyone else has anything they'd like to ask. 
22 UNIDENTIFIED SPEAKER: Is one of the industries 
23 that you're talking to the biotechnology industry? 
24 
25 
MR. GIBSON: Yes. 
DR. SALSER: What kind of a generic kind of a 
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ones -- do you see coming from the biotechnology industry, 
especially related to the Human Genome Project? 











right now. I think that's exactly what this kind of conference 





from here to there. And the program would certainly be available 
for hoping to achieve the incremental steps to the end result. 
So in other words, if we're talking about computer 
processing or a process achievement along the way, the 
program-- in other words --we don't see it as always being 
on the tail end where a product is going to cough out and 
we can go buy it at Sears. It's not intended to do that. 
14 On the other hand, it is intended to provide funding 
15 for projects that do have in mind the eventual commercialization 
16 or a product-oriented end result, or a process-oriented end 
17 result, if you will, for the good of the state and the companies 
18 in it. 
19 But it would be hard for me to answer that question 
20 because I'm not sure where you are on that. That's really 
21 more up to this kind of a group and the industry to tell 
22 us what they need out of this program. 
23 UNIDENTIFIED SPEAKER: Does your program have anything 
24 to say about or do with the public education of new technology, 
25 or have any interest in it? 
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MR. GIBSON: It has interest in it. It doesn't 
2 address it directly. Again, I think we'd be very open to 
3 that. But there is no concrete records of that in the statute, 
4 if you will. 
5 But, again, to the degree that it facilitates the 
6 kind of project that we're looking for, we're open for suggestions. 
7 And that's really the key point of this is that the concrete 
8 is still wet on this program. And we're very anxious to 
9 have input from a very wide variety of sources. 
10 UNIDENTIFIED SPEAKER: Could funding for your program 
11 serve to attract federal funding for a large project like 
12 this? 
13 HR. GIBSON: That's an excellent question. When 
14 the Governor said and when we say that we're trying to go 
15 our own way here and not be dependent on federal projects 
16 or federal funds that doesn't mean that we don't want to 
17 attract federal funds. 
18 And we really feel that if our program is successful 
19 it should tend to attract federal funding. And a major part 
20 of the project is to leverage private sector dollars, federal 
21 dollars, whatever there may be. 
22 DR. SALSER: Thank you very much. 
23 By the way, I've been told that there's not going 
24 to be a coffee break this afternoon, but there will be a 
25 few minutes between each of the segments for people to put 










slides in the projector trays and so on. And I'm told that 
there is coffee on the tables out there, and so you can come 
in and out. 
Our first panel this afternoon is chaired by Dr. 
Norman Arnheim. Dr. Arnheim is California trained, having 
received his Ph.D. in Berkeley in 1965. And since 1985, 
he has been chair of the Department of Biological Sciences 
at USC. 







as the Senior Scientist at the Cetus Corporation where he 
played a major role in developing the polymerase chain reaction 
approach that many of us are using. 
More recently, he's also played a major role in 
extending the usefulness of this powerful technique. His 
15 group has shown, for instance, that you can work with very 
16 difficult but very useful material such as thin sections 
17 of human tissue, of parraffin embeded tissue, or even single 
18 spermatazoa. 
19 And as Charlie Cantor mentioned this morning, related 
20 to that technique, this technique for analysis of single 
21 sperm sounds rather obtuse, but may become one of the most 
22 powerful techniques for fine structure of genetic mapping 
23 with human chromosomes which is a very important part of 
24 what we're discussing today. 
25 Dr. Arnheim will introduce the members of this 
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1 panel who will discuss the potential impact of the genome 
2 initiatives on basic research. 
3 DR. ARNHEIM: As was just mentioned, the purpose 
4 of this panel is to discuss the impact of the human genome 
5 initiative on basic research. And I think it's clear that 
6 there are at least two fundamental principles that we can 
7 rely on. 
8 One is that there clearly will be a technology 
9 transfer, that is all the technologies and technologies that 
10 we can't even possibly dream about perhaps will have an impact 
11 on people who are interested in doing basic research. And 
12 I think there's no question about that. 
13 It's also true that one of the major driving forces 
14 for the human ~enome initiative is the need to understand 
15 some basic fundamental principles of biology. And it's also 
16 equally clear that the kind of data that is going to be coming 
17 out of the mapping and sequencing part of the initiative 
18 is going to absolutely require -- in order to understand 
19 the data some applications of basic biological research. 
20 So I think each of the basic biology and the quest 
21 for fundamental information about basic biological principles 
22 is going to drive the human genome initiative, and at the 
23 same time the human genome initiative in order for it to 
24 understand its data is going to be driving the basic research 
25 community at the same time. 
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1 Now, three of our panelists this afternoon will 
2 be discussing how the human genome initiative will impact 
3 on general cell and developmental biology in animal models 
4 of disease in human genetics and also evolutionary biology. 
5 And, finally, our fourth speaker will more or less 
6 bridge this panel to the next one by discussing some basic 








I'd like Glen Evans, who is an Associate Professor 
at the Salk Institute to perhaps start off this afternoon. 
And he's going to be talking about areas that are related 
to generating animal models for human disease. 
DR. EVANS: One of the -- there are actually from 
my point of view two major important things to come out of 
the human genome initiative One, of course, is simply this 
15 sequence of nucleotides that make up human chromosomes or 
16 the human genome. 
17 But as Francis Crick is always very quick to remind 
18 us, we don't really care what the structure of the genes 
19 are. We want to know what they do, what their function is. 
20 And one can anticipate that knowing the complete sequence 
21 of the human genome is likely to give us a vast amount of 
22 information but, in fact, in many cases won't answer that 
23 last question: What do the genes do? 
24 To approach that and, in fact, to approach what 
25 is probably the most important question in biology at the 










present time, which is: How does the genome control or program 
development such that a single cell can turn into an individual 
human being requires another step in biology? 
And while what I'll talk about in just this few 
minutes is not directly under the auspices of the Genome 
Project, it's something that will be evolving at the same 
time as the Genome Project in terms of technology and techniques. 
Genetics has really undergone a major change these 
9 days in that one can now do experiments. Genetic experiments 
10 were not possible several years ago. 
11 Could I have the slides? Do we control that, or 
12 are they controlled from there? And you need to skip forward 
13 four slides or five, I think. 
14 One of the ways that we might begin to approach 
15 what genes do having determined them is, in fact, to reimplant 
16 them into an organisrrt, either in its normal configuration 
17 or after making some changes. This is now fairly routine 
18 in a large number of laboratories with a technique knmm 
19 as producing transgenic animals. 
20 This is a selection of mouse embryos at a very 
21 early stage, essentially a one-cell stage. And under the 
22 microscope, one can essentially hold that using micro tools 
23 and introduce back into that embryo a small amount of material, 
24 a gene, either a gene when it's cloned from a human being, 
25 from a mouse, from another organism in its natural state 
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1 or one in which one has expressed one's creativity and made 
2 a number of changes. 
3 Those embryos can then be reimplanted back into 
~ a pregnant animal. And the next slide shows that 21 days 
5 later one has mice. 
6 This mouse looks completely normal from the outside. 
7 On the next slide though, we can demonstrate by looking at 
8 the DNA that it has been genetically modified, and that it 
9 now has material present in its genome which was not there 
10 before. 
11 The animals that show the extra bands here are 
12 the ones where we had planted an extra piece of genetic material, 
13 and that genetic material can be from a large number of sources. 
14 One way that one might go about understanding what 
15 some of the genes do that will be uncovered by the Genome 
16 Project is essentially to reimplant those, having made a 
17 mutation in that, then ask: What effect does that mutation 
18 have? 
19 This can take a wide variety of can use a wide 
20 variety of different approaches which can go from simply 
21 inactivating the gene using techniques which are just nnw 
22 becoming available, that is turninq if nff, and aski~q: What 
23 is the effect of that ~h~ence of the gene product on the 
24 final organism? Or, in fact, one can ask that that gene 
25 be turned on somewhere that it's not normally expressed. 
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1 A gene that might normally be exprP-ssed in the liver, one 
2 could perhaps turn on in the brain, and ask: What would 
3 be the consequence of that? 
4 Both kinds of approaches are important because 
5 many of the genes that one might imagine being important 
6 to development if inactivated would be lethal. It 'dOU}_d 
7 not allow the animal to survive and develop. 
8 The next slide shows that this can actually be 
9 taken quite far, in fact, ~o the extreme in that one can 
10 model animals to simulate certain human diseases. This approach 
11 is now in its very infancy, but it has the potential of being 
12 extremely valuable fer making models o~ diseases for which 
13 we really can't imagine the underlying cause. 
14 This is an animal on the right which is completely 
15 norma~. This is an animal on the left in which we've modeled 
16 a genetic defect in the development of the eye. This has 
17 been done by implanting a plant gene from the castor bean 
18 in the genetic compliment of the animal under the control 
19 of elements which turn on at a specific time in development 
20 and kill certain cells that are responsible, in fact, critical 
21 for that developmental process. 
22 And a large number of labs are in the process of 
23 doing those kinds of studies to derive models for diseases 
24 such as Huntington's disease or neurodegenerative diseases 
25 in which certain cells may degenerate or die at particular 
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1 times in development but, in fact, we have no idea what the 
2 underlying causr: is. 
3 Eventually, as the Genome Project progresses, one 
4 can imagine a lot of the genes responsible for those diseases 
5 might be uncove=ed, but we may have no idea how they function 
6 in the animal. And these kinds of approacheG might allow 
7 us to go a little bit further along that. 
8 The next slide, I believe is the last one, is to 
9 emphasize the point that these modifications are not only 
10 the individual in which the gene is introduced but all of 
11 the progeny of that; that is it's a true genetically engineered 
12 situation where not only the initial animal but all of the 
13 subsequent progeny are also modified. And those animals 
14 can then be bred and extremely useful for a large number 
15 of studies. 
16 One final word which addresses a couple o:: comr1ents 
17 made this morning is that it is not possible to do experiments 
18 in human beings, particularly genetic experiments. Yet, 
19 it is possible to do those kinds of experiments in animals; 
20 therefore, it's very important that as one begins to understand 
21 the human genome that in parallel one begins to understand 
22 the genomes of other animals in which one can do those experiments, 
23 in particular the mouse which is a ,.,onderful genetic system 
24 and becoming a model for manipulation. 
25 Many of the regions of the human genome are, in 
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1 fact, colincar with the same regions in the mouse genome; 
2 that is if one finds a gene in a particular place in man 
3 and one looks in a similar place in the mouse, one finds 
4 the same gene. 
5 That's one way to anticipate that almost anything, 
6 aleost anything, one would find in the human genome, a similar 
7 gene would be present in the mouse, and that would allow 
8 one to, in fact, approach it in an experimental sense rather 
9 than in a descriptive sense. 
10 I think that's all I want to say. And I think 
11 we' 11 lead into David Cox. 
12 DR. ARNHEIM: Yes, our next speaker is David Co::: 
13 who is a human geneticist, and he will give us some insight 
14 about what he feels the consequences of the proje~t to he 
15 in that area. 
16 DR. COX: Let me just say that my comnents will 
17 sort of be focused more specifically on one aspect of what 
18 Jim Watson and Charles Cantor talked about this morning which 
19 was the overall broad-brush stroke of the Human Genome Project. 
20 But right now we're not waiting until we know where all the 
21 genes are before we start trying to apply some of the technologies 
22 and some of the approaches that we all hope to use in the 
23 future. 
24 And in the next couple of minutes what I'd like 
25 to do is show you at least one apsect of that that's being 
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San Francisco, but just as an aspect of what's going on by 
lots of different human geneticists around the country. 











with respect to recombinant DNA technology in human genetics? 
And it's no mystery to this audience that it's been a revolution 





to identify where in the genome various human dise~se gen~s 
lie even though we know nothing about the protein products that 
codes for those mutant genes. 
Just a minor list of examples: Huntington's disease, 
a gene for schizophrenia, a gene for manic depressive illness, 
a gene for Alzheimer's disease; it goes on and on. It's 
1~ truly remarkable. 
15 But just as though that's remarkable, it's been 
16 equally dismal how in some of those situations where we've 
17 known where the link gene was and on which chromosome it 
18 lay, how difficult it's been to get the mutant gene product 
19 out. 
20 And so while we think about developing ways to 
21 sequence the whole human genome, our approaches for coming 
22 up with that development, I think in human genetics, is being 
23 applied to present day problems. And at least in our labs, 
24 it's how to get those genes out and what kind of technologies 
25 cuuld then be developed for those specific problems. but 
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1 also in more general ways. 
2 So what's the experimental strategy? This is one 
3 such possible experimental strategy that one might take. 
4 The first is specifically with regards to the Huntington's 
5 disease gene, a simple dominant gene for a neurodegenerative 
6 disorder. It's knovvn to map to the distal short end of Chromosome 
7 4. 
8 If you simply take purified Chromosome 4 and try 
9 and isolate DNA probes from that, the chance that you're 
10 going to be close enough to show genetic linkage to the Huntington's 
11 disease gene is very, very slim. 
12 So what's an approach that will give you an order 













order of magnitude boost of getting probes in the region 
that you vlan t? 
Well, a simple approach would be to isolate the 
region of Chromosome 4 in a somatic cell hybrid so that it 
was the only human material there. If you could do that, 
then the next thing you could do is isolate human probes 
from that hybrid cell, and you'd be very close to the gene. 
So the very first step is a simple minded one, 
how you just crack off a piece of chromosome that you want. 
Once you have those probes though, you have a pot 
of full of probes, but you don't know what their relative 
order is to one another. It was mentioned today -- Charles 
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1 Cantor pointed out -·- the real magnitude of the problem of 
2 getting real fine structure genetic ~aps to order those probes 
3 relative to one another. 
4 What you'd like is a genetic ~ap that wasn't 
5 1 million base pairs per 1 percent recombination, but you'd 
6 like a genetic map that was much closer to the physical distance 
7 so that 1 percent of a genetic unit would be like 100 kilobases. 
8 So that's the second thing if one could come up with that. 
9 The third thing is that once you've ordered all 
10 the probes, you still don't know where the disease gene is. 
11 You have to go back into the affected families. You take 
12 probes that you think off of the ordered probes are the nest 
13 likely to be flanking markers, but then they have to be polymorphic. 
14 They have to be informative in the families that you're interested 
15 in. One needs a better technology ~or that for any particular 
16 probe. How does one approach that problem? 
17 And, finally, once you find the flanking markers, 
18 hmv you clone all the DNA out bet\veen those flanking markers, 
19 one needs a better technology for that. 
20 These are the problems that are posed by our embarrassment 
21 of riches; that is knowing where all these mutant genes are 
22 but having difficulty getting them out because of those four 
23 come back to identifying candidate 
24 genes at the end. 
25 So here's Chromosome 4. Huntington's disease is 
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1 way up at that light band on the tip of the chromosome. This 
2 is to scale, so it shows you the magnitude of the problem 
3 because the band is just 10 percent of Chromosome 4. 
4 Can I see the next slide, please? 
5 So one approach that we've taken js to start off 
6 with a cell line that has a single human chromosome and a 
7 hamster cell with a single human Chromosome 4, and that's 
8 shown in Panel A there with the little arrow, that's Chromosome 
9 4. And over to the right in Panel B is that same cell line 
10 stained just specifically for human chromosomes. And so 
11 you can see that fuzzier chromosome there, that's a whole 
12 Chromosome 4. 
13 If you take that hybrid, you expose it to radiation, 
14 and in a nonselective way isolate hybrids that have just 
15 pieces of chromosome in them, you can enrich be a factor 
16 of 10 for getting probes out around the Huntington's disease 
17 gene. And that's illustrated down in the bottom of the slide. 
18 If you have two pieces of DNA in that hybrid that it greatly 
19 
20 
enriches. It increases by a factor of 10. 
Step No. 1. Now, once you've got those probes, 
21 how do you order them? And what we intend to develop wa3 
22 alluded to earlier today is an approach that's analogous 
23 to meiotic mapping, but using just somatic cell hybrids. 
24 With somatic cell hybrids then, put a single human 
25 chromosome in that are irradiated, can be used like individual 
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1 hybrids as though they're individual meiotic products. And 
2 you use breakage by radiation as a measure of how far apart 
3 two genes are to one another. I don't have ti~e to describe 
4 this to you, but I wanted to show you a slide of what the 
5 result is. 
6 On the right is the meiotic map for region of Chromosome 
7 21 that is in the vicinity of an Alzheimer's disease gene. 
8 On the left are additional probes that are put on the map, 
9 plus the ones that are also on the meiotic map. And it shows 
10 you that with this radiation hybrid approach the map is expanded 
11 20-fold, and you're able to order probes relative to one 
12 
13 
another. This is with the 100 somatic cell hybrids with 
a medical student vvorking two months in the .summer. Step 
14 No. 2. 
15 Step No. 3 I don't have time to have a slide for, 
16 but that's once you've had these probes ordered, then you 
17 want to make them polymorphic to go back into the disease 
18 families and make sure that you're able to tell one chromosome 
from another and really know what 





at restriction enzymes and hoping 
base change, a single base change 
23 set. 
your flanking marker is. 
done by simply looking 
that you find the single 
that changes ·the restriction 
24 My collaborator Rick Myers has pioneered ways of 
25 identifying single base changes in human DNA. You think 
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1 that can't apply very much to human genetics? It's remarkable 
2 on human genetics, not only for identifying point mutations, 
3 but specifically in this problem for taking any probe that 
4 you want and identifying the single base change that allows 
5 you to map it meiotically. 
6 Can I see the next slide, please. 
7 The fourth problem, which is how to clone the DNA, 
8 Bob Mortimer will tell us about. The closest flanking markers 
9 are likely to be no closer than 1 million base pairs, as 
10 Charles alluded to today. If you have 1 million base pairs 
11 and you clone 50 kilobases 50,000 base pairs at a time, ~ou 
12 don't need to be a higher mathematician to figure out that 
13 that's going to take you a long time. But if you can clone 1 
14 million base pairs a time, or 300,000 base pairs at a time, 
15 and yeast artificial chromosomes, then one will be able to 
16 another order of magnitude --- speed up the possibility of 
17 getting all the DNA between the flanking markers. 
18 So far I've talked about three technological advances 
19 that allow us -- and not all of which have completely come 
20 to fruition yet, but which are on the horizon so that they're 
21 not just dreams. They're really going to happen, three ways 
22 that allow us in a general way to begin isolating human disease 
23 genes and solve these problems. 
24 Now, are they going and mapping the whole human 
25 genome? No, they're dealing with one specific gene at a 
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1 time, but they're general and will be, I think, very useful 
2 to the whole Genome Project, but they're very directed to 
3 human genetics problems. 
4 In the final 30 seconds or so I'd like to address 
5 what I think is going to be the real problem. This is nuts 
6 and bolts. We need these orders of magnitude boosts to get 
7 the genes out. But the real interesting thing is not getting 
8 genes, it's really finding out what they do. But we can't 
9 find out what they do until we find the gene in the million 
10 or so base pairs of DNA. That's the real problem for the 
11 future. 
12 One of the things from my point of view and 
13 for right now, we could sequence 1 million base pairs of 
14 DNA easily. We could go and very directly with better software 
15 identify all the genes in that million base pairs. There's 
16 probably 20 or so genes. Right now there's no easy way of 
17 doing that. 
18 I would think that that could be a major impact 
19 of the human genome initiative on human genetics. 
20 What are the approaches the people take now? Glen 
21 already alluded to it. It's using comparative mapping to 
22 try and find sequences that are conserved in one organism 
23 from those in another. 
24 This is an example that HSA-21 is -- a cartoon 
25 of the human Chromosome 21. And what it illustrates is that 
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there's conserved sequences of human Chromosome 21, large 
numbers of genes. To the left are on mouse Chromosome 
16, but not all on one mouse chromosome. Some are on mouse 
4 Chromosome 17 as illustrated to the right, three genes. And 
5 four genes are on mouse Chromosome 10. 
6 So this is very crude comparative mapping, but 
7 it illustrates the humps of the genome in other organisms 
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8 that you can use to identify genes that might be in the region 
9 that you want. This is the area of technology development 
10 that really needs to come about to get better. 
11 But identifying the mouse sequences, then from 
12 my point of view, one can go and make the animal models that 
13 Glen just talked about and get two birds for the price of 
14 one; and that is using them as models not only as assays 
15 for the mutant genes you're looking at, in the case of Huntington's 
16 or Alzheimer's disease, if you're lucky. But if you get a 
17 phenotype, then you're able to study the biology in those 
18 animal models. 
19 So to sum up, what have I said? I've said that 
20 I think that we don't have to wait for the impact of the 
21 human genome initiative on basic biology. It's here. Even 
22 though we don't know exactly how to approach and do the whole 
23 human genome, approaches that are stimulated by thinking 
24 about that are having major impacts on human genetics right 
25 now, and I think that they're only to get better, largely 
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1 in terms of helping us figure out where the genes are in 
2 the large pieces of DNA that we isolate, but more importantly 
3 constructing animal models or cell models that allow us to 
4 understand the function of the genes. 
5 DR. ARNHEIM: Our next speaker is Walter Fitch 
6 from the University of Southern California. And Walter will 
7 tell us a little bit about how he thinks the initiative is 
8 going to affect evolutionary biology. 
9 DR. FITCH: I'll stick to evolution, but I hope 
10 I'm less technical, that was my intent. And I may be thinking 
11 a little broader, perhaps over generally. 
12 But I want to start off by first of all saying 
13 that well, most of you understand evolution, I think, 
14 as a process akin to a family tree. The genealogy of your 
15 family is not all that different from the genealogy of organisms 
16 and really can ask about the relationships of animals and 
17 plants and plants to bacteria and all of that. 
18 With the sequencing of the genome, there's another 
19 kind of family tree that I'd just like to bring to your attention. 
20 Our chairman in his youth studied a protein from eggs of 
21 birds, but humans have this tOOi it's called lysozyme, and 
22 it breaks down bacterial cell walls and is part of our ability 
23 to resist infections. 
24 Now, one of the things that can happen in the course 
25 of the history of a group is that a gene can duplicate, and 



















this gene has done it. And so you have sort of a brother 
and sister here. And in this case the sister evolved and 
changed in such a way that while we can clearly recognize 
that this is a brother and sister, the sister is really quite 
different and is absolutely required for the lactating female 
to synthesize milk. And your first reaction is likely to 
143. 
be: What possible relationship can there be between something 
that breaks down bacterial cell walls and making mille for 
human lactation? Well, I won't go into why it's there, it's 
obvious if you get into the details. 
But this process of creating a family is something 
that goes on continually in the genome. There are lots 
of these. Some families are larger, perhaps we should call 
them clans. And asking: What happened? When did they happen? 
in the case of the duplication that I just described, not 
surprisingly that gene duplication that led to this lactating 
gene, lactation gene, occurred right at the origin of the 
mammals. And it's present in all the mammals, but it's not 
19 present in birds, unlike lysozyme which is in both. 
20 So we can ask questions like this. And there are 
21 some clans in which there are hundreds of copies of genes, 
22 the duplication has occurred many times in this spread. And 
23 we can ask: How are they related to each other? 
24 
25 
Searching for these is a simple problem in the 
first place. If you've got one pattern, you look to see 
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1 if there's anything like it, and that's how this lactation 
2 gene was found. You look to see if anything in your data 
3 base looked like what you already had, and that's how it 
4 
5 
vvas found. That process, of course, will continue. 
But in terms of the future and here's where 
6 I'm going to be a little nebulous -- in this case, we had 
7 a simple problem. We knew the pattern that we were trying 


















going to be fun is to search for patterns that are meaningful 
because every time you look at something there's a pattern 
there. The question is: Does it have any significance? -- without 
knowing the pattern you're trying to look at. And, of course, 
you can do that by things like restricting it. 
Supposing you would just look at pituitary cells, 
that is brain cells of some sort. And then you ask: What 
things do I know that occur only in the brain and nowhere 
else are present in my sample? And are there characteristics 
about those that are not characteristic of things that are 
turned on in other kinds of cells like the liver or the lung? 
And you start looking then for things that you don't know 
what you're looking for, but you know that if you find it, 
it's going to be a great help in terms of answering questions 
like development, answering questions maybe about disease 
and a lot of other things. 
So part of the problem is unsolved, but there will 
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1 be a real cottage industry out there of people looking for 
2 techniques for finding these patterns. And how can you go 
3 about searching for them, whether they're at the protein 
4 level or at the gene level? 
5 Another thing about this is trying to find out 
6 these relationships that I've just described. We'll be doing 
7 that across species, of course, because we're going to be 
8 learning a lot at the same time about genes from other animals. 
9 So we will be getting that classical kind of evolutionary 
10 relationship that I mentioned. But we will also be getting 
11 them for the duplications of the genes within the genome. 
12 And finding those relationships is rather a tiresome process. 
13 It turns out that if you had 100 different genes 
14 that were all related to each other, and you wanted to know 
15 their ancestory, the number of possible histories is greater 
16 than the number of stars in the universe, maybe greater 
17 than the number of protons in the universe. 
18 So you've got to have good efficient ways of attacking 
19 those problems, and that's going to be a part of what's going 
20 on in developing new methods. So that's another new thing. 
21 I think it's going to have an impact in the following 
22 sense: What I've said up to here is what we sort of need 
23 in order to brouse through this large volume of material 
24 that we have. 
25 What's going to happen in the future, I think, 


























is that scientists, especially in molecular biology, are 
going to start doing the research rather differently, that 
the first thing you do before you write an NIH grant is go 
search this large encyclopedia of material to see how much 
of what needs to be known is already there before you screw 
up on your grant application and get rejected because its 
been done or it's obviously there and you just didn't look 
for it. 
146. 
And so we're going to have a whole generation of 
scientists who are going to be looking at this kind of prospect 
before they even do any work. And, in fact, there will be 
people like me who, in fact, will never leave that encyclopedia 
to go into the lab and do any wet chemistry. They're going 
to spend their life browsing through this looking for the 
patterns that maybe the people who did the hard work and 
got the sequences --- although it maybe it won't be so hard 
when everything has been done here -- maybe have missed. 
And so I see that there will be a whole new pattern 
of the way that research is done. I think the implications 
are very strong for that. 
DR. ARNHEIM: The next talk will be by Bob Mortimer 
who is from Berkeley and is the Chairman of the Department 
of Biophysics. 
DR. MORTIMER; Former chairman. 
DR. ARNHEIM: Former chairman of biophysics. He's 



















go to talk to us about YAC vectors. 
DR. MORTIMER: Well, just by way of introduction, 
I'm not a human geneticist. My specialty is working with 
yeast genetics. I'll make a point that yeast is not that 
far away from humans. But I have spent a lot of time working 
on genetic mapping, developing the genetic map of yeast. 
We have not had the audacity yet to compare the 
order of genes in yeast to that of a human, but maybe it's 
not an unreasonable thing to do. 
I want to talk about YAC cloning, yeast artificial 
chromosome cloning, which is one of the approaches that is 
being considered for developing physical maps of the human 
genome. The other principle is cosmid cloning. And I think 
that after I'm through, you'll see that there's reason that 
both of these are still being considered and possibly other 
approaches. 
Could I have the first viewgraph, please? 
The procedure was described by Burke Carle Olson 
147. 
19 a couple of years ago. And basically there's a special vector 
20 which they constructed that contains two telemeric sequences, 
21 and if one clones into this exogenous DNA from any source 




chromosomes in yeast, that's in principle. So this is the 
vector, and then the two arms, and then basically the chromosome 
here. And this then can be human DNA. 
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1 And Olson developed this method and has had a lot 
2 of success cloning human sequences into yeast. And several 
3 other groups, including our own, have been working on this 
as well. 4 
5 Can I have the next one, please. 
6 One of the technologies that needs development 
7 is making viewgraphs that have a sufficient range of grays. 
8 This is all just black and white, and there should be some 
9 in between. But the point is that the size of YAC's can 
10 vary anywhere from about 50 kilobases up to the order of 
11 a megabase. 
12 This is a total [inaudible] digest of the human 
13 genome. The bottom is about 50 kilobases. Up at the top 
14 is several megabases. And the experience, at least in our 
148. 
15 group and I understand most groups, is that we're not obtaining 
16 any representative sample of the restriction map -- restriction 
17 fragments from not one. And I think it would be necessary 
18 to obtain such a representative sample for developing a proper 
19 physical map. 
20 I guess this indicates that it would take a large 
21 number of these YAC's to cover [inaudible.] 
22 If you want end in a particular chromosome -- can 
23 I have the next one, please -- it will be necessary to separate 
24 from this large library of YAC's those that come from a particular 
25 chromosome. And this will either by standard techniques 
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If one can obtain purified or semi-purified chromosomes 
either from the human cells or from rodent human hybrid cells, 
then the job is much easier. In other words, if one in principle 
is interested in Chromosome 21, if one could have a large 
sample of Chromosome 21, and make YAC's from that, then the 
job is much easier. 
Current technology -- the best technique is [inaudible] 
10 activated cell sorter technique, and it can purify chromosomes 
11 but not in sufficient quantity for YAC cloning. 
12 I wanted to now just discuss some areas that I 
13 think call for additional research, and the first one is 
14 related to this. 
15 Can I have the next one, please. 
16 Related to the last point would be to explore new 
17 areas for separation of large numbers of specific human chromosomes. 
18 Several years ago it was shown that it was possible to separate 
19 [inaudible] chromosomes by [inaudible] and several groups 
20 are exploring this procedure again. 
21 The pulsed-field gel techniques that were developed 
22 by Charles Cantor can separate DNA molecules up to about 
23 7 megabases in size. This is still in the order of 4 or 
24 5 times smaller than the smallest human chromosome. Future 
25 developments in this area are marketable, I can't say. 
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Can I have the next slide, please? 
This just shows the study that was done several 
years ago. This is the chinese hamster karyotype. 










And this is after one passed through in a zonal cPntrifuge. 
at 3 runs , and three different fractions, you can see 
that there is an excellent purification of the smaller chromosomes. 
This was a study done 15 years ago. So I think it's true 
that this approach can at least give enrichment for particular 
10 sizes of chromosomes, but not purified samples. 
11 Another point, the size of the YAC transformance 
12 that our group is obtaining, and I think it's a general -- is 
13 not representative of the size of the fragments that are 
14 in the restriction fragment unless one does presize fractionation. 
15 And this could either be due to selective sharing of the 
16 larger molecules or some selection in the ligation or transformation 
17 step or possibly instability of the larger YAC's in both 
18 cells. I think the latter possibility is not too realistic. 
19 But this would call for research in manipulation 
20 of large DNA molecules and also in general studies of yeast 
21 transformation, ligation and transformation. 
22 
23 
Well, another area that-- the size of YAC's is 
determined by pulse-field gel electrophoresis For instance, 
24 this is the one that I showed you originally. These are 
25 lambda. And the upper gel -- the only difference between 
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And you can see that the gel is spread out between 50kb up 
to over a megabase. If one goes to 22 second pulses, then 
only the bottom three of these chromosomes are resolved, 
but their spread out over most of the gel. If one one goes 
to the 15 seconds, then regions smaller than the smaller 
chromosome are spread out. 
8 And so by selecting particular switch times one 
9 can expand different parts of the gel and resolve different 
10 sized YAC's with the yeast chromose. 
11 But as I say, most of our information on [inaudible] 
12 is empirical, and I think a lot more work is needed to give 
13 better understanding of these factors. 
14 One other area that I think calls for research; 
15 in fact, all of the physical mapping procedures that I know 
16 of involve autoradiography of gel blots and using film. If 
17 a two-dimensional data detector were available which could 
18 be just placed on top of the blot and I think such things 
19 are feasible from just talking to physicists -- that this 
20 would allow automation and automatic digitation of the data. 
21 And it seems to me that this is an area that calls for future 
22 research. 
23 One area that we're quite interested in just strictly 
24 for basic reasons, if one had a diploid cell that carried 
25 two yeast artificial chromosomes, which are mostly human 
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normally seen for yeast cells or frequencies normally seen 
for human cells. There's about a 300-fold difference in 
miotic recombination frequency between the two species. And 
I think that it would be quite an interesting point to look 
at. I haven't the slightest idea which result would occur. 
Finally, just David Sheldon in my group, just relating 
to the evolutionary argument, is cloning human genes by functional 
9 complimentation of the yeast mutants. And has obtained several 
10 of the purine metabolism genes, human purine metabolism 















DR. ARNHEIM: I think the first thing that we can 
do is just ask if anybody has any questions that they would 
like to address for our panelists. 
DR. SALSER: Maybe it should wait until after we 
get into the next one, but I'm very interested since these 
are not representative, and similar problems may occur with 
the cosmid physical maps; are any of you in the cosmid or 
the YAC groups thinking about how to overlap your sets of 
data and piece it together from all of the -- together? 
panel. 
DR. HORTIMER: Yes. 
DR. SALSER: Have their thoughts only been frustrating? 
DR. ARNHEIM: That will be discussed in the next 
DR. COX: They're all at very different levels. 











So going from the level of cracking off a whole hunk of chromosome 
to then making YAC's is and ordering those YAC's -- is 
at one level that you can well understand. 
DR. SALSER: I realize it's not a trivial technical 
question that I'm asking. 
DR. MORTIMER: I think Maynard Olson has one approach 
that gets around us by -- such as using size fraction equal 
our one partial fragments. I think that's probably obtaining 
a representative sample of the total genome by this approach; 
10 as we try to go for the huge one, something in the order 
11 of 300 kb. 
12 DR. EVANS: I think a number of people have shown 
13 with yeast that by doing an awful lot of work you can begin 
14 to overlap by cosmids by picking them at random, restriction 
15 mapping them, putting all of your information into a computer 
16 with an appropriate program that will match things up. 
17 I think there's no question that that works with 
18 a certain limitation. There are a number of people around 
19 thinking of ways of doing the same thing not requiring such 
20 a vast amount of work, number one, which involves analysis 
21 of multiple clones once, multiplexing, and now I guess to 
22 the George Church sequencing method and then having appropriate 
23 programs to sort that out. 
24 And I can think of three or four different groups 
25 in the process of working on those things. Some of the ideas 
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1 appear to work. Some of them theoretically will work, but 
2 technical limitations such as the Hans Laroff method in using 
3 all of the nucleotides are very difficult to overcome. 
4 In my mind, the technical advances that will really 
5 make that efficient are two-fold. One, to be able to speed 
6 up the process by doing multiplexy. Secondly, to have machines 
7 do it rather than people because it's very difficult to convince 
8 postdoc's to do that experiment, practically impossible 
9 to get graduate students to do it, but robots like that kind 
10 of thing. 
11 DR. FITCH: As a remark of frivolity, I was reminded 
12 during this conversation of my youth which was preceded 
13 Dr. Arnheim's by quite a bit I think. But I was listening 
14 to Fred Allen who routinely visited Allen's Alley, one of 
15 whose residents was Falstaff Oppenshaw, the poet laureate 
16 of the alley, one of whose poems was entitled, "Alas, Alack, 
17 What Is a YAC?" 
18 DR. BOYER: I had a minor question for Walter Fitch. 
19 This humanian lactation gene, what's known about its biochemical 
20 function? 
21 DR. FITCH: A great deal. The association between 
22 the lysozyme which breaks down the cell walls and bacteria, 
23 they happen to be carbohydrates, the cell walls. And so 
24 the lysine breaks a particular bond. 
25 In the case of the gene related lactation, what 
Pike Court Reporting (805)658-7770 
155. 
1 it's trying to do is to impose the system a recognition of 
2 a specific configuration of carbohydrates so as to join them 













DR. BOYER: It's actually the lactose synthetase? 
DR. FITCH: Yes. It's not the whole synthetase, 
it's a part of it. 
DR. ARNHEIM: I'm wondering whether there's anybody 
from the industrial sector who might want to make a comment 
concerning what they feel the human genome initiative might 
terms of their basic, if they have any basic research programs, 
but in terms of their basic research programs -- what impact 
they might see. 
volunteer? 
Is there anybody here who would like to 
[No response.] 
DR. ARNHEIM: No. 
16 Are there any other additional questions? Otherwise, 
17 we're more or less on time, and we can go to the next session. 
18 UNIDENTIFIED SPEAKER: It's not a question. But 
19 I'm curious. Do you think as a valid to labor, I think that 
20 what I just heard is that contrary to what some people feared, 
21 it sounds like the Human Genome Project -- technology if 




biological basic research. 
what I just heard? 
Is that a fair conclusion to 
DR. ARNHEIM: Well, certainly, I think a lot of 
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1 us would agree with that conclusion, yes. 
2 
3 
DR. FITCH: I mean it's absolutely necessary. 
DR. COX: I would say that that's a very succinct 
4 way of saying what I've tried to say, yes. 
5 DR. ARNHEIM: I'd like to thank the panel. 
6 
7 Recess 2:20 p.m. to 2:30 p.m. 
8 
9 DR. SALSER: I thought it would be good to give 
10 everyone about 10 minutes I think we've taken to stretch 
11 your legs. But it's time to get underway again. 
12 It's a pleasure to introduce the moderator of our 
13 second panel, Tony Carrano. He is a section leader with 
14 the genetic section at the Lawrence Livermore Laboratories 
15 of the Department of Energy and the University of California. 
156. 
16 Dr. Carrano also received his Ph.D. from the University 
17 of California, Berkeley. 
18 I've known Tony for a very long time, and I've 
19 always been impressed with this group's ability to apply 
20 very elegant physical and instrumentation techniques to carry 
21 out difficult genetic analyses. 
22 In the National Gene Library Project, they used 
23 flourescence activated chromosome sorting to make chromosomal 
24 assignments for various genes and also to make chromosome-specific 
25 human clone banks. 
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1 More recently, Tony has been successful in using 
2 the ABI, Applied Biosystems, DNA sequencer as a powerful 
3 tool for a new purpose, not for sequencing but to automate 
4 the creation of ordered sets of cosmid clones to create the 
5 so-called physical maps of the human chromosomes just as 
6 was discussed in the last talk of the preceding panel. 
7 These physical maps are going to make clone by 
8 phone an incredibly powerful approach, and that's totally 
9 independent of the uses of the main goals of the Genome Project. 
10 But they're also, I think, an essential starting point for 
11 a well-organized sequence analysis program. 
12 Tony is going to introduce his panel, who will 
13 consider development of the needed technologies, both hardware 
14 and software. 
15 
16 
DR. CARRANO: Thank you, Winston. 
be back at UCLA again. 
It's good to 
17 As Winston indicated, the charge to our panel is 
18 to discuss the development of needed technologies as well 
19 as hardware and software. 
20 What I thought I'd do to try and set the mood for 
21 this is to actually take the biology of the human genome 
22 initiatve as we had seen displayed and try and put it against 
23 the disciplines and the technologies that might be necessary 
24 to get the initiative accomplished. And I think the first 
25 viewgraph sort of sums that up. 

















The human genome initiative really is at least 
two projects, two major projects, and separate in terms of 
the technologies that are needed in a sense. It's, first 
of all, a project of ordering; and, secondly, a project of 
DNA sequencing. 
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We start with human material in the form of a cell 
and we want to wind up with the genetic code, the DNA sequence. 
And there are really many steps that we have to go through 
to get there, and there's many technologies and disciplines 
involved. 
For example, as we heard earlier, the human genome 
is huge. It's 3 billion base pairs in size. And to tackle 
that problem as a whole is extremely difficult, if not impossible, 
at least with the present state of technology. 
And so everybody's consensus is that we've got 
to fractionate this human genome in some way. One way is 
17 to break it up naturally into its components, the chromosomes, 
18 the 24 different human chromosome types that we have. Another 







We've heard about yeast cloning from Bob Mortimer 
a few minutes ago. The other approach is to use physical 
methods to separate individual chromosomes. We've pioneered 
at Livermore and at Los Alamos simultaneously the development 
of fluorescence activated cell sorting to purify chromosomes. 
And this basically separates chromosomes on the basis of 
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1 DNA content and DNA base composition. 
2 Now, it's an interesting feature because this particular 
3 methodology can analyze chromosomes at the rate of several 
4 thousand per second and it can separate chromosomes at the 
5 rate of 700 per second. Now this works just fine -- after 
6 several years now -- it works just fine for cloning DNA into 
7 certain types of vectors, lambda vectors or cosmid vectors. 
8 But it doesn't provide us enough DNA just yet to 
9 clone into systems which require a little more cloning efficiency 
10 such as the yeast-artificial chromosome. 
11 For example, we can sort on good days, purifying 
12 good days, about 5 million chromosomes of any one type. That 
13 provides about 1 micrograms worth of DNA equivalent. And 
14 as I talked with Bob a little bit before at lunchtime, it 
15 looks like that to clone into yeast-artificial chromosomes 
16 it's going to require about 10 8 chromosomes or 20 times that 
17 much DNA, or on good days, 20 good days of actually sorting 
18 with the instrumentation. 
19 That's sort of a balloon of practicability right 
20 now. It only gives you one shot. If you miss you have to 
21 do it another 20 days. And so right nmJ we're not quite 
22 there. 
23 But there are other mechanical methods that can 
24 accompany that such as prepurifying the chromosomes on 
25 systems and then using that as an enriched fraction to sort. 
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1 And all these things can be looked at. 
2 Well, once chromosomes are purified, then one has 
3 to then go into the molecular biology genetics and clone 
4 these pieces, fractionate the chromosome further and clone 
5 the pieces of DNA. 
6 And this is an interesting area because we don't 
7 have to wait until a project is finished to get something 
8 commercialized. We immediately create a set of consumables 
9 right here. We immediately create a new set of vectors, 
10 cloning vectors, which are marketable, are being marketed. 
11 We immediately create libraries of specific chromosones which 
12 are marketable. We immediately create from this probes from 
13 that DNA where certain genes are markers for genomes which 
14 are marketable. So this creates a set of consumables which 
15 can and are being commercialized right from the very start 
16 of the project. 
17 Once we have these libraries, then one has to put 
18 them all back together again, take these little pieces that 
19 we've now got separated into little tubes and put them 
20 all back together again. 
21 So we've actually come a full circle. We started 
22 with an entire chromosome, cut it into pieces and then we 
23 want to put it back together again. 
24 This is a very labor intensive process, and it's 
25 also a process that requires a heavy dose of mathematics 
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1 and statistics. So the mathematicians, staticians and the 
2 computations experts get involved in this problem to a very 
3 large extent. 
4 We have developed a technology, as Winston just 
5 mentioned, to automate this process. The present methodology 
6 relies upon not radioactivity but using the fluorescence 
7 tag to label these fragments and to analyze them on automated 
8 DNA sequencer, which is commercially valuable. This was 
9 a project that we did in collaboration with a group at Applied 
10 Biosystems in Foster City, California. 
11 With the technology that we have, it allows one 
12 to progress at the rate of putting these pieces together, 
13 and I believe it's about a million bases per week. There's 
14 still a long way to go to do the whole human genome, but 
15 this can be improved further, we think, by at least a factor 
16 of 4. 
17 Once these pieces are put together, then one can 
18 take the probes that are established here and pull out those 
19 pieces of DNA that contain the genes of interest, the genes 
20 of interest that you're working on which could then be sequenced, 
21 that could then be used certainly in diagnostics or the treatment 
22 of certain diseases. And so there's definite commercialization 
23 and human benefit at this end right here. 
24 So what I want to impress upon you here is that 
25 this is really a multi-disciplinary project. It involves 



























physics. It involves chemistry. It involves engineering. 
It involves mathematics. It involves computer sciences. 
It's not just a biology project. And so what it requires 
is that groups get together. Fortunately, at least the national 
laboratories, all those components exist. At universities 
those components exist. It's a question of how you can get 
them together to talk to get the project done. 
Now this group is going to address some of the 
issues related to these technologies. And our next speaker 
up I think will sum up what we're going to talk about I hope. 
The components of that, I mentioned they're here. They're 
going to continue to be here, and they change. They change 
rapidly. What's being marketed today in terms of vectors 
and libraries may be different than what's marketed six months 
from now. So it's an ever-changing market. 
Mapping I've briefly mentioned. But an important 
component of this whole process is robotics, and we're going 
to hear a little bit about that and how that can -- other 
technologies in this area can help accelerate this process. 
DNA sequencing, of course. We've heard some of 
that all ready. Multiplex is' still in its infancy. It's still 
in what I call the first generation perhaps of DNA sequencing, 
and I can see at least two more generations coming beyond 
that right now what's on paper at least. 
We need the hardware, and we certainly need the 


























software to be able to put all this information together 
and to analyze it and to disseminate it. We're going to 
hear a little bit about that as we go along. 
So each of our speakers will address these areas. 
Our first speaker is going to be in the area of robotics, 
and that's Dr. Nebojsa Avdalovic. He graduated from the 
University of Zagreb in Yugoslavia where he got both an M.D. 
and a Ph.D. degree. He carne to the United States and worked 
in Birmingham, Alabama and then at the Rissler Institute 
in Pennsylvania. And then he carne to Beckman Instruments 
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in 1985 in Palo Alto where he's associated with the Spinco 
Research Department there. And he has been working on exploring 
robotics in DNA sequencing and mapping and has made contributions 
in the automation of the Sanger sequencing reactions using 
vector robot. 
DR. AVDALOVIC: I hope I wouldn't murder the English 
language the same way he murdered my name. 
I'm going to try in these couple of minutes which 
are allocated for my discussion to cover certain topics. 
Would you please show the first overhead. 
I would like to address some need for automation 
in robotic devices, and then I would like to show some examples 
of what is available today and perhaps what is needed for 
tomorrow. And I will address a couple of questions of impact 
of the Human Genome Program on certain issues for each goal 


























beyond science, or direct science. 
If we stripped the past of bare necessities, and 
you decide to invest more than two days a week in molecular 
biology, as some speakers mentioned today are investing, 
and you start really planning your research in trying to 
address these issues, you will now realize that this is an 
enormous task. And I think the best introduction of that 
was done by friend and colleague from Lawrence Livermore, 
Tony Carrano, when he fractionated that task, which is really 
an enormous task, into manageable components. 
So if I just take two examples for this discussion, 
the first example I would like to mention is making an order 
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to overlapping libraries. I'm not going to go into a discussion 
of how you're going to pick up your first clones. You can 
do it by hand today. But if you realize that to make a reasonably 
good overlapping library, you need approximately five genome 
equivalents, that's the minimum of the minimum. This is 
approximately 1 million clones. It's not such a big task 
to do it by hand, but you could. And the reason we are doing 
this by hand is because we would like to assign parking space 
in a [inaudible] for each of those clones. 
you will make this in and duplicate it. 
If you are smart, 
If you don't do it in duplicates, about 10 times 
a month -- microtiter plates. If you would like to make 
replica clones, if these are by some chance [inaudible] they 


























would like to make this as replicas, it means 2 times million 
replica clones, which you will like to screen by certain 
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means. You will also have to isolate DNA for probing. And 
those people like Tony, or some others, who are trying to 
characterize each and every clone by doing a restriction 
mapping, either using single or double digest, or using partial 
digestion maps, it means 1 million -- approximately 1 million 
clones isolated and labeled for screening. 
You can see that this is not an easy task. It 
will require enormous bookkeeping to start with if you want 
to have a use. So you will have to have robotic devices, 
or a device which is capable of reading bar code on your 
microtiter plates, which will also manipulate those microtiter 
plates and understand and realize the X/Y relationship in 
that microtiter plates. 
On the other hand, if we would like to do plating 
or making a very dense restriction map of your clones either 
on a [inaudible] or on an Agar plate, you will have to have 
a robotic device which will do it because the desire is to 
put at least 100 microtiter plates in the same size as is 
in microtiter plates. This cannot be done by hand. The 
reason you would like to do it would be because you want 
to decrease the amount of possible manipulations in hybridization. 
So you will have to read those. You will have 
to have an automatic system which will recognize each parking 
























space of your clone and relate it to your existing data base 
with your microtiter plates and then play with with regard 
to retrieval, cataloging and manipulating. 
I even didn't mention here the need for a computing 
abilities to make some overlapping clones. 
addressing this at all. 
I'm not even 
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As an example of the trouble with autoradiography or 
fluorescence, Tony Carrano mentioned a machine made by ABI 
which was run in conjunction with the University showing 
good collaboration with industry and the University if you 
choose the right partners, and which was vastly approved 
by ABI. They can use restriction mapping and fluorescent 
technology and somehow enter those data in the data base. 
But if you are doing this with autoradiography -- could 
I see the next slide, please? 
This is example of how high-resolution restriction 
mapping done on C. elegans. These are the number of restriction 
fragments, and it's standard in between, which you will have 
to deal with if you want to enter those data and make overlapping 
segments. 
Well, to tell you the truth, somebody said that 
this technique might be working. Well, it might be working 
for small genomes. Here, when you are looking in an E. coli 
system, you are examining overlaps or relationship 1 clone 
versus 200 clones in a library. But when you take the human 



























genome, this is 1 clone versus 2,000 clones, or 200,000 --excuse 
me -··· clones. 
In that case, physically you either have to have 
100,000 times more information to produce that or you have 
to have 100,000 times bigger fragments. Well, good luck 
with YAC's if you think you can do that here. 
enormous problems. 
So there are 
So what I'm trying to tell you is that we have 
to have a little more humility in all these aspects because 
our aspirations at the moment are much higher than our abilities 
are to do that job. 
Could you go back to the --
So that's a big issue with autoradiography. I 
will have similar remarks in analyzing DNA sequencing later. 
Could I see the next -- thank you. 
The other example is DNA sequencing. You have 
to isolate and purify DNA. And there are more and more data 
showing that the purity of DNA is extremely critical for 
good results. It's not only for radioactive sequencing, 
but it's even more so for fluorescene sequencing, especially 
if you would like to have a double-standard DNA as a source 
for your sequencing. As I say, this all comes from us who 
are spending more than two days a week in doing the work. 
So now when you take a robotic device perhaps and 
you say, "I would like to run 100 or more templates per day, 



























which is possible -- I can show it to you -- is 400 pipetting 
steps, 100 to 400 loading for electrophoresis. I say 100 
versus 400 regarding this using fluorescent sequencing protoca1 
where you can combine certain lanes together, or radioactivity 
where you have to run a lane separately. 
I would like to see you really more than the two 
days in a row sequencing films of the size 14 by 17 inches 
carrying 24 templates on it. 
It was a good remark of a colleague of mine who 
said that when I asked him: "How do you do your sequencing, 
and do you have any problems?" He said, "No, no specific 
problems, but I'm changing my technicians." I said, "How 
do you change them?" He said, "Every 100,000 base pairs." 
So on the other hand, again, if you would like 
to read those interesting films automatically, we need a 
device, and right now we don't have it. And if you have 
it, you will have to shotgun merge 50 to 70,000 base pairs 
in one day on a small computer, or a big computer if you 
want. 
I did an exercise, which was an exercise in futility, 
I cut genome in manageable pieces of 350 base pairs as a 
source of possible sequencing data and did some manipulation 
to use single base changes, and then trying to do a base 
on a computer, and I can tell you this is a very tough task 
for just 4,000 or 4.1 kilobases of bbi. 


























Right now I'm trying to do a similar simulation 
on the EBB lighters which are 170,000 base pairs, and I 
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can visualize what kind of problems one can get on a computer. 
We just don't have that technology. 
So what I would like to show to you is a humble 
approach to the present day needs by showing a robotic workstation 
which Beckman Instruments has developed and which is successfully 
being used for DNA sequencing in many laboratories all over 
the world right now and is capable of addressing both fluorescent 
sequencing technology and radioactivity protocols. 
Some of the aspects on that workstation were worked 
out together with Dr. Lee Hood's laboratory whose colleagues, 
Wilson and others, have contributed --· and Steve Clark --
contributed by designing a nice heater system which now comes 
with a robotic station. 
And then I will show you what is in the making 
with some new aspects of robotic device, and then we can 
talk about automated electrophoresis and detection which 
was accomplished very nicely by our colleagues at ABI. And 
I will show you some data with electrophoresis which is a 
fully automated system. 
So this is a robotic device which has pipetting 
device tools on the right-hand side. The tips and the heated 
plate on one side, the plate, platform and microtiter plate 
together with the solutions. 



























When you look at this scheme you can see that where 
the tubes are located by pipet tips, microfish tubes carrying 
the samples of the [inaudible,] and then the heating plate 
where you can heat inside from 10 to 90 degrees at your desire, 
and you also have a 4 degrees cooling system. 
Then you make some patterns for those reactions. 
And since the time is running you can incubate this very 
easily at any desired temperature using any enzyme available 
today. 
And this shows the profile of the temperature and 
the time which elapsed in doing all these jobs. 
This will give you your chance at running [inaudible] 
to run 24 templates in a run which gives to you approximately 
about 12,000 base pairs per run on that machine. 
And this is the approximate result which you see 
here on the right-hand side where the gel was done by machine. 
The left-hand side was done manually. And you can see there 
is practically no difference. 
by machine and by hand. 
This is what is new. 
It's the same quality done 
This is a side-loader arm 
which helps you to change those microtiter plates from your 
workstation so that you can run multiple reactions. They 
are like towers, like hotels with the microtiter plates, 
or test tubes if you need them, or if you want to have an 
electrophoresis apparatus on it.too. 



























So basically this system will allow very high throughput 
in both sequencing and mapping because the tools are being 
made which can stamp the [inaudible] both on an agar or on 
the filter paper, and in this way you can exchange and go 
through the process with not only one plate but with multiple 
plates. 
This is one of the towers with different kinds 
of consumables on it. 
This is something to provoke curiosity. Automation 
of electrophoresis is becoming a reality by using capillary 
electrophoresis. Where the driving force in an open tube 
is not a regular charge mass ratio like you have in a polyacDJlarnide 
or Agarose system. And this shows the example that you can 
separate in 10 minutes using [inaudible] gas system from 
12 to 30 [inaudible] in 10 minutes. 
Thank you. 
I didn't have time to address some impacts, but 
we can talk about this later. 
DR. CARRANO: Our next speaker is going to address 
the area of DNA sequencing, and that is Dr. Norm Whiteley 
whose from Applied Biosystems. He received his Ph.D. in 
'74 from Harvard University. And he's worked on the DNA 
synthesizers, the DNA [inaudible] and the sequencing. 
DR. WHITELEY: I'd like to be in some ways a little 
more optimistic about the ease of some of \vhat v'Ve' re about. 


























to do. Everybody has talked about how hard it is. I think 
there are some aspects of it that are very hard. I think 
there are some aspects of it that require a lot of work but 
are relatively straight forward, try and draw the distinction 
between research and development as it were. Development 
may actually require much more work in terms of man hours 
and effort and dollars, but it's relatively straight forward. 
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It comes back to the little question that Dr. Watson 
addressed this morning which is: How do you get all these 
good people to do this? I think what he was thinking was: 
How do you get good researchers to do this? I think the 
key is that you want the good researchers to do the hard 
creative parts and you want other kinds of people to do the 
other parts because they like to do it, and they're good 
at it. 
In order to sequence very large amounts of DNA, 
I think everybody has almost totally agreed that we need 
a lot of automation, whatever the techniques. And the rest 
of this brief talk I'm going to focus on the existing scheme 
of somehow generating clones doing, if you will, Dideoxy 
sequencing or perhaps Maxon Gilbert sequencing, electrophoretic 
analysis of that and conventional data collection. 
At the moment, there's essentially no automation 
of the clone, and that's the part that I was referring to 
as very hard. Part of the slide is what we need and what 

























people are working on are global strategies for the mapping 
und genPrating sequencing clones. The point has been made 
a lot. I agree with it. 
The other three areas doing the reactions, we just 
saw a way that's been automated by our colleagues at Beckman. 
And there's a number of other systems on the horizon, and 
that's about to truly-- or has really happened. 
say it's about to truly happen. 
I should 
The data collection, as you know, our company sells 
an automated DNA sequencing based on fluorescence. There 
are a number of other DNA sequencers commercial, or in the 
works, and there are a number of people, and I think some 
will address it later, who are very interested in automated 
data analysis. 
The point is, those last three things are, if you 
will, in the chute. I think that they are totally within 
the range of being able to do the. kind of work we are talking 
about, that the real holdup is the first step, that many 
people have addressed, that is truly the really hard point. 
May I have the next overhead, please. 
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To illustrate my point that the others are in the 
works, this is a huge slide indicating the progress in commercial 
automated DNA sequencing. This is not -- this is something 
you can buy in 1986, or you can buy now, and just in that 
time from the middle of '86 to the middle of '88, about 


























two years, the number of bases that can be sequenced, and 
the accuracy with which they can be sequenced, has improved 
fairly dramatically, as well as a decrease in the amount 
of DNA involved. 
I think that that -- all of that improvements has 
been based on changes in [inaudible] changes in software, 
none of them changes in hardware. That graph will continue 
for awhile, in terms of improving throughput. 
If I can have the next slide. 
To do a thought experiment -- I am not proposing 
that someone do this -- to do a thought experiment, you just 
want to take that fraction of the process and automate it 
with today's existing commercial, off-the-shelf technology. 
What would it cost you? What would you have to do? Well, 
you could do about 500 bases a line, and if you were to run 
it twice a day -- which nobody in a research lab would do 
because that means coming in in the middle of the night to 
turn it on the second time -- you can figure that to have 
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a 1x coverage of the human genome is about 750 instrument 
years, or for 4x coverage, in 12 years that is 250 instruments. 
That is $23 million of hardware, bought one of, which again, 
no one would do, and it would take you something like 50 
people, maybe 100 people, to run those things. 
That is within the scale of the kinds of money 
and time the people are talking about. That is today's 


























technology. Easily there is a factor of three in throughput 
there that will happen in the next year or two. Without 
any doubt, the company that doesn't do it will go out of 
business, regardless of whether it is us or our competitors. 
So, my point is you really -- this is within the 
realm of reasonableness already. 
May I have the next slide. 
Now, obviously, if you can get very clever and 
inventive you will do it even better. 
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The next point is that in actual sequencing reactions, 
how are they done? However clever we get about this strategy, 
we are going to be repetitive. They are going to be done 
on a large number, when we are talking about something like 
sequencing the human genome, and you want, obviously, routinely 
high quality. Whoever does it, v;hether it is done under 
an academic auspices, or university, or a national lab, or 
an industry, it is a manufacturing type of operation. And, 
again, I raise the word "contract" which offends a number 
of people, but it is inherently an operation in which you 
want to define what you are doing well enough that you don't 
need research scientists to do it. You, in fact, want manufacturing 
type of people doing it. 
To use an example, DNA synthesis, a few years ago, 
was worth a Nobel Prize. It is now currently the reagents 
and the instruments are made by people who don't have 



























college degrees. They are made every time, perfectly, consistently, 
they work. It is a routine thing. The reason it is routine 
is that some development scientists, not research scientists, 
took the time to figure out exactly how to do each step, 
so that they could do it right every time, and then they 
hire some people who are very bright and care about their 
work, that don't know anything about chemistry or biology 
necessarily, but they know that they need to be careful with 
what they are doing to execute that every day. It works 
quite well. They are regularly available, and that is the 
kind of operation that is totally feasible, even at the scale 
we are talking about, if we had the strategy to do it. 
Another illustration, about ten years ago I uorked 
for a company that made clinical diagnostics, and they made 
100 million reagents packs a year, and it is complex chemistry. 
The pipettings were done with precision of fraction of microliters, 
and those were made at a cost of $.20 to $.30 each. I don't 
think that is inherently a great deal more difficult than 
doing the operations that would result in conventional sequencing 
strateging today. However, you can only do that again, if 
you know the strategy itself. 
The last couple of minutes, I just wanted to address 
the other theme that is running here about cooperation within 
California and the effects on industry -- I hope there are 
still a few of the political people in the audience. 
Pike Court Reporting 
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1 As a practical matter, industry must cooperate with 
2 [inaudible]. The previous speaker referred to it. This is 
3 a brief list of those products that I've been involved with. 
4 They are DNA products. And it's a list of California academic 
5 collaborators. They're industrial collaborators. There are 
6 people that I couldn't think of, and I did this off the top 
7 of my head. There's lots of people outside of California. 
8 But every product that we have -- DNA synthesizer, 
9 DNA sequencer, and acid extractor, and the mapping 
10 that Tony is working on -- has had academic collaboration. 
11 It's vital, it's important, and I'm glad people are encouraging 














we're pretty good at it. 
The last side is a competitiveness concern specific 
to California. Competitives really means good people. It 
doesn't necessarily just mean good researchers. It means good 
people in the operation at whatever level they're working. 
We have a lot of advantages here in California. We 
have great universities. There are a lot of people, so it's 
easy to find good people if you have a lot of people to start 
with. It's a fun place to live for all sorts of reasons. 
There are some serious disadvantages that are for 
the political people in the audience, I think, very important. 
We lose people because either we're not trying very hard to 
keep them or because they've got some wonderful new opportunity 


























to join a start-up company or become a massage therapist or 
whatever. Those people leave eagerly. 
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The other category of people we lose, and we lose 
them frequently, are people who are sad about leaving our 
company, and they're going some place where they figure their 
kids can get a better education, where they can afford to live 
close to where they work, which is a function either of 
transportation or cost of housing. 
We've lost in the last six months people I'm involved 
with, not necessarily ones that work for me, somebody to 
Indianapolis, somebody to Philadelphia, two people to North 
Carolina, lost a potential recruit because his wife is a teacher 
and came out and checked out the schools in the area and 
decided they could educate their kids better in Georgia. 
So it's a serious problem. It's a daily problem. 
It's one that people like myself I like to think of myself 
as inventive and clever -- but I am concerned about things 
like that instead of strategies in automation. 
The last thing which is both a concern and an 
opportunity, I think, in terms of competitiveness for California 
is if we could encourage better public understanding of what's 
going on. I think that would be an advantage for the state 
and, indeed, for all of us. Your neighbors would have a little 
bit better idea of what you're doing and maybe appreciate 
you a little more. 
Pike Court Reporting 
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1 DR. CARRANO: Thank you, Norm. 
2 Our next speaker is Tim Hunkapillar. He's from 























MR. HUNKAPILLAR: Well, we seem to be bouncing back 
between what's being optimistic and pessimistic. And Norm 
was optmistic, and I'll say that I'm pessimistic, in the sense 
of how hard this problem is. And mine is particularly, at 
the current level, a computational sort of issue in handling 
the data and analyzing the data and this sort of stuff. 
And one thing we can kind of keep hearing a 3 billion 
bases and all that sort of stuff. And that sounds --well, 
it's an attractible and noble figure. But in reality I think 
if -- well, the issue is not just that size. The issue is 
the complexity of that data as well as the size of that data, 
which makes it a significantly different problem. And the size 
alone is down, forgetting the notion of say 10 to 15 which is 
like way in the future, by the time you have the 3 billion 
bases that are your human genome, more or less complete, you're 
talking about having an enormous number of other bases. 
You're talking about --well, if that's the 3 billion 
of the single strand you're talking about having to sequence 
thousands of clones, of course. You don't have any history 
of these clones. You don't have any record of where this 
comes from, the annotation of this sequence. And you have at 
that time also a lot of other genomes, or partial genomes, already 



























s~quenced. You have a lot of pieces of the human genome sequenced 
multiple times for comparative analysis. So it's not unreasonable 
even at that point, which is relatively the foreseeable future, 
but when you have the first more or less genome of the human 
now, you will have approximately, say, 100 billion sort of 
base equivalents of information, whether that's annotation or 
whether that's bases or whatever. 
Now, that already sort of ranks it as a large data 
base by anybody's standards. There are, in fact, larger data 
bases in the world; but, nonetheless, that's a huge amount of 
information. 
And I would argue -- I've argued many times on this 
fact -- that there are problems with that because of its size, 
because of its complexity that, in fact, there are not tremendous 
sort of paradise for handling it. That means at the data base 
level and the analytical level. And that 100 billion bases, 
or base equivalents, of course, does not even count the sort 
of entire literature data bases and the other biological 
data bases, the NSF sort of ecological data base, stuff like 
this that all tie back into this sort of stuff where you end 
up getting terabytes of information eventually. 
Now, nothing we have, either hardware or software 
or even strategies, come anywhere near approaching this problem. 
Ancl there's no reason to believe we know how to do it even if 
we had the money right now. It's not the issue of "Oh, well, 
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1 we just need to build bigger computers or put work stations 
2 at everybody's desk." It's not that simple an issue. 
3 It's an issue of rethinking the -- or thinking the 
4 process now as to what really are the issues. What do we need 
5 to do with this data? How do we manage it? And start thinking 
6 at a research level how to handle this new paradigm, or construct 
7 rew paradigms, with this new model of data. 
8 You have a chromosome that's 250 million bases long. 
9 It's not just 250 million a, d, ~·sand t's in a row. It's 
10 all the sort of landmarks. It's all the context. It's all 
11 the history of how it was sequenced. All these sort of things 
12 are all tied together. 
13 And as a single sort of data object -- and I could 
14 be wrong, and I've had this argument with computer scientists 
15 but there is no real current sort of model for that. You're 
16 not going to go out into the industry and find somebody that 
17 says, "Oh, we've solved that problem. We have a personnel 
18 data base system that will do that for you." I've been told 
19 that actually. I don't believe it. 
20 So there are issues of research involved here as 
21 defining these problems. It's not a matter of just applying. 
22 It's a matter of going to NIH, to the DOE, the NSF, or whatever 
23 and saying, "He need to do research. " 
24 There's no reason to believe right now we know the 
25 approach. We have to take many approaches and see where they 



























lead. And I'm very keen on that notion that there's software 
approaches to handling these obvious problems and there are 
hardware. I have a keen interest in hardware. I'll talk to 
you about it in a second. I have this particular keen interest 
in that. 
Now, this is a very collaborative sort of operation. 
It has to be. A lot of the sort of stuff we as biologists 
have used in the past up to this point are both sort of -- while 
hardware means that we all have our PC's and the lucky ones 
have a little work station on their desk, and we all have a 
package of software that was written more often than not by 
people like me, people who are biologists and thought that 
they could learn computers. 
The level of software, generally-- that doesn't 
mean that there aren't exceptions to this -- but the level of 
software tools that are available in the world are not 
state-of-the-art technology. I mean regardless of the fact 
that you're not working on state-of-the-art hardware, you're 
not even -- at the level of hardware you're using, you're not 
generally using state-of-the-art software that can take 
advantage of that hardware. 
So we're in pretty primitive sort of circumstances 
rignt now in dealing with this data, in managing it, distributing 
it. There are a lot of people -- a lot of effort obviously 
at places like GenBank and the NBL people and stuff like this 
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1 that are putting a lot of thought and concern about how to 
2 deal at the present time with the data that we have, which is 
3 an enormous -- even though it's not 100 billion bytes of data 
4 it's an enormous amount of data, again, given its complexity, 
5 given the fact that it's being sort of contributed by several 
6 
7 
thousand people, which is an issue in and of itself. 
got to keep this thing of complexity in mind. 
So we've 
8 Now, I have a particular interest. I have a lot of 
9 particular interests, but the one particular interest -- I'll 
















an approach to some of these questions. We're interested in 
some of the hardware sort of things that are not using, per se, 
the computers. 
The problem with using sort of the general computer 
model is that the problem is growing you might say logarithmically 
whereas the speed of computers is not. The speed of computers 
may be getting a lot faster and a lot cheaper but not at the 
same rate the problem is growing. You're not going to keep 
up just by relying on the fact that next week you'll have a 
faster sun on your desk than the week before. It's not going 
to work. 
Just a real quick general notion of what the problem 
is, one of the bottlenecks is that the notion is on a model 
with a normal sort of computer architectures that we deal with. 
If you had data coming in, the data that handled and manipulated 
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1 and everything and processed all within the [inaudible] a 
2 traditional sort of computer model, the variation on this is, 
3 in fact, is to separate out permanent computational question 
4 before it gets to the computer. It's going to do your post 
5 processing and report writing and inferencing and all this 
6 sort of stuff that preprocess the data, that you can make 
7 simple but very fast. They don't do very many things, but 
8 they do them very fast. And you can make those so that they 
9 are essentially the speed of that data transfer, not the speed 
10 of your computer. 
11 Now, this is the approach that we are taking. This 
12 is the generic notion of how to do this now. We at Cal Tech 
13 have a few collaborations. One is with Mike Waterman's group 
14 at U.S.C. And it's a good paradigm for the sort of collaborative 
15 multi-disciplinary sort of issues that Mike and I collaborate. 










determined commercial partner as well. So there's four essential 
units in designing some specialized hardware for dynamic programming 
avenues that will allow you to compare and search through data 
bases. 
Now, we also at Cal Tech, as mentioned by Bob this 
morning, are collaborating with TRW on an analogous-type system 
for explicit pattern matching which is the FDF -- TRW/FDF 
thing. And both of these systems, both are dynamic programming 
systems for the broader questions of relationships, and the 
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1 n~R system for dealing with explicit pattern matching, are 
2 based on systolic models. 
3 Systolic means that you essentially -- you get a 
4 lot of little cells, a lot of little tiny cpu's stuck in a 
5 row, each one of them does exactly the same thing, and you 
6 could have a lot of them. And what they do, they do one 
7 calculation, more or less, and they outbreak by streaming 
8 the data, refer to it as systolic because of the pumping. 
9 You need to take one byte into the next, into the next, into 
















So you've got a pumping operation that essentially 
means that once a day it gets through the [inaudible] it's 
finished. There's no turning around and thinking about it. 
So you can do it, essentially, as fast as you can read 
the data. So systolics isn't some generic sort of inherited 
[inaudible]. It's constant speed which is independent of 
the complexity and the relationships that you'd find, whether 
it's gaps in insertions or what kind of data is going through 
there, all this sort of stuff. 
The problem with most of this sort of either pattern 
matching or relational matching sort of schemes now is that 
you either have huge amounts of membrane or huge [inaudible] 
process going on that essentially blow up with the length of 
the data; hence, you can't do them unless you've got a crane 
sitting on your desk. 
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1 And the notion of massive parallelism at the bottom 
2 means that you can make these things, essentially, as big as 
3 you want to make them. You just keep putting more and more 
4 chips in a row, essentially. I'm simplifying somewhat; 
5 nevertheless, it's pretty much the model. 
6 Now, as a paradigm for that, again, the TRW sort of 
7 stuff real quick, I'm not going to go through what this is. 


















GenBank. And I can load into the FDF system that is 
searching things on both the top for the biology, the history, 
and the sequence. The sequence has motifs of both DNA and 
protein and composition and proximity, all this sort of stuff. 
Now, I can load that in as a query, a single query. 
Now that means that I can do this query in the time against 
all of GenBank as fast as I cah GenBank off of my desk. 
Now, I use this as a cute example; nonetheless, it has 
limitation. What it does now is significantly noted. 
Using systolic sorting systems has tremendous promise 
in speeding up complex operations. It means it allows 
biologists to sit there and make quiries against this huge 
amount of data in real time. Now, of course, at 3 million 
bases even, if this is running at 10 million bases a second, 
which is a very, very fast disk, you're not going to get it 
much faster than that, at least for a while, you're still not 
worried. 
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I show this for entertainment value alone. r show 
that Bob was right this morning about where this technology 
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for where this chip came from. But I use it to illustrate 
the point that, in fact, there's an enormous amount of technology 
in the world. But the notion is that there are people I 
have companies corning to our lab all the time saying, "We have 
technology. How can we use it?" And it's actually pretty 
amazing. 
And this collaborative effort between industry, 
between computer scientists, between biologists, between 
mathematicians can be amazingly productive, and it's something 
that in California we have a tremendous amount of, so we should 
encourage it. 
Thank you. 
DR. CARRANO: Our next speaker is Elbert Branscomb 
from Lawrence Livermore National Laboratory. Elbert got his 
Ph.D. in theoretical physics. And he's responsible for our 
computations at the genome project at Livermore. And he's 
going to tell us a little bit about hardware and so forth. 
DR. BRANSCOMB: About a year and half ago at the -- I 
think it was the second Santa Fe meeting -- Wally Gilbert gave 
a talk on the Human Genome Project in which he described what 
biology in the 21st century would be like and emphasized that 
it would be entirely unlike all the biology that had proceeded 
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1 it. And the picture he drew was of large groups of people 
2 sitting in front of large monitors and not getting their hands 
3 wet. And whereas that certainly is not a very pleasant prospect, 
4 I think there's no doubt that as several people have said that 
5 the biological activity is going to -- biological research is 
6 going to see a rather large shift towards people -- towards 
7 the task of analyzing a data base, which is rather than having 
8 a bunch of data collected by someone who then analyzes it 
9 and publishes it, there will be a big shift towards large 
10 efforts, industrial efforts, to obtain a large part of the 
11 fundamental data base of biology and then that will be a public 
12 resource which is analyzed. 
13 And that then shifts towards a very heavy burden on 
14 data analysis, and it's very likely this will prove to be for 
15 the limitations that Tim was just talking about a weight-limiting 
16 step in the process. 
17 And part of what I was going to make a few remarks 
18 about is: What might we think are the critical problems there? 







now available. I was trying to describe what a current good 
work station can do and what its storage capabilities are. 
And there's a reliable predicition that about a 10-fold boost 
in most of those properties will occur within a few years. 
A typical arrangement for a well-endowed lab is 
quite a few of work stations like this slave to a large compute 
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1 server over finaudible] which has essentially the powers that 
2 work stations will have four years hence. And in four years 
3 this table will flip and the compute servers will be about 
~ 10 times bigger. And it's plain that we will see limitations 
5 both in hardware and software. 
6 I wanted to say a word about the data base. I don't 
7 disagree with the previous speakers about what they will be 
8 though, except in some details. But they are going to be 
9 very large. And the problem is not, however, in the size of 
10 the data base. There's just a number of bytes. There are 
11 really storage techniques that not very rich people can buy 
12 and can store probably all the data we will have in this project 
13 10 years hence on a single disk of maybe 200 gigabytes or so, 
1~ and that is certainly not the problem. 
15 I think, in general, we will for most cases be more 
16 software limited than we're hardware limited. One of the 
17 things that I think that's going to happen to biology is that 
18 it will become as compute insatiable as physics. And I wanted 
19 to just mention a few areas in which I think that's going 
20 to be the case. 
21 There are the obvious ones about -- in particular, 
22 what Tim was just talking about -- involving the sequence 
23 analysis, pattern recognition, homology searches, consensus 
2~ searches and so on where we have problems at all scales. 
25 We don't really know what to doy and we have to figure out 
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1 what we should do in principle. We don't [inaudible] for doing 
2 it economically, and even when we do, good software is generally 
3 not available for reasons having to do with the economics of 
4 this problem more than the history of computational science 
5 and of the history of the industrial production of computers. 
6 One of the problems that's clearly-- will exhaust 
7 all the computational ability for a long time, I think, is 
8 the problem of protein folding and predicting protein function 
9 from underlying sequence. And one of the things that's impressed 
10 me about why that's such a profound problem is the fact that 
11 the difference between a properly folded and unfolded protein 
12 is only a few weak bonds. And, moreover, that that appears 
13 in many cases to be the result of excluding water access to 
14 a very small number of hydrophobic residues, a handful, and 
15 that that implies extremely subtle issue about the folding 
16 properties, but we are out of our league in trying to compute 
17 that straight ahead. And it's a very profound problem which 
18 will engage us for a long time I think. 
19 Item No. 4 is an idiosyncratic fantasy of mine and 
20 a lot of other people for sure, but in the end of -- or pretty 
21 soon after we have gone after genetic analysis, linkage analysis 
22 to get where we can in understanding the 3,000 or so most important 
23 loci in the catalog, we can then -- we will be empowered and 
24 motivated to turn our attention to the more general issues of: 
25 How does the genotype orchestrate phenotype? 
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1 And I believe it's arguable, but if we have 1 eM 
2 VNTR map, which is characterized by about 5,000 probes in 
3 order to get it dense enough to really be functional at 
4 1 eM map, with about 70 to 80 percent average heterozygosity, 
5 which is apparently what these --what goods the VNTR's deliver, 
6 will be in a position to-- and if we can, as I think it's 
7 arguable that we -- as I think Charles said earlier -- automate 
8 the genetic analysis using these probes, it will be feasible 
9 to go a fair way towards genotyping individuals at the l eM 
10 shot all together. 
11 The fantasy is that we characterize what is the 
12 specification of people more or less completely for a complete 
13 set of 1 eM VNTR's. The advantage of that in principle has 
14 been used in some other standard genetic analysis now is 
15 that a single 1 eM locus is quite a durable piece of DNA and 
16 has, in general, a very respectable history in time. And 
17 the human population is to one degree or another more or 
18 less clonal in single alleles. So if we characterize someone 
19 as having a particular two-point allele, Lander and Botstein 
20 have emphasized the importance of recently, that particular 
21 allele will be shared completely by a lot of other people who 
22 have the same two-point allele, so that we can in some sense 
23 make a rather complete genetic characterization of individuals 
24 at that degree of resolution. And it makes it feasible, I think, 
25 to look for genotype/phenotype correlations on a population 

























basis rather than on a kindred basis, and be able to ask a 
very general question. 
192. 
As Tim emphasized, I think the overpowering problem 
is that we don't have good software. We don't have good cheap 
software to do all these problems. We don't have the software 
tools in place, though we certainly could, to fulfill Charles' 
fantasy of having a reasonable, friendly, appropriate and 
indjvidualized work station which would be -- have common 
interfaces and be recognizable and talk to everyone and run 
on all sorts of -- talk to everyone in the same language and 
run on all sorts of hardware. 
And the critical issue, it seems to me, and an issue 
where state policy and governmental policy have a very big 
role is in trying to enforce and further the development of 
standards which will overcome these problems. And the standards 
matter at a large number of levels in computer design. 
just tried to indicate a few of the dominant ones here. 
And I 
There's the operating system, the window environment, 
what the windows look like and how do they behave. You have 
to sit there and learn a whole new window paradigm every time 
you sit down at a computer. What's the visual interface software 
that talks through the window? What are the graphics conventions 
for drawing? There's very little agreement there. It's really 
a Tower of Babel as someone said before. What are the network 
conventions? 
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And the last item is one that I think is particularly 
2 important and can drive an awful lot of economy here, and that 
3 is the prospect of having so-called applications by or near 
4 interfaces, which means that you don't have to recompile software 
5 to run on one computer or another, but it will run straight 
6 across. 
7 And there's the prospect now, but stimulated by 
8 some's aggression in this field in large part that there will be 
9 not one, that's too much to hope for, but maybe five or six 
10 such groups of computers that at least within those groups 
11 you won't have to cross-compile. And the big significance of 
12 that is not, I think, just that it allows you to be vendor 
13 independent so that you can compete vendors against each other, 
14 which is important enough, but rather that it would make it 
15 economic, much more economic, for people to build software 
16 because now it will be -- there will be many, many more customers. 
17 And I think that can help us a great deal in getting good software 
18 for this problem. We are too small a user audience to justify 
19 enough software development for our problems, particularly if 
20 we split ourselves up into lots of groups. 
21 DR. CARRANO: Thank you, Elbert, catch your breath. 
22 Our last speaker is Michael Waterman. He's a professor 
23 of mathematics in biological sciences at the University of 
24 Southern California. 
25 DR. WATERMAN: I'm certainly here to speak as a 
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1 mathematical scientist. And I'm glad that my education wasn't 
2 in theoretical physics because I was just told that I have 
3 negative time. 
~ This is supposed to be about hardware and software. 
5 And I have a really hard time talking about hardware and 
6 software when we don't talk about why we need the hardware 
7 and the software. And so let me -- maybe this is a bridge 
8 between this session and the next session. So let me just 


















Most of what has been talked about today, I think, 
is data generation. People have talked about mapping, both 
genetic and physical mapping, and they talked about some of 
the analytical problems entailed therein but not too much. 
And the reason the analytical problems are interesting, I think, 
is to get accurate maps in the genetic case and just to decide 
whether you're going to have your postdoc's working five 
years or 50 years on the physical mapping scheme. And those 
are worthwhile analyses to perform. 
I think as well there are certainly some 
hardware/software issues in reading your classical or automated 
sequencing projects. And that's definitely been talked about. 
Tim talked something about after the data is generated 
how we're going to manage it. He said there was certainly some 
research required there. And I think there's a point I'd like 
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1 to make about that. 
2 There's a nucleotide data base as we see it today 
3 is called GenBank or NBL's data base, which are almost but 
4 not quite the same, and there's a model of sequence that's been 
5 published, that's been annotated, .. at least in the literature, 
6 and is sort of a final product. 
7 I think when we start cruising through genomic 
8 sequences, an entirely different model of how to manage the 
9 data-- that just hasn't been thought through. And the management 
10 and the access and how we correct stuff after it's out there, 
11 whatever percent wrong, is a really interesting problem that 
12 people like Cantor are going to have to face. 
13 Well, after you've got all this data, I think there's 
14 a new piece of action that certainly wasn't around 15 years ago, 
15 and that is that you take a look at the sequence and you try 
16 to find biological and meaningful patterns and chain. We 
17 talked about that sort of thing. 








or statistics or computer science in this? There's one kind 
of problem, if you've got eyes like mine and it's after dark 
and you're trying to find your way to a specific address in 
Los Angeles and you pull out the Thomas Guide, it's hard work. 
Finding your way to an address even when you know, even when 
you have a map and you know where you are going is hard. And 
that was the Moslim slide that Tim showed basically. It's 
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1 some idea of what they were looking for. 
2 What is a lot harder is to find your way around when 
3 you don't have a map and you don't know what you're looking 
4 for. Or perhaps a better analogy, if you have a map of Los Angeles 
5 and a map of New York, what parts look a lot alike? Again, you 
6 don't know what look alike means. So that's a hard problem. 
7 And one of the most exciting versions of it, I think, is 
8 
9 
predicting protein structure from sequence there. 
of that. 
It's a version 
10 I think there are a couple of approaches to these 
11 kinds of problems. One is to buy a bigger computer. And NIH 
12 does this, buy a great big new Cray and run the old ideas on 
13 it. Tim and I are involved in that with generated chips. It's 
14 a lower-scale technology thing, thank goodness, but just new 
15 hardware, same old ideas. And, obviously, what I'm [inaudible] 
16 is getting people to have new ideas. 
17 One of the things as a mathematical scientist interested 
18 Ln biology, one of the things that I'm impressed by is how 
19 smart biologists are at analyzing their own data. Now, that 
20 doesn't surprise any biologists, of course. But you can learn 
21 a lot about this, but it requires in the end people who know 
22 about both sides of the fence, and there aren't very many of 
23 these people around, I don't think. 
24 And that's sort of my pitch today is that W<' 
25 need-- no one has mentioned education today 1 don't think, 
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1 and there are lots of universities here. We need to train 
2 some people who are trained to think in a nontrivial way 
3 both about an analytical side of things and about the biological 
4 side of things. And that's -- and I don't mean just two courses 
5 in each one, some real training. And I think that's a challenge 
6 for our universities to come up with these people because they'll 




















DR. CARRANO: Thank you very much. 
I'm going to defer to our moderator here, Winston. 
DR. SALSER: Well, let's take a few questions and 
then a short break. 
MR. KISSLER: I just wanted to make a statement. 
T'm Jerry Kissler. 
While this session is going on, there's also another 
session going on on light sources. Light sources are another 
technology that rnightbeimportant to this project. There is 
a group of people representing basically the same universities 
and labs that are here working on light sources. 
So for any of you who might be interested in compact 
light sources, sort of room-size light sources, at very short 
close length, there will be a green paper in the back of 
the room. You might want to check it out. 
DR. CARRANO: Anything else before we turn this back? 
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1 MR. BRENNEN: Thomas Brennen, Genomyx. 
2 One of the things that -- is there a unit underway, 
3 anything sort of like a biological computer? When you clone 
4 a filter, or something like that, you're actually performing 
5 a [inaudible] There's a lot of stuff-- biology on silicon, 
6 is there anything -- in other words, as opposed to the sequencing 
7 part of it where we have [inaudible]. This is an area where 


















there anything like that in progress? 
DR. CARRANO: Who wants to tackle that question? 
Tom. 
MR. MARR: Tom Marr, Los Alamos. 
There's a group at MIT who has been working on 
biological materials and how those apply to computing problems. 
I think they've actually built some prototypes. 
There's a fellow named Arvin who is a computer 
scientist whose been working on data flow problems, architectures, 
who is looking at biological materials as an avenue for 
implementation. 
MR. BRENNEN: What I meant was actually using biology 
as [inaudible) probe on any kind of an actual array. 
[At this point, the question went on, but the 
reporter was unable to hear the question.] 
DR. SALSER: We're going to take a brief five-minute 
break to stretch your legs, and be back here at a quarter till. 
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2 
DR. SALSER: Before I start the next session, I 
want to just summarize something from the last session that 
I was interested in. 
I cornered Tony Carrano, and he has just taken off 






8 interested in his project of doing the cosmid overlaps. It 
9 wasn't clear to me just how far along it was and what the 
199. 
10 capabilities of the method were as they see it at this point. 
11 And he says that they're starting a project on the 
12 Chromosome 19 cosmid library that they think that at the rate 
13 they're going that they could cover it to a depth of 1 in 
14 about a year. That means that after about a year's sorting 
15 on the ABI machine of the restriction digest about two-thirds 
16 of the clones they would have analyzed would have an overlap 
17 with another member of the set and that about roughly 1 over E 
18 of the sequence would be uncovered. 







to tell us whether that's working out as they planned. But 
he thinks that they can do it on whole chromosomes. And that's 
where they're at. 
And that is so important, either that or the YAC 
approach, that I thought it was really useful to summarize 
the status of that. 
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1 Now I want to introduce the next panel which will 
2 be moderated by Elizabeth Neufeld. It turns out that having 
3 a Ph.D. from Berkeley was an absolute requirement apparantly 
4 for all of today's panel moderators. And I asked Paul Boyer 
5 why that was. And he said that was because Berkeley guarded 
6 the education game earlier than UCLA, not to worry. 
7 Elizabeth has been one of the leaders in studying 
8 the molecular genetics lysosomal storage diseases. She 
9 served as Chief of the Genetics and Biochemistry Branch of 
10 the National Institute of Arthritis, Diabetes, Digestive and 
11 Kidney diseases up to 1984. And at that point she got tired 
12 of all those names and came to UCLA as Chair of the Department 
13 of Biological Chemistry, which is easier to remember. 
14 Her research accomplishments have been acknowledged 
15 by a host of scientific awards, which she told me not to 










she was elected to the National Academy of Sciences in 
recognition of some of her work. 
Dr. Neufeld will introduce her panel which will 
discuss utilization of the data generated by the Genome 
Project. 
DR. NEUFELD: Thank you, Winston. 
Before I introduce the panelists, I would like to 
introduce Ellen Philhower who is the stenographer for this 
meeting. And she's been assiduously taking notes. And she 
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1 has a very special request of the speakers and the panelists. 
2 Jf you have any notes, any transparencies, she would like a 
3 copy thereof. She says that it will make her job much easier. 
4 DR. SALSER: Can I add to that? If you have copies 
5 but you don't want to give them up to her, give them to me 
6 and I will xerox them immediately. There are xerox machines 
7 all around, and you can have your copies and leave them too. 
8 DR. NEUFELD: Since we are the last panel, we thought 
9 that there might be some issues which have not been touched 
10 during the day. And Dr. Simpson, who is a Professor of Biology 
11 at UCLA is going to touch on one such issue, which is: What 
12 happens when your gene product is not really included in 
13 your DNA? 
14 DR. SIMPSON: Well, most of my thoughts on this 
15 subject have already been mentioned. So I guess I'll go 
16 directly to my one unique thought on this, and that is that 
17 I'd like to throw out a cautionary note as to the difficulty 
18 in interpretation of raw sequence data that will be generated, 
19 the huge amount of raw sequence data, that will be generated 
20 in this project. 
21 In fact, I go along with Tim in his thinking that 
22 the most practical and the most valuable aspect of this project 
23 will come as a result of the effort required to improve the 
24 computational aspects. I think the most immedate spinoff will 
25 be the development of new Algorisms to analyze this maximum 
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1 amount of new sequence data and recognize patterns. 
2 And in line with that, I think that the most 
3 valuable information from the scientific point of view will 
4 come from the initial sequencing projects involving the E. coli 
5 yeast and Drosophila genomes because there we have a large 
6 background of genetic information. We can do experimental 
7 testing of hypotheses, which you can't do with a human. 
8 What can we learn from the human data, the human 
9 sequence? Well, we can look for open reading frames. We can 
10 identify known genes by similarity or hemology with genes 
11 already in the data base from lower organisms. We can perhaps 
12 identify unknown genes that have been previously mapped to 
13 precise sites or by prediction of secondary structure or a 
14 function of the proteins. 
15 However, in the absence of an experimental genetics 
16 approach such inferences are going to be very difficult to make 
17 and substantiate. 
18 I'd like to add one additional cautionary note stemming 
19 from work in my own laboratory, and that is that we either 
20 found that in some cases in messenger RNA's in the mitochondria 
21 of certain types of protozoa, known as tropatazomes, the 
22 nucleotide sequence information encoded in several other 
23 messenger RNA's and transcribed from the mitochondria DNA 
24 differs from that encoded in the mitochondria DNA. 
25 Let me just show this slide. This diagram -- this 
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1 cartoon just shows what I'm talking about for the nonspecialists 
2 here. We have a DNA sequence and we have the messenger RNA 
3 sequence. And what we found is that in the mature messenger 
4 RNA sequence we have additional nucleotides, which in our 
5 case are all uridines, at specific locations in coding 
6 regions which are not present in DNA sequence. And we have 
7 uridines there present as thigmodines in the DNA sequence that 
8 are not present here. 

















one particular gene in the mitochondria. And here is from 
two different species of these protozoa. Here is the DNA 
sequence, and here is the RNA sequence. And what you see 
is that dots indicate uridines that we found in the RNA 
sequence that are not present in the DNA sequence. And 
these circles indicate thigmadines present in the DNA sequence 
that are not present in the RNA sequence. 
And this is conserved, at least the pattern of 
the addition of uridines, conserved in these two species 
that differ by about 100 million years of evolutionary history 
but the pattern of deletions differs, and they both give 
rise to exactly almost the same amino acid sequences. 
The next slide -- this just shows how common this 
is. This just compares the two complete mitochondria genomes 
and sequences of which we know. And I just want to point 
out that this occurs in five genes in this mitrochondria genome. 



























It's not an isolated event with one or two nucleotides. lt 
occurs in this gene. There's three here. There's 29 U's added, 
15 U's deleted. It occurs here, here, here, and here with 
the indicated number of deletions and additions. And in 
[inaudible] it occurs in a very dramatic way in this region 
here, and now we know this region here, where of 731 nucleotide 
sequence, 407 are resulting from additional uridines at 145 
sites and 19 uridines deleted. 
So this just shows you -- this is the work of Gene 
Fagan and Ken Stewart, by the way, this last piece of information. 
So we don't yet understand the mechanism for this, 
apparently, nontemplated, non-normally-templated sequence 
information, and we don't know the biological generality of 
this. But I just want to throw it out to say that you may not 
always be able to go directly from a DNA sequence to a protein 
sequence. One should keep this in mind. 
DR. NEUFELD: Does anybody want to comment on 
this rather important cautionary note? 
[No response.] 
If not, we'll go on to Dr. Esposito who is from 
the Human Genome Center and is Deputy Director of the Cell 
an8 Molecular Biology Division at Lawrence Laboratory in 
Berkeley. And he'll talk about the applications of biotechnology 
to complex human genetic disorders. 
DR. ESPOSITO: Because the hour is late and time is 
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short, and I think most of us have received perhaps more 
2 information than we can hopefully deal with, let me assure 
3 you that what I want to do is not to talk about the arcane 
4 aspects of human genetics and population genetics as it applies 
5 to complex human disorders but rather to focus on an issue 
6 that arises when we consider the fact that many of the human 
7 genetic disorders that are of interest to us are very difficult 
8 to study genetically. 
9 But as we see the human genome mapping and sequencing 
10 project perceived, there is an enormous target of opportunity 
11 that develops for California-based biotechnology and pharmaceutical 
12 industries, and that is to begin a dialogue, and if I could 
13 have the next slide. 
14 To begin a dialogue, to start an intent at applying 
15 the information to the vast array of very complex human genetic 
16 disorders that -- as well as those that are attractable. 
17 Now, most of the applications that we've heard 
18 about today in mapping refer to wise choices of known simple 
19 Mendelian genetic defects in which almost anecdotal analysis 






this is a single gene defect. That is a very wise choice 
on the part of these investigators. 
But we know that -- and not only will we be able 
to proceed to analyze such diseases very carefully, but there 
are many diseases that are extremely frequent as far as 



























diseases are concerned. 
There are many very important human genetic diseases 
for which we have information that these genes are highly 
complex, complex in the following sense: There are probably 
more than one genetic locus involved. 
Two. Complex in the sense that if you have the 
disease genotype, you don't necessarily get the disease, limited 
penetrance. And they include a collection of diseases that 
I've simply broken down as those associated with the human 
major HLA. They include insulin dependent diabetes, rheumatoid 
arthritis, multiple sclerosis, and some of them which are 
complex multi-genic unknown degrees of penetrance -- alzheimer's, 
epilepsy, asthma, various cancers, schizophrenia, non-insulin 
dependent diabetes. 
But the interesting thing that has happened in the 
struggle to understanding complex genetic diseases is that 
a mathematical apparatus for dealing with such diseases 
emerged here because in the region of the HLA locus in 
humans and in other organisms, there is a tremendous degree 
of polymorphism, genetic polymorphism, which provided markers. 
So there is a population out there of human geneticists 
who have the mathematical apparatus in hand. And this is 
part of the Branscomb fantasy, and I was glad that he mentioned 
it. But I think it's more than a fantasy. I think it's a 
very important point to note that we are on the threshold 
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1 of making an interesting combination between the mathematical 
2 apparatus that has evolved to deal with these diseases with 
3 the limited amount of genetic information that was available 
4 in the emerging map. 
5 They are refractory because, as I mentioned, there 
6 are multiple disease loci involved. There are many disease 
7 loci involved. And when you have the genotype, you don't 
8 necessarily have the disease. This makes these diseases 
9 difficult to localize. 
10 But with the apparatus in hand, that has allowed 
11 us to sort out the number of loci involved, the degree of 
12 heterogeneity, and make [inaudible) of penetrance; that together 
13 with the genetic map will allow us to proceed to other parts 
14 of the genome, all of those non-HLA associated diseases which 
15 are among the most common human genetic disorders and the most 
16 costly to society. 
17 And it would seem appropriate that this organization, 
18 this loose affiliation or consortium of interested people 
19 should reach out to that community and put together some 
20 thoughts about how California-based biotechnology could 
21 exploit that development. 
22 Thank you. 
23 DR. NEUFELD: Thank you very much. 
24 Our next speaker is Dr. Michael Kelly who is President 
25 of Intelligenetics and will tell us about some computational 




























DR. KELLY: I just wanted to say that some of the 
previous speakers depressed me a little bit about the future 
of computational abilities for the human genome. But I'd like 
to be more like the gentleman from ABI and say that we think 
that there are a few clouds on the horizon, but for the most 
part I think the sun is shining as far as computational 
capabilities is concerned for the near future. 
Today I'd like to talk a little bit about the 
information generated by the human genome and also the 
computational needs for the human genome. We'd like to talk 
about that in terms of not about the restriction mapping 
because I think that was talked about earlier in detail, but 
more about things such as fragment assembly, the data base 
hardware and software needs and sequence analysis and 
specialized data bases that have been generated for the human 
genome. 
In terms of the computational needs, we have to 
manage the genetic and the physical maps. We have to manage 
the cosmids and the YAC's. We need management and analysis 
of all the sequences that are generated. We need to have a 
network communication available worldwide for all the researchers 
to be able to instantaneously communicate, and we need to analyze 
the genome and also to look at inter and intrachromosomal 
interactions. 
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1 In terms of fragment assembly, there are a number 
2 of commercial packages available, and they are quite adequate 
3 at analyzing and managing the sequencing of the individual 
4 fragments. We have, as was told to us earlier, we're up to 
5 500 base pair fragments. Now how do we overlap these fragments? 
6 Well, to give you an example of this, and that is 
7 the proeram GEL. It allows you to display and eliminate the 
8 vector sequences so that you can eliminate any of the cosmid 
9 sequences included in the sequencing, and also you can 
10 automatically merge these functions. 
11 Surely Intelligenetics will have a program called 
12 the SymGel out on the PC which will be able to handle over 
13 100,000 base pairs. And there is no limitation for the 
14 future. It's only a limitation of the size of the hardware 
15 in this particular case. We have a new Algorisms that allows 
16 us to do millions of base pairs. 
17 In terms of the generation of all these sequences, 
18 I'd like to give you some perspective on the growth of GenBank. 
19 This is through March of '88. And you can see that it at that 
20 particular time, it was just below 20 million nucleotides, 
21 and r,rowing exponentially. 
22 So when Intelligenetics was awarded the contract 
23 for GenBank, we did an analysis to decide exactly what will 
24 be the needs for the next five years since this is a five-year 
25 contract. And on that basis, we started out in 1987 and there 
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1 were 15 million nucleotides in the data base at that particular 
2 time. By 1992 -- and I think this is a little optimistic --
3 that there will be 250 million nucleotides in the data base, 
4 but that depends on how fast Dr. Cantor's group and other 
5 laboratories move in terms of entering sequences. 
6 But right now these are the estimates that we have. 
7 We will have the capability -- the computer capability -- of 
8 the storage of all this data in a relational format, and I'll 
9 tell you a little bit more about that later. And we estimate 
10 that it will only require about two gigabytes at that time. 
11 There was a previous slide that I think either 
12 Tim Hunkapillar or Mike Waterman had that said or Elbert 













for the whole human genome. But there is currently hardware 
available and software available to access that in a fairly 
reasonable way. 
In terms of rapid retrieval, we need to develop a 
sophisticated network communication with easy access to a 
PC host-type of system. And that currently does not exist. 
There is the NSF map which is being developed and will have 
a fairly wide band width up to 1 megabyte per second, but 
not every researcher will have access to that currently. 
But this is an area where, I think, the NSF and 
other organizations can take a step in furthering this 
particular network so that we can access quite rapidly the 
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1 information generated. 
2 There are natural language communication devices 
3 heing generated, both at Intelligenetics and also at Los Alamos 
4 among other laboratories for the sequence entry and manipulation. 
5 And I'll tell you a little bit more about the software for 
6 entry of the data in a little bit. 
7 In terms of distribution of the data bases, currently 
8 it's released on magnetic tape. And right now it takes about 
9 two or three reels of magnetic tape to do the whole GenBank 
10 release. In terms of 1.2 megabyte floppies in compressed 
11 format, it's about 19 1.2 megabyte floppies, and that does 
12 not include all the annotation. It's actually about 80 360k 
13 floppies at the current release. 
14 So we have a problem for people using PC's right 
15 now. Their arms get tired entering the data. So what 










CD ROM. It will be a single entity because we have high-storage 
density. We can store actually close to 500 megabytes, but 
we said 300 in here because we're thinking about adding other 
data bases to the format as well. 
We are currently under negotiations with PIR and 
other data bases to try to develop a single system so that 
it makes it easier for the researcher, but that will require 
some more negotiations. 
So this is ideal for the current needs. A CD ROM 



























costs about $1,000, and it's quite easily accessible from a 
PC. There are some problems with that, however, because of 
access times. And so as was stated earlier, the access time 
of this information is dependent upon the time of the type of 
search done, whether you're doing a straight match, a pattern 
expansion, a local or a global alignment. It depends on the 
type of CPU and the load on that CPU. So if you've got a 
large VAC's and you have 15 or 20 people on it all doing 
searches, you can grind it to a halt, and it depends on the 
structure of the data base. Is it indexed so that you can 
easily access the portion of the data base that you want to 
look at and it also depends on the storage medium. And in 
this case the CD ROM is a slightly slower mechanism of access 
of the data. 
But if you want to do an overnight search or something 
like that, you can do that. But I would like to second 
Tim Hunkapillar's plea that we have more research done on 
things like parallel processing and also Mike Waterman's 
suggestion that we have more education in the area of 
computational molecular biology. 
Now, what about the future directions of the data 
base? It needs to become more current. When we started the 
contract, the GenBank contract, in October of '87 the data -- we 
estimate the data for which GenBank is responsible, not for 
which European Molecular Biology Laboratory is responsible, 
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and GenBank's portion of the overall nucleotide data base 
2 represents about two-thirds of the total. GenBank was somewhere 
3 in the range of 80 percent of the data would be in within 
4 12 to 14 months of publication. And this was totally inadequate. 
5 And we recognized that. 
6 And there were steps taken by the NIH to improve 
7 this by providing more resources to allow us to become more 
8 current. And as of the last release, we believe that the 
9 data -- 80 percent of the data is getting in within five 
10 months. So there's been a drastic improvement in the currency 
11 of the data. And we expect that trend to continue and become 
12 much more up to date. 
13 We want to organize this for more efficient use. 
14 We will be doing new indexing routines to allow the researchers 
15 to access it more rapidly. We want to develop links to other 
16 data bases. And in terms of this, a relational data base 
17 structure is being generated mostly through the group at 
18 Los Alamos. And they are working very closely also with the 
19 HGML data base, and so that the relational structure will 






Also, we are developing an author entry set of 
software. And as Elbert Branscomb was talking about, we need 
to have the same interface on most computers. And we are 
working towards that goal so that when the individual researcher 
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1 wants to enter his sequence and annotation information that 
2 you will be able to do it with the same format in every type 
3 of computer. This author entry software will be developed 
~ for both -- it will be on the PC first, and it will be available 
5 in the Spring of '89. Also, it will be developed on the 





















And this also, in terms of data bases, is spawning 
specialized entities that are just coming into the four, and 
some of these are the cytogenetic map data base, the RFLP map 
data bases. We already have the Brookhaven Coordinate 
data base. VectorBank is a data base of all the plasmids. 
Roberts' Restriction Enzyme data base, and what we call a 
Signature Region data base. 
In terms of analyzing sequences, as of March there 
were over 19,000 DNA sequences and over 6,000 protein sequences. 
And we ought to look at them in terms of their structural and 
their functional properties. 
In terms of sequence patterns, we're looking at 
groups of bases or amino acids associated with a particular 
function or aspect. Examples of this, of course, are the 
tata box and consensus sequences for DNA or proteins. 
Key Bank is a data base of known sequence patterns. 
And this has been generated by Intelligenetics as reported 
in the scientific literature. And currently in Key Bank we 



























have over 1300 entries of known structure function-type 
relationships. These entries are all fully referenced. And 
they're classified into categories and then indexed. And we 
currently have 16 categories of protein keys and 112 categories 
of nucleic acid keys. 
Examples of these categories are amino acid modifications, 
signal sites, binding sites, enzyme active and allosteric sites, 
regulatory regions, binding sites and repeats and ends. 
Key Bank was designed for use with the Quest program. 
Quest searches the sequence files for key words and sequence 
patterns. It searches the single sequence or many sequences. 
It retrieves sequences while searching. It allows use of 
ambiguities and boolean operators in the patterns and allows 
patterns to be combined to form complex patterns. 
There's another program on the PC which does similar 
things for the protein. It's called Procyte. And here is an 
example of actually delineating. And currently we have 
something like 120 individual signatures or patterns that 
can be delineated on proteins. And this will be coming in 
the next version of PC Gene. 
In summary, we think the Human Genome Project will 
generate vast numbers of large sequences, cosmids, YAC's and 
restriction maps. The data base growth will generate needs 
for better distribution, storage, access times and use. And 
we think that new computational tools as well as the existing 
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1 computational tools will be needed to analyze this data. 
2 DR. NEUFELD: Thank you very much. 
3 I think we'll go on to Dr. Marr who comes from 






















on computational aspects. 
DR. MARR: Unless I have to, I think I'll go ahead 
and stand here and use what few relevant slides I have 
left myself. 
Not knowing who was going to be here or what was 
going to be discussed, I sort of naively put this set of 
overheads together. So I think it's clear that I shouldn't 
bother going over some of the things that have been discussed 
here already. 
Let me just put up one thing that hasn't been clearly 
pointed out to the group, and that is some of the computational 
complexities involved with some of the problems that have 
been discussed here today. 
If N represents the length of the sequence, and 
complexity is some index of -- well, in this case -- the time 
to compute, being proportional to -- in the case of similarity 
searching -- the length of the sequence squared. We start 
looking at some of the real interesting problems that confront 
us in going over the examining the DNA sequences. 
We see that the problem gets complicated very quickly 
as we move from the relatively simple problem of similarity 



























searching, which is the thing that GenBank is used for on a 
daily basis. Somebody sequenced a piece of DNA, and they want 
to see what it looks like so they go through and apply some 
type of searcl, Algorisms to GenBank, and it shows up to 
be similar to some other pattern that exists in the data base. 
Well, as we start looking at predicting RNA secondary 
structure from primary sequence, we see that complexity or 
time to compute goes up as the cue of the length of the sequence 
and to the where the most interesting, in my opinion, problems 
is predicting tertiary structure from primary sequence data. 
And I don't know what that really scales at, but it's apparently 
some large number. Right now it takes one cray, one hour, to 
do this for a tetramer. 
And if you think on the average --what's that? 
DR. SALSER: Tetramer of what? 
DR. MARR: If you take primary sequence and you 
do a good calculation to come up with tertiary structure, it 
takes about one cray, one hour. There are simpler ways to do 
it on PC's, et cetera, but they're not believable structures 
they end up with. 
This is using a Monte Carlo approach to energy 
minimization in the structure. So if you think -- if you want 
to do this over a larger piece of DNA, it gets up into many 
thousands of cray one hours very quickly. 
So that's some more numerical view of the complexity 
Pike Court Reporting 
218. 
that we're confronted with. 
2 It has come up that what the speakers are doing is 
3 viewing this problem from different backgrounds. My background 
4 is in evolutionary biology and system science. And the 
5 challenge that this is really -- or the new things that the 
6 DNA technology is opening up to evolutionary biologists, of 
1 course, is being able to test hypotheses that we've made 
8 glaring assumptions about for many years, that is evolution 
9 within populations. 
10 Now we can measure gene frequencies, allelic frequencies, 
11 in populations by looking at distributions of Jeffry's-type 
12 probes in populations. We're not involved in doing that. 
13 We can apply the DNA technology to very practical wildlife 
14 management problems. So we can go in and take blood from 
15 whooping cranes and tell who is related to whom. And, therefore, 
16 if we're going to be doing artificial insemination studies, we 
17 shouldn't be pairing brothers and sisters in that situation. 
18 So I think the technology in a broader sense opens 
19 up a whole range of new problems to other types of scientists. 
20 And that's what I think is exciting about potential spinoffs. 
21 DR. NEUFELD: Thank you very much. 
22 Our last speaker is going to address an issue which 
23 I think has been omitted from much of today's discussions; namely, 
24 where are we going to get the manpower to do all this computing 
25 and biology? 
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1 Dr. Steven Dahms is a Professor of ClH~mistry at 
2 San Diego State University, and he's also the Director of 
3 the California State University Program For Education Research 
4 in Biotechnology, which is a nice acronym of C-SUPERB. 
5 DR. DAHMS: I'll try and keep my comments brief. 
6 This topic doesn't address how or with what the initiative 
1 will be conducted, but by whom. It relates directly to 
8 biotechnology training programs, both in predoctoral, postdoctoral 
9 levels as well as below. 
10 My initial comments will temporarily disregard the 
11 mapping and sequencing initiative and will focus instead on 
12 current manpower demands and projections in California and 
13 training programs in the biotech arena. 
14 I do this largely because the new and existing 
15 programs have not taken into account the potential initiative 
16 to any extent. 
17 My initial comments will focus upon the NIH and 
18 California. NIH has recently addressed the problem. It was 







the action of Senator Chiles to assess what the NIH 
was doing and the biotech arena that involved biotech research 
and training. 
It charged the NIH with supplying an internal 
analysis to the Senate by the end of January and also with 
establishing an advisory panel to establish the needs for 
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1 new training programs and to make recommendations therefore. 
2 The report was submitted to Wyngaarden on February 1st, 
3 by Wyngaarden on February 1st to the Senate. And a panel was 
4 appointed and met at the end of March for several day. It 
5 focused upon specific areas to be developed in the biotech 
6 arena on all levels of instruction. I won't go into that. 
7 It's a matter of public record. There was a considerable 
8 discussion on manpower needs on the Ph.D., Masters, Bachelor's 
9 level and the Associate Arts' degree level as well from the 
10 11 academic panel members and the six corporate members. 
11 Considerable focus was on the trends of: What's 
12 happening in the next 10 years with regard to faculty replacements 
13 in the United States in the sciences? 
14 A good example of the problem that exists now is 
15 in California is: What will be happening within the California 
16 State University system in the next 10 years where between 
17 40 and 60 percent of all faculty will be turning over? 
18 With about 20,000 faculty in the system, this means that in 
19 the next 10 years about 750 faculty will be hired in chemistry 
20 and biology. At the same time the exponential hirings will 
21 be occurring in the corporate biotech arena. 
22 Well, finally the report was submitted first to 
23 the Senate and eventually it was incorporated into Chiles 
24 and was a bill that was entitled "Biotech Competitiveness" and 
25 resulted in $2.7 in new money to NIH. It was supposed to be 
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1 $5 million, but NIH didn't separate it correctly. It's 
2 resulted in 150 new predoctoral trainingships in the biotech 
3 arena and a number of postdoctoral and some in the M.D. side 
4 as well. 
5 A lot of the discussion focused on the predoctoral 
6 level. And I think in the next year the NIH might be 
7 reinterpreting the word predoctoral to mean pro pre level 
8 of training programs in the biotech arena below the Ph.D. 
9 granting area. 
10 Moving onto California in particular. With about 
11 20 percent of corporate U.S. biotechnology in San Diego our 
12 all Molecular Biology Institute and the State Biotech Program 
13 have conducted a survey in that area on the needs for the next 
14 five years. You might be surprised that these translate to 
15 800 Bachelor's, 300 Master's and 200 Ph.D.'s in the next 
16 five years. 
17 A recent committee composed of Salk/Scripps' corporate 
18 CEO's have in turn projected a need for at least 200 Associate 
19 of Arts degree level individuals for San Diego. And this is 
20 a new phenomenon on the west Coast, and it appeared to be 
21 popular on the East coast. So I what I think you'll be seeing 
22 in California, more and more junior colleges moving into 
23 so-called biotechnology training positions to conduct some 
24 of these activities. 
25 We have not completed the survey in the Bay Area, 



























but the initial figures agree with those in San Diego. It's 
clear that we're going to have difficulty meeting those manpower 
needs between UCSD and San Diego State, and major problems 
exist. 
The impact of the sequencing initiative has not been 
addressed in any surveys. It's important to realize that not 
only are manpower needs to be considered for the Ph.D and 
Masters' and Bachelor's level and below for the initiative 
but for life thereafter in the life sciences, that is thereafter 
the sequence initiative is completed. 
I think once Dr. Salser gave projections of 4500 
man years. If you take the suggestion by Norman Whiteley earlier 
today that assuming a dollar were a base pair, and three 
billion base pairs, and 8 to 10 man years per $1 million 
expense, this translates to about 30,000 man years. If you 
want to do this over a five-year period, that means 6,000 
personnel, and that's at 3 billion base pairs, not a 100 billion 
base pairs, the panel has not evaluated any data of this type 
to consider where it should be going. All NIH has done so 
far is to project a program within five years that will have 
1500 Ph.D. trainees in the works. 
Right now this first year there will be 150. Elementation 
will take place next year for another 150, plus 300 more. So 
it will be building. 
The 6,000 personnel needed nationally, very conservative 
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1 estimates, assuming 10 percent goes to California, that means 
2 roughly a 25 percent increase in demand projected in the 
3 next five years. What the real figure is nobody knows. It 
4 could be 10-fold higher due to spinoff technologies and 
5 related endeavors. What this translates to in terms of 
6 the number of Ph.D.'s and non-Ph.D. 's isn't clear; but, generally, 
7 it's about a 5 to 1 ratio of non-Ph.D. 's to Ph.D.'s in this 
8 area. 
9 According to the evaluation, the impact upon the 
10 manpower pool needs to be conducted in California with about 
11 360,000 students in the California State University system 
12 and 140 in the U.C., together there's about a 20 percent 
13 coverage of higher education in the United States. It 
14 might be wise for a joint CSU/UC committee to evaluate 












CSU is contributing quite significantly to meet 
these manpower needs through a modest number of Ph.D.'s that 
are produced, but in particular to a large number of Masters' 
and Bachelor's level people that are brought through strong 
research programs. There are a number of novel alternate 
training programs, non-degree, that in specific biotechnologies 
have been established. They involved postdoc's, technicians 
and other individuals. 
Biotech training programs at UCSU are in the exponential 
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phase resulting in new research programs being established 
2 and training programs, but these, I emphasize, have been 
3 conducted without new state monies and have impacted existing 






















I guess there are several take-home lessons. In 
California we're having severe difficulty meeting manpower needs 
now. What will be able to do with the initiative? Probably 
not much unless we take action soon. 
Secondly, NIH has not considered the sequencing 
initiative. It needs to. And it has been recommended to the 
advisory panel that this be discussed as soon as possible. 
Thirdly, a number of other federal agencies are 
initiating new biotechnology training programs. And it's 
clear that there's not much communication taking place between 
the agencies, and this should be taking place. 
Lastly, there was a quotation earlier today, something 
to the effect that "I hope our aspirations don't exceed our 
abilities." I'd modify that somewhat to say, "I hope our 
aspirations in the manpower arena are not greater than our 
abilities to provide it." 
Thank you. 
DR. NEUFELD: Are there questions from the audience? 
DR. SALSER: I have a question for Dr. Kelly, and 
that is: Are you planning to support the next computer or 
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1 will its unit system be compatible with some software package 
2 you're already supplying? 
3 DR. KELLY: We are not currently planning on supporting 
4 the next computer. We are waiting to see when it will be 
5 viable as a system. 
6 DR. SALSER: Do you have reservations about that? 
7 DR. KELLY: Yes, only since we've only seen the 
8 initial stages of it. And we're waiting to see whether it 

















DR. BOYER: I have a question for Dr. Dahms. If 
UCLA -- one of the depressing statistics is the fraction 
of the entering freshman class that indicate an interest 
in science and chemistry and biology as a major. This is 
down dramatically from what it was a decade ago. There's only, 
I think, something about half or 60 percent or as many 
indicating this interest. 
I wonder if that's the same trend you have in the 
state college system. A much smaller fraction of our entering 
class of freshman is indicating an interest in science as a 
major. 
DR. DAHMS: I think it's a national phenomenon. It's 
clearly been a discussion on the NIH advisory panel level. 
There's even been discussion of NIH putting money into high 
school instructor training programs so that they can affect 
the quality and numbers of students who elect careers in 


























science. It's a subject of discussion among a number of 
professional societies. I think it's a national phenomenon 
that the NSF has not sufficiently addressed. It is the 
agency that should do it. 
DR. AVDALOVIC: I have a question and a suggestion 
which I didn't have a chance to make during my presentation. 
226. 
We all realize that there is a big problem 
UNIDENTIFIED SPEAKER: You probably should move that 
up somewhat. 
DR. AVDALOVIC: 
the first question. 
I didn't want to obstruct you with 
-- is to promote some postdoctoral projects with 
the interdisciplinary education with emphasis on computer 
applications because we all see the need for a cross hybridization 
between molecular biology and computer sciences. 
What we have here is more a lack of good and f~esh 
ideas and approaches than a lack of computational speed. 
So that could be perhaps one of the proposals for interdisciplinary 
postdoctoral programs. 
The question which I had is for Dr. Kelly. Last 
month at the human genome meeting in Valencia, Rich Roberts 
from Cold Spring Harbor raised a very interesting question 
asking: Are there any efforts in the arena of literature 
on computer? In other words, all these efforts in human genome 
might be perhaps faster expedited if we had the access to the 
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1 rea [inaudible] through the computer to access to the data 
2 like structural analysis, crystalography data and so on. 
3 A e there any efforts in that area? Do you think that is 
4 something feasible? 
5 DR. KELLY: Could you rephrase that question? I'm 




















DR. AVDALOVIC: Access to the real articles. When 
you retrieve the sequence you get a sequence, but you would 
like to know what that sequence does. This is translated 
into protein somewhere. 
DR. KELLY: So the complete article in an electronic 
form? 
DR. AVDALOVIC: Yes. 
DR. KELLY: I think there are some indications that 
people want to put journals on CU ROM. The access to that 
information only would occur through programs such as Quest 
or other programs such as that where you do key word searches 
currently. 
There needs to be more research in that area. And 
I don't think there is a strong effort to do that. On Rionet 
we are not starting to put the abstracts of articles on the 
system. So if individual journals want to have an electronic 
abstract system, Bionet will be a vehicle for them to look at 
the abstracts electronically. 
DR. MARR: I might be able to say something about 



























that as well. 
We've been talking to Dennis Benson at the National 
Library of Medicine. Right now we can take GenBank accession 
numbers and pull up abstracts out of MedLine from the medical 
literature. It's just a question of dollars. If somebody 
puts significant a sufficient amount of money into the 
National Library of Medicine for them to digitize the primary 
literature, then the technology is there to do it. It may be 
a little slow right now, but certainly within the next few 
years high-speed communications networks will be available 
to support full text retrieval in pointers across network 
data bases. 
So it's just to point out to funding agencies the 
requirement for that. 
DR. KELLY: Along with that, there is an experimental 
program that NLM has generated called IRX that will do a 
sophisticated type of key word search. 
DR.DAHMS: Could I comment on your statement about 
the postdoctoral training programs? 
The new program that has just come on line within 
the past month, the first deadline for application, I think, 
is January 1. It would cover that clearly. It's looking 
for industry interactions in the predoctoral and postdoctoral 
level. 
And if I could provide another comment to Dr. Boyer. 


























The most recent publications in the National Academy of 
Science indicate that students make their decision on 
Pntorinp, a careor in science usually at the latest hy th0 
lOth grade. So there is a concerte effort that has to be 
made to influence students to elect science as a career. 
And there are some activities within the state now in the 
molecular life science arena that are doing this. 
229. 
There's a collaborative program between San Francisco 
State and Santa Cruz that is bringing high school students 
through DNA training programs in the summer in an attempt 
to educate them and affect them to the point of increasing 
the number of students electing science as a career. 
DR. NEUFELD: Any other comments? 
Larry. 
DR. SIMPSON: I'd like to make a comment about 
commercially available software for analysis of sequences. 
I realize that by the time it gets to be commercially available, 
it's certainly not state-of-the-art, but it's what is available 
to most people out there in the field. 
And I'd just like to say that most of the packages 
are foreign sequence unfriendly. In other words, I guess I 
understand why, but they try to be self-sufficient and 
self-contained whereas the user out there, the noncomputer 
expert who just wants to use and understand the sequences, 
has to use the best things of this package, the best parts of 


























that package, and the best parts of that package. So should 
be easily able to switch from package to package. And part 
of this problem is simple sequence format problems. 
I'd just like to emphasize that this is a major 
problem for the user. 
DR. NEUFELD: Thank you very much. 
DR. SALSER: Well, I thought that the best way 
to wrap this up would be for me to twist Charles Cantor's 
arm to give us his overview. And he has graciously agreed 
with little notice to do that. And so I'm going to turn 
this over to him. 
DR. CANTOR: As if you haven't heard enotigh from 
me already. What I thought I would do is spend, I hope, no 
more than five minutes just summing up what I think are the 
main things that were said today. 
230. 
The title is the Human Genome Projects. And I would 
contend that one of the things that you heard today, at least 
within the United States, is that there is only one project, 
that DOE and NIH seem very likely to be sufficiently 
coordinated so that there really is no discord between them. 
It remains to be seen whether this coordination can be spread 
internationally. But I'm optimistic about what's happening 
within the U.S. 
Issues. I think there really are two major issues 
that we have to keep in mind. The first, and I think the 
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1 major concern with the biological community that led originally 
2 to a lot of oppositjon to the project was the fear that it would 
3 sap resources on traditional biological research. I think 
4 that this simply hasn't happened. 
5 And it hasn't happened for two reasons. One, thus 
6 far we've been successful at raising new money for the project, 
7 roughly $46 million dollars in totally new money in fiscal 
8 '89. We have to make sure this continues. 
9 Two, the project has been broadened in its definition 
10 and scope so that it actually encompasses quite a bit of what 
11 was traditional, albeit, fairly high-tech biology. And so 
12 it probably is actually providing indirectly additional funding 
13 from mainstream biology labs and sapping it. I think it's 
14 important that we make sure that that be the trend. 
15 The second issue that I want to touch on briefly is 
16 the ethical issue. I think the ethical consequences of this 
17 project are quite considerable. But from all I've heard, 
18 they are quantitative and qualitative. There are no issues 
19 being raised by the Human Genome Project, just the existing 
20 issues are being amplified. And I think it's important that 
21 we face those issues early in the game and up front and deal 
22 with them. 
23 I think Jim Watson mentioned this morning that he 
24 
25 
plans to use some NIH funds for education. What I've been 
struck by thus far is that the agencies have made -- especially 
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DOE and also NIH small efforts to educate the press. And 
2 if you have very few bucks to spend on education, it seems 
3 to me this is probably the best place you could put it right 
4 now because if we can get more accurate reporting on what's 





















those are the key issues. 
Goals. It strikes me that there's a remarkable 
consensus at this point as to what the short-term goals of 
the project ought to be. And considering how new the project is, 
this is very satisfying. I think we will be mapping. We will 
be developing techniques. We all agree that at this stage a 
major hurdle is to try and organize the informanics and 
computing aspects of the project. That's clearly the arena 
where at least nationally, and probably internationally, 
efforts will be made to try to orchestrate things properly. 
I think we also all agree, although it came very 
late in today's discussion, that the project today is 
people limited, and it's likely to be so for quite a considerable 
time. So it's critical to build a training component into 
the Human Genome Project somehow. That's what I wanted to 
say about goals. 
One other thing about goals, you heard an enormous 
spectrum, especially in this afternoon's session, of optimism 
and pessimism. I think that's appropriate for people who are 
actually trying to do the work with their own hands. And I 
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1 think it's simply a natural part of human nature and science. 
2 And as always, I'm in the middle of the road. I don't think 
3 the optimists are right. I don't think the pessimists are 
4 right. This project is going, and it's going to continue 
5 p;oing. 
6 I want to talk about California for a second. I 
7 think the simplest thing I can say is that I don't think any 
8 other state could put together such a program with only 
9 one exception, only people whose home is or will be in this 
10 state. Since the project is people limited, it's destined 
11 that California will play a major role in the project so long 
12 as it holds all these people. 
13 The only bad note is that it's quite clear from 
14 what was said this morning that you have to have two jobs 
15 to somehow succeed. That's a little taxing to say the least. 
16 I think that one other way that I could just in the 
17 process of arranging for a meetin& which will be held in 
18 October in San Diego on the Human Genome Project, co-sponsored 
19 by Science Magazine and by the Human Genome Organization, 
20 and in organizing a meeting, you usually worry about your 
21 travel budget. And I was very surprised as we began to invite 
22 all the people we wanted that we don't have any trouble with 
23 our travel budget because so many of them come from California 
24 that it's not going to be so bad. 
25 Finally, let me turn to what I still consider to be 



























the most difficult challenge with this project, and that is 
organization. We as scientists are simply not used to being 
told what to do, and justifiably we resist it. And we're 
also used to a system in which people sort of individually 
compete in many research areas, and the person who eets 
there first almost beautifully gets the awards. 
Those concepts have to change a bit if you're 
talking about live science. I mean the physicists have 
gotten used to the fact that they have 50 or 60 people working 
on a physics project at a major accelerator center. And 
somehow, even though someone was 50th over, they get a Ph.D. 
And the biologists haven't dealt with this problem yet of 
how you coordinate very large efforts and share the credit 
in an appropriate way. 
And I think a model to this has its strains but 
also it's successes is the search for the Huntington's disease 
gene coordinated by the Hereditary Disease Foundation 
represented by Nancy Wexler who is in the back of the room. 
That project has been going for four years, and it is 
coordinating internationally, seven or eight research groups, 
which have their cooperation and their intentions. 
But I think it serves as a pretty good local 
since it's California model for the fact that it's possible 
for biologists to carry out relatively large collaborative 
research effort and still remain friends. 
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1 So I think that's what I wanted to say. I look 
2 forward to another meeting of this type, hopefully, with 
3 even more optimism. 
4 DR. SALSER: Thank you, Dr. Cantor. And thank 
5 you all for participating. And I hope we see you again 
6 as this project goes forward. 
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